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Abstract
Released in response to cellular activation, microvesicles are a major vector
mechanism for the delivery of protein, nucleic acid and bioactive lipid payloads
in local tissues and plasma. Large numbers of microvesicles (including those
from neutrophils) are found within inflammatory sites, such as the rheumatoid
synovium. Human neutrophil microvesicles promote tissue protection, and in
some cases repair, by affecting function and phenotype of other inflammatory
cells. Of these, tissue macrophages are central to the recovery of homeostasis
after an inflammatory insult.
The data herein indicate that microvesicles released by activated neu-
trophils impede lipopolysaccharide and interferon gamma-induced “M1-like”
polarisation of macrophages via phosphatidylserine (PtdSer) exposure, and in-
duce annexin A1-dependent release of transforming growth factor beta (TGFβ).
Macrophages treated with these vesicles stimulate the production of cartilage
matrix from chondrocytes, and are unable to induce an inflammatory phe-
notype in fibroblasts. The efficacy of these vesicles is reproduced in two in
vivo models of acute inflammation, zymosan-induced peritonits and K/BxN
serum-transfer arthritis.
Finally, the possibility of using both autologous, and cell-line-derived mi-
crovesicles as pharmacodynamic tools is explored. Microvesicles generated
from neutrophils from patients with rheumatoid arthritis are found to be
protective, and can outcompete the pro-inflammatory effects of both platelet
microvesicles, and those isolated from synovial fluid of patients with rheuma-
toid arthritis. By building on the observation that anxA1 on microvesicles
stimulates TGFβ release in macrophages, a cell line was transfected to release
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Chapter 1
Introduction
1.1 The observation of extracellular vesicles
In 1946, Chargaff and West noted that centrifuging platelet-poor plasma at high
speed prolonged its clotting time6. The clotting factor, which was not depleted at
5,000×g but formed a pellet at 31,000×g, could restore the clotting time of depleted
healthy and haemophiliac plasma in a concentration-dependent manner. The authors
ascribed this activity to a thromboplastic lipoprotein of high molecular weight and
postulated that the pelleted fraction may also contain “minute breakdown products
of the blood corpuscles.” The identity of the prothrombotic agent remained elusive
until when, twenty-one years later, Wolf confirmed using electron microscopy that the
pelleted fraction responsible for this prolonged clotting time consisted of particulate
matter rich in phospholipids7. In refinement of Chargaff and West’s hypothesis
that the material was a product of circulating cells, Wolf suggested these particles
were released from activated platelets and that their function was to potentiate the
clotting process. Wolf termed these particles “platelet dust.”
Following a separate line of research in 1954, Palay and Palade described the
presence of vesicular structures in neurons, containing smaller vesicles, some of
which appeared to be inward invaginations8. The same structures were identified
in regenerating nerve fibres9, epithelia10, granulocytes and monocytes11, and were
termed multivesicular bodies by Sotelo and Porter in 195812. Extracellular vesicles
of the same size and morphology as those found within multivesicular bodies were
detected in breast cancer biopsies13 and virtually all sera14. Initially mistaken for
viruses, these vesicles were termed virus-like particles, although Dalton asserted
this nomenclature was unwarranted and preferred the term microvesicles15. While
microvesicles and multivesicular bodies continued to be curiosities within electron
micrographs, their biological relevance remained unknown16–18.
The first report of a functional importance of extracellular vesicles came in 1981
when Trams et al. proposed they were non-soluble vectors for ectoenzymes, enzymes
found on the extracellular leaflet of biological membranes19. Importantly, this study
identified two main populations of what the authors termed “exosomes” released
from glioma and neuroblastoma cell lines: small vesicles around 40nm in diameter,
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and larger vesicles ranging from 500nm to 1,000nm. It was later demonstrated that
prostasomes, vesicles released by prostate tissue, are formed by inward budding
into the lumens of late endosomes, defining the origin of multivesicular bodies20.
Considered a tissue-specific case of the exosome, prostasomes were externalised
when multivesicular bodies fused with the plasma membrane, a process subsequently
termed exocytosis.
While the first physiological roles for exosomes began to emerge (in protein
recycling and shedding during reticulocyte maturation21–23), the problem remained
that the larger vesicle population described by Trams et al. was too large to be
derived from multivesicular bodies. Instead, Stein & Luzio proposed the term
ectocytosis in 1991 to describe the direct budding of larger, right-side-out (where the
outer leaflet of the cell remains the outer leaflet of the vesicle) membrane vesicles
from the plasma membrane24; initially observed by Scott in 197825. These plasma
membrane-derived vesicles (whose release was [Ca2+] and temperature-dependent)
were termed microparticles, and were presumed to represent the observed larger
fraction of vesicles26,27. The term ectosome was proposed in 1999 to maintain
consistency with the exosome terminology, but has fallen out of favour as the two
are phonetically very similar. This nomenclature is still used (more commonly to
describe neutrophil-derived vesicles), but “microvesicle” predominates, despite these
vesicles being sub-micron in size.
Finally, distinct from exosomes and microvesicles in size, morphology and release
mechanism, are vesicles first observed in 1965 being released from cells undergoing
apoptosis28. These larger (1µm - 5µm) and irregularly shaped vesicles are considered
a hallmark feature of programmed cell death and were named apoptotic bodies by
the same group’s seminal review in 197229. Apoptotic bodies form from membrane
blebs during cell death which fragment and undergo fission. Prior to apoptotic body
formation, phosphatidylserine (PtdSer), a membrane phospholipid usually maintained
asymmetrically on the cytosolic membrane leaflet, is exposed, contributing to plasma
membrane instability and blebbing30. Outward expression of PtdSer is a property
apoptotic bodies and microvesicles share, as the same process occurs prior to the
formation of a subset of microvesicles also31.
Together, exosomes, microvesicles and apoptotic bodies form the family of ex-
tracellular vesicles (Figure 1.1 and Table 1.1). Far from being functionless waste
products (indeed, nature is rarely so wanton), this family have been directly impli-
cated in a plethora of physiological and pathophysiological processes. While these
structures have both distinct and overlapping functions, microvesicles are emerging as
a remarkably pivotal vector of intercellular signalling in the context of inflammation.
For example, monocytes, endothelial cells and platelets release microvesicles capa-
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ble of promoting inflammatory and clotting responses32–35. Conversely, neutrophil
microvesicles can promote tissue protection, and in some cases repair, by affecting
function and phenotype of other inflammatory cells36,37. Of these, tissue macrophages
are central to the recovery of homeostasis after an inflammatory insult and there is
some evidence to suggest a re-programming of macrophages by neutrophil-derived
microvesicles37,38.
Table 1.1: Extracellular vesicles
Member Size Source Release
PtdSer
expression
Exosomes ~40nm - 200nm MVB Exocytosis No
Microvesicles ~100nm - 600nm PM Ectocytosis A subset
Apoptotic bodies 1µm - 5µm PM Membrane blebbing Yes
MVB multivesicular body; PM plasma membrane
1.2 Microvesicle formation
The controlled release of microvesicles from the plasma membrane is a property
shared by all eukaryotic cells39. Bacteria also shed outer membrane vesicles; similar
nano-scale vesicles from which eukaryotic ectocytosis appears to be conserved40.
Evolutionary persistence of these structures is indicative of their importance as a
fundamental mechanism of cellular membrane dynamics and signalling. The process
of ectocytosis itself is not fully annotated, but is governed by interactions between
Ca2+, Rho GTPases, plasma membrane asymmetry, and filamentous and cortical
actin cytoskeletal architecture41.
1.2.1 Ligand-induced Ca2+ flux
Initial work into the mechanism of ectocytosis took a top-down, functional approach,
focussing on exogenous stimuli which induce microvesicle release rather than the
molecular pathways involved. “Activating” stimuli like adenosine triphosphate (ATP),
thrombin, and lipopolysaccharide (LPS) potently induce microvesicle release from all
cells expressing their cognate receptors32,42–44. The common denominator between
all ectocytosis-driving stimuli is their induction of a potent flux in intracellular Ca2+.
Blockade of Ca2+ mobilisation with the intracellular, bivalent cation chelator, BAPTA-
AM, universally negates microvesicle release in both the steady state and in cells
treated with these activating stimuli1,45. It would seem that any ligand which induces
biologically significant Ca2+ movement into the cytosol, also induces ectocytosis; the
two processes appear immutably linked. Therefore, any ligand-receptor interaction
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Figure 1.1: Formation and classification of extracellular vesicles. A Mi-
crovesicles (MV) are membrane vesicles that bud directly from the plasma membrane
of all eukaryotic cells. Their diameter is in the range 100nm - 600nm, with a modal
diameter around 300nm - 400nm. B Exosomes (Exo) are vesicles which bud inwards
into late endosomes to form multivesicular bodies (MVB). During exocytosis, these
bodies fuse with the plasma membrane and release their cargo of 50nm - 200nm
diameter exosomes. C Apoptotic bodies (AB) are larger, irregularly shaped vesi-
cles which are formed from large membrane blebs during apoptosis. D Activation
of receptors coupled to Ca2+ signalling promotes PtdSer exposure on the outer
leaflet by modulating flippase, floppase and scramblase activity. Ca2+-activated
µ-calpain (which can be inhibited by calpeptin) cleaves cortical actin and activation
of rho-associated protein kinases (ROCK) by RhoA (and possibly NFκB) induces
cytoskeletal contraction. Budding vesicles take membraneous proteins, and cytosolic
components before a fission event releases the microvesicle into the extracellular
space. GTP, guanine triphosphate; IL-1β, interleukin-1β; PAMP, pathogen-associated
molecular pattern; ROCK, rho-associated protein kinases; TNFα, tumour necrosis
factor α.
CHAPTER 1. INTRODUCTION 5
resulting in the opening of bivalent cationic ion channels, Gq-protein disassembly
or membrane depolarisation, will prompt rapid dissemination of microvesicles from
the cell. Microvesicle release can also be induced experimentally, independently of
ligand-receptor interactions with Ca2+ ionophores, such as A2318746. This coupling
to Ca2+ flux appears to explain the promiscuous and ubiquitous nature of ectocytosis
in eukaryotic cells, and is the signal required by the downstream cellular machinery
responsible for vesicle formation.
1.2.2 Rho GTPases
The Rho family of 23 small, membrane-bound GTPases (G proteins), such as Cdc42,
Rac1 and RhoA, are master controllers of signalling that results in changes to
the actin architecture47. In their inactive state, Rho family members bind guanine
diphosphate (GDP) via a nucleotide binding domain. Activation of guanine nucleotide
exchange factors (GEF) by upstream receptor signalling or Ca2+ and cyclic adenosine
monophosphate signals allows them to bind to Rho enzymes and sterically hinder
the interaction between GDP and the GTPase48. This allows dissociation of GDP
and frees the nucleotide binding domain for an available guanine triphosphate
(GTP) molecule (both molecules compete for binding, but the latter is ~10x more
concentrated in the cytosol49). Once bound to GTP, classical Rho molecules bind to
their respective effectors and propagate the signal. This signal is temporally regulated
by the enzymes’ intrinsic GTPase activity which dephosphorylates GTP back to
GDP, returns the GTPase to its inactive state and is promoted by GTPase-activating
proteins50–52. The functions of Rho family members are diverse and are required for
cell division, migration, adhesion and membrane dynamics.
Of the best studied Rho proteins, RhoA activation is required during microvesicle
formation53. When RhoA is GTP-bound, it interacts with and affects a confor-
mational change in ROCK54–56. This conformational change increases the kinase
activity of ROCK, which phosphorylates myosin light chain phosphatase and may
phosphorylate myosin light chain directly55. The net effect of this is increased
association of myosin light chain to the actin filaments and a subsequent increase in
cytoskeletal contractility57. ROCK homologues I and II can also be directly activated
by cleavage of their regulatory domain by caspases 3 and 2, respectively53,57. The
particular ROCK which transposes a cellular signal into microvesicle release appears
to depend on the nature of the signal. For example, thrombin-mediated activation
of human endothelium results in ROCK II and not ROCK I-dependent microvesicle
release53. On the contrary, ROCK I predominantly controls apoptosis-associated
microvesicle release57. Activation of either ROCK homologue is a critical checkpoint
during ectocytosis, and their inhibition with Y-27632 (a partially-selective small
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molecule inhibitor) arrests microvesicle formation57.
Just how ROCK-induced contraction of the actin cytoskeleton facilitates mi-
crovesicle release is still under debate. A predominant theory is that contraction
needs to be secondary to depolymerisation of the cortical actin mesh proximal to
the elected patch of membrane58–60. This is demonstrated by the inhibition and
potentiation of microvesicle release by jasplakinolide (a peptide which promotes
actin nucleation and polymerisation) and cytochalasin D (an alkaloid which prevents
polymerisation of actin monomers), respectively1. This theoretical sequence of events
would allow decoupling of actin from membrane components and its retraction into
the cytosol, leaving a patch of unsupported membrane. The unanchored patch of
membrane is then free to bow to entropy and form a membrane bleb in response to
changes in membrane asymmetry (discussed below).
One issue with this theory is that ROCKs also activate LIM domain kinase which
phosphorylates and inactivates cofilin61. Cofilin promotes depolymerisation of actin
filaments, so its inhibition by ROCKs stabilises the cortical actin mesh62. Both RhoA
and ROCK also activate PI(4)P 5-kinases, which promote actin filament assembly63.
Cofilin and PI(4)P 5-kinase activity need to be overcome to allow detachment of actin
from the membrane, a role fulfilled by Ca2+-dependent calpain proteases (most likely
µ-calpain)64,65. µ-calpain directly binds cytosolic Ca2+ in the µM range (whereas
m-calpain is sensitive only at mM Ca2+ levels, hence their respective prefixes) and
becomes catalytically active66. The activity of calpain enzymes does not appear
selective for defined amino acid sequences but rather depends upon tertiary structure,
and so they have a wide range of cellular targets, including notably, filamentous
actin. Inhibition of calpains with the small molecule inhibitor calpeptin blocks
the production of microvesicles from platelets and abrogates actin degradation67.
The importance of calpains in membrane release during ectocytosis is perhaps
demonstrated by calpeptin’s blockade of microvesicle release despite concurrently
activating Rho GTPases (including RhoA)68. While detachment and contraction
are required to free membrane patches destined for blebbing, changes in membrane
phospholipid asymmetry may drive the entropic formation of the bleb, as well as
facilitate cytoskeleton detachment.
1.2.3 Membrane asymmetry
Eukaryotic lipid bilayers are given structure by a family of amphiphatic aminophos-
pholipids, the glycerophospholipids69. This group of lipids consists of phosphatidyl-
inositol, phosphatidic acid, phosphatidylcholine (PtdCho), phosphatidylethanolamine
(PtdEth) and PtdSer. The bilayer of the plasma, golgi and mitochondrial mem-
branes maintain an asymmetrical distribution of these lipids between membrane
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leaflets70. The exception to this is in the endoplasmic reticulum, where most of the
cell’s membrane lipids are synthesised, which maintains equal proportions in each
leaflet71,72.
The functional consequences of a non-uniform distribution are related to the
signalling capacity of bioactive lipids. By actively controlling exposure of certain
lipid ligands to the extra and intracellular space, the cell can exert spatial and
temporal control over signalling events. For example, the translocation of PtdSer
(which is almost exclusively reserved to the inner plasma membrane leaflet) to the
outer leaflet, promotes activation of the clotting cascade and provides a phagocytosis
signal to myeloid cells30,73. Active membrane redistribution also allows the generation
of lipid rafts and both inward and outward membrane blebs (including structures
such as caveolae)69. Changes in membrane lipid distribution also alter the fluidity of
regions of the bilayer, facilitating formation of pseudopodia and other membrane
extrusions74. The simplest mechanism by which phospholipids translocate across
membrane leaflets is spontaneously under equilibrium69. For small and/or negatively
charged lipids like cholesterol and diacylglycerol, the “half life” for translocation is
seconds, and their retention is controlled by the relative abundance of larger lipids
with which they interact. For the large glycerophospholipids, the half life is hours
to days, and so effective control of membrane position relies on transporters that
transfer lipids to the opposing layer71.
Eukaryotes and some prokaryotes express a family of P-type ATPases which
actively pump cations across membrane against their electrochemical gradient75.
The P type IV (P4) ATPases catalyse unidirectional transport of phospholipids
across lipid bilayers and therefore maintain asymmetry. This family of transporters
largely transfers PtdSer, PtdEth and possibly PtdCho from the outer to the inner
membrane leaflet (with particularly high selectivity for PtdSer). Lipid transporters
which act in this direction only are collectively known as flippases76. Conversely, the
ATP-binding cassette (ABC) transporters (specifically the ABCA subfamily) catalyse
the ATP-dependent efflux of cholesterol and PtdSer to the outer membrane leaflet,
and are known as floppases77. The actions of flippase and floppase transporters on
PtdSer directly oppose each other, but the inward translocation is heavily favoured
at equilibrium, and so PtdSer is actively retained in the cytosolic leaflet.
Changes in intracellular Ca2+ rebalance lipid equilibrium by inhibiting flippase
activity, and enhancing floppase and scramblase activity. Scramblase enzymes
are Ca2+-dependent but ATP-independent enzymes which allow the bidirectional
movement of lipids across both membrane leaflets78. As the process is passive,
activation of scramblases allows Le Châtelier’s principle (that a system in equilibrium
adjusts itself to counteract the effect of an applied change) to take precedence, where
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membrane distribution becomes more equal. The net effect of decreased flippase and
increased floppase and scramblase activity is significant exposure of PtdSer on the
cell surface.
A key scramblase which appears important in PtdSer exposure is TMEM16F, a
Ca2+-activated Cl− channel79. A loss of function mutation in TMEM16F has been
linked to Scott syndrome, a bleeding disorder due to impaired scramblase activity
and thus, reduced microvesicle release in platelets80. Mice in which the TMEM16F
gene has been knocked out exhibit reduced PtdSer exposure on activated platelets
and subsequent defects in coagulation and haemostasis similar to those in Scott
syndrome78. Exposure of murine TMEM16F-/- platelets to high concentrations of the
Ca2+ ionophore A23187, or human Scott syndrome platelets to three hour stimulation
with proapoptotic agonist ABT737, is still able to induce PtdSer exposure, suggesting
a role of TMEM16F-dependent and independent PtdSer exposure on activation and
apoptosis, at least in platelets78,81. While it seems TMEM16F is the most important
scramblase involved in rapid PtdSer exposure, other scramblases may therefore play
a role.
As many cytosolic membrane lipids act as anchors for the cytoskeleton, this
redistribution severs those connections, freeing the patch of membrane to change
shape (which is facilitated by the change in ratio of membrane pliability between
the leaflets).
The timely convergence of all these mechanics allows the formation of a membrane
bleb which takes a passive sample of the cell’s plasma membrane and cytosolic
constituents, as well as being actively enriched in others82. Due to the extremely
rapid release of microvesicles upon stimulation, it seems reasonable to assume
this enrichment occurs at susceptible membrane patches (or lipid rafts) prior to
vesiculation.
Traditionally, most literature has defined microvesicles as being PtdSer+. An
issue with this definition, however, and the biogenesis pathway so far described,
is that not all microvesicles are positive for PtdSer, and in fact the majority of
microvesicles in plasma are PtdSer−83,84. There may be two explanations for this:
firstly, that all microvesicles do express PtdSer on release, but either lose expression or
the expression is masked by the many PtdSer-binding proteins present in plasma, or
secondly that PtdSer− microvesicles exist and there is therefore a biogenesis pathway
which is independent of the lipid’s exposure. The former explanation seems unlikely
as gold labelling of annexin A5 (anxA5) in cryo transmission electron micrographs
produced by the Brisson group shows a clear distinction between microvesicles which
express PtdSer and those which are completely negative83.
Whether PtdSer exposure is involved or not, once an outward bleb has formed,
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a fission event must occur at the neck of the bleb to release the microvesicle into
the extracellular space. Although this fission event has not been delineated in the
context of ectocytosis, it is likely similar to dynamin-mediated fission observed in
endocytosis85.
1.3 Isolation of microvesicles
The isolation of microvesicles from biological fluids and cell culture medium requires
the removal of cells and objects in a similar size range as microvesicles, such as
platelets, apoptotic bodies and exosomes, and should have minimal protein contami-
nation. The most common technique to isolate microvesicles both historically and
currently is differential centrifugation, although commercially available isolation kits
are now in use (discussed below).
Differential centrifugation involves applying centrifugal fields to homogeneous
mixtures of particles at sequentially higher relative centrifugal forces to speed up
particle sedimentation. The larger and denser a near-spherical particle is (with
respect to the fluid in which it is suspended), the faster it will sediment. Therefore
generally speaking, larger objects sediment and form pellets faster than smaller
objects in the same suspension. Thus the basis of differential centrifugation in
microvesicle isolation is to pellet cells during low-force centrifugation, collect the
cell-free supernatant (within which any smaller particles are still mainly present) and
apply a greater centrifugal force to pellet platelets and apoptotic bodies, resulting in
a suspension highly enriched in microvesicles and exosomes. As microvesicles are
generally larger than exosomes, the next step is to pellet the microvesicles while
leaving the majority of exosomes in suspension.
While this process is easy, cheap and the most widely used method for the isolation
of both microvesicles and exosomes, it has two main problems associated with it.
Firstly, due to small overlaps in size distribution, microvesicle preparations will
typically contain contaminating platelets and/or apoptotic bodies (depending on the
source) and exosomes. As such, it is virtually impossible to generate a pure population
of microvesicles; thus preparations should be referred to as microvesicle-enriched.
The second and most difficult to control for problem is the breadth of centrifugation
forces and times reported in the literature for each step of the centrifugation process.
There is currently no consensus on the most appropriate parameters to use with most
laboratories using their own protocols. Parameters reported for pelleting cells range
from 600×g for 10 min86 to 4,000×g for 20 min (twice)87, for platelets and apoptotic
bodies range from 1500×g for 20 min to 13,000×g for 2.3 min88 and for microvesicles
range from 10,000×g for 30 min89 to 100,000×g for 90 min90. This variation in
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isolation also explains variations in reported vesicle size distributions91–93.
Even if a standard relative centrifugal force and centrifugation time were agreed
between researchers, these parameters are not enough to standardise pelleting time
without controlling for different k factors between centrifuges. The k factor (or
clearing factor) parameter is intrinsic to a particular centrifuge and rotor combination
and represents the relative efficiency of that combination at pelleting particulate
matter. The k factor can be used to estimate the sedimentation time for a particle





where t is the time in hours it takes for the particle to sediment and s is the particle's
sedimentation coefficient. k for a particular centrifuge setup depends on the minimum
and maximum rotor radius, the angular velocity (which can be calculated from the





where rmax and rmin are the maximum and minimum rotor radii, respectively. As
such, as k increases, so does the time required for a particular particle to sediment.
This equation gives kmax for the centrifuge setup; for runs which use lower than
maximum speeds, the kadjusted is calculated
94,95:






The sedimentation coefficient, s, is a property of the particle in suspension which
depends only on its mass, radius, and the viscosity of the medium through which it





where m is the mass of the particle, η is the viscosity of the fluid and r0 is the
particle radius. Combining these equations yields a single model to estimate the















Using this model, Figure 1.2 shows the estimated sedimentation time for a microvesicle
with 150nm radius and 0.24pg mass96 in different fluids at 20oC and 4oC, at a range
of k factor setups. Figure 1.3 illustrates the change in fluid viscosity as a function















































Figure 1.2: Hypothetical pelleting times of microvesicles. Hypothetical
curves generated using Equation 1.5, displaying pelleting time for microvesicles of
radius 150nm and mass 0.24pg with increasing centrifugal force. Panels indicate
pelleting times in different fluids at 20oC and 4oC at a range of centrifuge k factors.
Dotted lines highlight the range of k factors for which the particles pellet between
20 and 30 minutes at 20,000×g.
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of temperature (at 1 atm) for these fluids with the corresponding sedimentation
coefficients and sedimentation times of microvesicles under these conditions (assuming
150nm radius and 0.24pg vesicle mass).
It is important to note, however, that this model makes several assumptions.
Firstly that the particles are perfectly spherical and remain so in the centrifugal field,
that the particles do not come into contact with the walls of the tube or each other,
that the fluid viscosity is constant along the path of the vesicle and that the speed
of the rotor is immediately that which is specified. As most of these assumptions
are not viable and as the mass of an individual particle is very difficult to measure
(only a single paper has attempted such measurement96), this model serves as an
approximation only. What this model does solidly allow, however, is the comparison
of relative pelleting times between centrifuge setups with different k factors.
As the field of vesicle research has expanded, a number of commercially available
kits for isolating exosomes from samples have been released which can be used
to separate them from microvesicle preparations. These antibody-based kits still
require larger contaminants to be removed by differential centrifugation first, and
include products such as ExoQuick™ (System Biosciences, USA), ExoCap™ (MBL,
USA), Total Exosome Isolation Reagent (Thermo Fisher, USA), Exo-spin™ (Cell
Guidance Systems, UK) and PureExo® (101Bio, USA). While used by some labs
due to their applicability to small volumes (where centrifugation would result in
excessive sample loss), a handful of papers comparing one or more of these kits to
differential and/or sucrose-gradient centrifugation have typically found that while
they may improve yield, they may form vesicle aggregates and may co-precipitate
non-exosome associated proteins97–99.
Finally, sucrose density gradient centrifugation has been successfully used to
isolate highly enriched microvesicle populations100, but requires centrifugation times
in excess of 15 hours, and depending on the downstream application, the microvesicle
fraction may have to be centrifuged again in buffered-saline to remove the sucrose
buffer (causing excessive vesicle loss).
1.4 Detection, enumeration and phenotyping of
microvesicles
1.4.1 Electron microscopy
Due to their small size, it is nearly impossible to visualize, size and quantify mi-
crovesicles using conventional light and fluorescent microscopy techniques. The gold
standard in accurate small particle visualisation and sizing is cryo transmission






































































Figure 1.3: The importance of fluid viscosity on particle pelleting time. A
Changes in viscosity of human plasma, serum, RPMI medium and water/phosphate-
buffered saline (PBS) at different temperatures. B Differences in sedimentation
coefficient and sedimentation time of 150nm radius, 0.24pg mass microvesicles in
fluids of decreasing viscosity. Labels indicate individual conditions.
electron microscopy which, when combined with immunogold labelling, can be used
to probe for up to two markers simultaneously on the vesicles.
While scanning electron microscopy can generate high detail images of the 3
dimensional structure of small objects and can also be combined with immunogold
labelling, the non-aerial topography data it generates makes it hard to measure
the dimensions of vesicles. Standard transmission electron microscopy generates
images of planar electron density and allows the dimensions of a field of vesicles
(and their purity) to be measured. Sample processing for standard transmission
electron microscopy can be harsh on biological structures and may introduce artefacts.
For example, a once considered hallmark of exosomes, that they exhibit a “cup”
shape when imaged by electron microscopy101, is due only to the dehydration step
involved in sample processing102. In fact, exosomes and microvesicles are spherical,
as demonstrated by cryo transmission electron microscopy which involves as little
sample manipulation as possible102. The sample is snap frozen in liquid ethane and
imaged, such that the specimens are unfixed and can be imaged in their native
structure.
The main caveats with these techniques, however, is that they are low throughput,
highly technical, and don’t allow estimation of vesicle concentration103. In response
to this poor scalability, a staple method of particle measurement in the microvesicle
field has become flow cytometry.
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1.4.2 Flow cytometry
Flow cytometry has revolutionised multiparameter characterisation of cells at ex-
tremely high throughput. It allows quantitative assessment of relative and absolute
object numbers per unit volume within and between samples, and semi-quantitative
assessment of changes in cell phenotype, viability and cell cycle, Ca2+ flux and more.
Flow cytometry is commonly used to discriminate between distinct cell populations
by their relative size by measuring the forward angle light scatter (FSC), and their
relative granularity by measuring right angle light/side scatter (SSC). When samples
are combined with bead standards of known concentrations, absolute concentrations
of different cell populations can be reported. For these reasons, flow cytometry has
become a common method of identifying and phenotyping microvesicles (by their
cell of origin and/or contents). Traditionally, however, published flow cytometry
data on microvesicles has been plagued by uncritical use of instruments, and poorly
controlled experiments, making the interpretation and reliability of much of the
published experiments difficult. While flow cytometry can be the most powerful
method of analysing vesicles, there are many challenges and limitations which must
be acknowledged and mitigated by the researcher.
1.4.2.1 Differences in refractive index
The most commonly used method of microvesicle identification in aqueous samples
is by their size. In cytometry, by including beads of known sizes (typically in the
range of 100nm to 1,000nm in diameter), the microvesicle population can in theory
be identified by its position in the FSC and SSC plot, relative to the size beads.
There are, however, significant problems with this strategy. Firstly, while the FSC
parameter is often thought of as a direct measurement of object size, it is not.
Generally speaking, the greater the diameter of an object passing through the scatter
laser, the greater its FSC will be, relative to other objects of the same refractive
index. The issue with using beads to size (and identify by size) microvesicles is that
polystyrene and latex beads possess refractive indices of ~1.61 compared to ~1.38
for microvesicles104–106. This is compounded by the fact that refractive index varies
considerably within a single population of vesicles, largely dependent on diameter,
and between vesicles from different sources106. Therefore one cannot simply construct
a standard curve of bead sizes and interpolate microvesicle size from their FSC107.
This difference in refractive index can also convince researchers to exclude much of
the microvesicle population, which may fall below the 100nm or above the 1,000nm
bead populations on the FSC and SSC plot.
Synthetic liposomes of known sizes and refractive indices more similar to those of
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biological vesicles have been shown to be superior calibrators than beads, but these
must be generated freshly for each experiment and are not commercially available108.
Additionally, the size and coefficient of variance of the size will depend upon and vary
with each generation, and the liposomes must themselves be sized using a technique
able to resolve small particle size accurately.
1.4.2.2 Vesicles scatter very little light
The most common way of triggering events when analysing cells on a flow cytometer,
such that the pulse data is recorded and integrated for a particular event, is by
setting a threshold on the FSC detector. For particles as large as cells, this is more
than sufficient to detect each object as it passes through the flow cell, as the amount
of light they scatter in the forward direction is considerable. Cells scatter so much
light in the forward direction that, in many instruments, a photodiode is used as its
detector rather than the more sensitive photomultiplier tube (PMT) generally used
for other parameters, and this is preceded by a neutral density filter to prevent the
detector from saturating easily.
The light scatter produced and detected by a particle depends on the ratio
between the particle diameter and the wavelength of light it is interrogated with,
the refractive index of the particle, the angle of light detection, and the intensity
of the laser. This creates problems when trying to detect the scattered light of
microvesicles, whose diameter is around or even smaller than the wavelength of the
scatter laser (most commonly a 488nm).
The phase function of scattered light (the probability density that photons of
light will be scattered in any direction in a sphere) for particles of varying diameters
from lasers of different wavelengths is simulated in Figure 1.4. Note that while the
shape of the phase function of submicron particles can be seen when logarithmic,
the scatter becomes negligible when plotted in linear coordinates. Note also that
as the ratio of particle diameter to wavelength approaches zero, the phase function
approximates Rayleigh scattering, where light is scattered equally in all directions,
and that for cell-sized particles, the phase function exhibits Mie scattering, where
light is predominantly scattered in the forward direction109. Finally, these simulations
demonstrate that forward scatter is inversely proportional to laser wavelength. As
such, when the cytometer is set up to trigger on FSC, the majority of microvesicles
do not scatter enough light to be detected above the optical and electronic noise.
The ability to resolve small particle populations by their FSC is also variable between
cytometer models and even between machines of the same model because it is the
most alignment-critical parameter (and thus most susceptible to variation). SSC has
been used as a trigger as it is typically detected with a PMT and is not preceded
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by a neutral density filter, allowing for more sensitivity, but many of the smaller
vesicles still will not scatter enough light to be detected above the noise.
Alternatively, the wavelength of the scatter laser can be reduced to decrease the
ratio between it and the particle diameter and increase the amount of scattered light.
Nevertheless, even when using violet or even ultraviolet lasers (typically 405nm and
355nm, respectively) for the scatter parameters, the majority of the microvesicle
population has a diameter smaller than this, and will scatter very little light.
Additionally, next generation flow cytometers are available which have much
lower limits of detection. These include the Apogee Micro and Micro-Plus (Apogee
Flow Systems, UK) small particle cytometers which are shown to have detection
limits of ~200nm and <100nm, respectively, especially when used in conjunction
with silica sizing beads (whose refractive index is more comparable to phospholipid
particles)110.
1.4.2.3 Separating weak signals from noise
Even in the absence of light, photodiode and PMT detectors produce a “dark current”
as background output. If a photon of light collides with either form of detector,
electrons are released to produce current. When the light received is being scattered
or released from particles in the flow stream of a cytometer, the number of photons
results in a peak of current output, where the current increases as the particle enters
the interrogation point, and declines again as it leaves, returning to dark current
output. As both optical and electronic noise can cause small fluctuations in the
dark current, what constitutes a peak generated by an object of interest must be
defined by setting a threshold current or “trigger”. If the output current of a detector
reaches this threshold, an event is “triggered”, and the electronics of the cytometer
can measure the width, height and area of the peak which are saved as data.
The voltage gain of the detector (which indirectly controls the number of electrons
produced in response to one photon) correlates with the noise of the dark current.
For example, if some optical disturbance in the flow cell, such as a bubble, causes
photons to be scattered onto the detector, the current generated during this event
would be larger if a high gain is applied to the detector, compared to if a low gain
were applied. This can become a problem when the signals from objects of interest
are very small, as increasing the detector gain will not only increase the current
generated by these objects, but also of fluctuations in the dark current.
When the detector voltage gain is high and the threshold is low on a scatter
parameter set as the instrument trigger, a large amount of optical and electronic
noise (although the former is far more consequential) masks much of the vesicle
population and raises the lower limit of detection. Sources of optical noise can be























































































































































































































































































Figure 1.4: Particle light scattering profiles. The shape of scattered light
from particles depends on their size (columns) and the wavelength of light (rows).
The polar axes denote angle of light scatter from the angle of incidence (for example,
in the flow cell of a flow cytometer), the y axis denotes the phase function of scatter
(the probability density of photons being scattered in that direction; log10 in the
top panel, linear in the bottom). Each facet shows the simulated phase function of
scattered light from a particle of a specific diameter, at a specific laser wavelength.
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split into those intrinsic to the sample, and those intrinsic to the cytometer.
Air bubbles in the sheath fluid can refract enough light to create scatter signals
of a similar intensity to those from vesicles, as can any salt aggregates or microbial
contamination. As such, degassing and filtering the sheath fluid prior to use can
remove these contaminants, as can running a detergent or bleach through the sample
line prior to acquisition or even widening the obscuration bar which blocks the
scatter laser in the line of incidence (if triggering on FSC). More drastic instrument
modifications to reduce noise include optimising the detection geometry, replacing the
FSC photodiode with a more sensitive PMT or, less drastically, switching the trigger
channel to one which employs a PMT (SSC for example)111. These optimisations,
however, become difficult when the cytometer is used by many researchers for many
applications; not to mention the increased risk of noise events in this situation. Noise
intrinsic to the sample can be from air bubbles, salt and protein aggregates (including
from antibody conjugates), membrane fragments and any other objects of a similar
size to vesicles.
In the last five years the main change in approach to tackle issues of low scatter
detection and high noise has been to switch from using scatter-based triggering, to
using fluorescence-based triggering instead. This involves running vesicles, all of
which have been fluorescently labelled with a fluorescent protein or dye, and using a
fluorescence channel as the trigger instead. The value of this approach is that the
fluorescence signal depends on the number of photons released from fluorophores
associated with the vesicle, and is therefore only indirectly related to vesicle diameter.
Although smaller vesicles will carry/contain fewer fluorophore molecules, if the
fluorophore is sufficiently bright, the signal will generally be considerably larger
than those in the scatter channels, and as such, a much greater proportion of the
population can be detected.
1.4.2.4 Avoiding coincidence
An often overlooked hurdle when analysing vesicles by flow cytometry is that due to
their small size, several microvesicles can pass through the interrogation point of the
laser at once, being recorded as a single, coincidence event. The major challenge
in detecting and excluding such events, which may give false positive results when
phenotyping or counting, is that traditional doublet discrimination techniques used
for cells do not work for microvesicles. This is due in part to microvesicles having a
much greater range of relative sizes than cells, where a vesicle 400nm in diameter may
have a scatter profile similar to two vesicles each 200nm in diameter (and therefore
the two events cannot be discriminated from each other) and also that the closer
a signal is to the instrument’s lower limit of detection, the greater stochastic error
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associated with the signal.
The only way to mitigate the contribution of coincidence events is to serially
dilute the vesicle sample and run each dilution. When the drop in threshold rate of
the cytometer becomes linear with sample dilution, the researcher can be confident
that the majority of the events recorded are single vesicles. The result is that any one
experiment may require three or more times the number of acquisitions as original
experimental samples.
1.4.2.5 Low antigen density
Perhaps the most challenging limitation of analysing vesicles by flow cytometry (and
indeed all analysis techniques) is that the total copy number of antigens of interest
per vesicle is very low, particularly in weakly expressed antigens.
A hypothetical relationship between vesicle size, antigen density and total antigen
copy number is modelled in Figure 1.5, using 5,000, 40,000 and 80,000 copies per
platelet as examples of low, medium and high antigen density, respectively. If a
platelet is assumed to have a 5µm2 surface area112, then the product of the antigen
densities for these copy numbers and the surface area of a vesicle (calculated as
π×diameter2) gives an estimate of the copy number for that vesicle. This relationship
assumes that the vesicle is perfectly spherical, that antigen density is uniform across
the membrane, and is only applicable to surface antigens (though vesicle volume
could in theory be substituted in the case of luminal antigens). Nevertheless, this
relationship predicts that for vesicles smaller than ~250nm, weakly expressed antigens
are very difficult to detect above background. A major implication of this is that
the true proportions of vesicle subsets in a population can be difficult or impossible
to ascertain, and that a vesicle preparation may be declared devoid of a particular
antigen when it is in fact weakly expressed.
This challenge can be mitigated in several ways, each of which aims to maximise
the signal to noise ratio of the fluorescence measurements. Firstly, fluorophores
which are as bright as possible (given as the product of the extinction coefficient
and the quantum yield) should be used and at concentrations titrated to maximise
the signal to noise ratio. The quantum yield (or efficiency) is the ratio of emitted
photons per absorbed photons, and the extinction coefficient is the amount of light
of a particular wavelength a compound absorbs (therefore fluorophores which absorb
more photons at a particular wavelength and emit a greater proportion of them will
be brighter).
The PMT gain voltages should be set so that a negative population is sufficiently
separated from noise, and the fluorophore panel should be designed such as to
minimise the amount of fluorescence compensation required. Finally, weak antigenic
























Figure 1.5: Relationship between the total copy number for a particular
surface antigen and vesicle diameter. The three coloured lines represent the
relationship for antigen densities equivalent to 5,000, 40,000 and 80,000 antigens
per platelet with a 5µm2 surface area. The dotted line represents the lower limit
of detection of the molecular equivalent of soluble fluorescein molecules for many
modern flow cytometers. Each relationship assumes the vesicle is perfectly spherical,
and that the antigen is uniformly distributed across the membrane.
signals can be amplified by probing for the antigen with an unconjugated primary
antibody, followed by a secondary antibody-fluorophore conjugate. The benefit of
this approach is that more than one secondary antibody may bind to one primary
antibody, thus increasing the number of fluorophore molecules per antigen. The
major drawbacks of this technique are that it requires more time and more controls
to ensure any signals seen are not a result of non-specific binding.
1.4.3 Nanoparticle tracking analysis
Nanoparticle tracking analysis is a technique that allows the size of individual small
particles and their concentration within solution to be quantified in high throughput,
where sample recovery is possible. The technique estimates particle size based on
their Brownian motion in solution i.e. smaller particles resonate at a higher frequency
than larger particles. Individual particles are imaged and tracked over time by a
video camera which detects the light they scatter from a laser which illuminates the
chamber.
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While fluorescent probes aren’t necessary for sizing and enumeration, they can
be included so that target particle populations can be identified and interrogated
(e.g. PtdSer+ vs. PtdSer− microvesicles) as the instruments can be fitted with an
excitation laser and fluorescence bandpass filters91. To circumvent the problem
of rapid photobleaching while fluorescently-labelled vesicles are being excited, this
technique is commonly performed under flow conditions, so that the time an individual
vesicle remains within the laser beam is minimal. Nevertheless, nanoparticle tracking
analysis has, as yet, poor fluorescence sensitivity compared to flow cytometry.
1.4.4 Tunable resistive pulse sensing
Another technique which is both sensitive and high throughput in quantifying vesicle
size is tunable resistive pulse sensing (TRPS). TRPS measures the current through
a nano-sized pore whose diameter can be dynamically changed (i.e. tuned) to allow
particles of varying sizes to pass through it. Particles on one side of the pore are
driven through it by a combination of pressure and voltage, and the impedance of
the pore is measured at 0.5MHz. As a single particle passes through the pore, it
increases the impedance (i.e. decreases the current passing through the pore), the
magnitude of which is directly proportional to particle volume, which is used to
measure particle radius. The duration of the impedance can be used to calculate
each particle’s ζ-potential, the potential difference between the surface of a particle
and the charge of its medium, and the frequency of impedances can be used to
calculate the concentration of particles in the medium113.
While TRPS has a similarly low size limit of detection as nanoparticle tracking
analysis and can estimate particle concentration, it is arguably less flexible in
phenotyping particles as there is no capability to measure fluorescence. Instead,
binding of aptamer probes to target molecules on microvesicles can be quantified
by measuring changes in ζ-potential. Aptamers are small peptide or oligonucleotide
molecules which are screened for their affinity to molecular targets of interest, however,
they are not as widely commercially available as antibody probes114.
1.4.5 Imaging cytometry
While nanoparticle tracking analysis and next generation flow cytometry provide
useful techniques for small particle analysis, one of the most powerful but underused
technologies is the ImageStream platform. Pioneered by Amnis, the Flowsight,
ImageStreamX and ImageStreamX Mk II are cytometers which take brightfield,
darkfield and fluorescent images of each object that passes through the flow cell.
The major implication of this is that the researcher can interrogate ambiguous
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populations by directly viewing the images associated with each event. In other
words, the user can see individual microvesicles and differentiate them from noise
and artefacts.
Not only do these systems allow visual inspection of microvesicles, they also boast
extremely minimal noise and therefore have lower limits of fluorescence detection,
allowing resolution of fluorescent objects as small as 20nm in diameter1. This is due,
in part, to their time delay integration mode of object imaging, which allows a single
particle to be imaged for orders of magnitude longer than in standard cytometers.
It must be noted, however, that while these instruments can resolve very small
fluorescent objects, as all object measurements are made directly from their images,
objects smaller than the wavelength of visible light (~400nm) cannot be resolved
using brightfield detection alone. Their resolution of particle SSC is similarly poor
compared to standard cytometers and so still rely on fluorescence triggering to resolve
as much of the microvesicle population as possible.
Usefully, ImageStream cytometers utilise syringe-driven sample injection, and
therefore accurately aspirate and measure the volume of sample injected into the
flow cell. This means the number of objects per mL of sample can be reported with
a reasonably high degree of accuracy without the need for counting beads. The
implication of this is that the density of microvesicle preparations can be adjusted
and standardised prior to their experimental use.
Additionally, the ImageStream technology has an extraordinary number of param-
eters that can be used to characterise populations. These include up to 9 fluorescent
channel parameters (the images of which can be overlaid with each other and the
brightfield image), morphology measurements, such as circularity, aspect ratio and
symmetry, SSC and many more. Although the instruments do not have a FSC
parameter, object area and/or diameter can be used to estimate relative size. Using
these parameters, it was shown that the technology allows linear separation of size
beads and microvesicle into discrete, resolved populations (Figure 3.1).
The main drawback of the ImageStream platform, however, is that because data
on each object is collected via a charge-coupled device (CCD) rather than a PMT,
the instrument has a smaller dynamic range for separating fluorescence signals than
most modern flow cytometers.
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1.5 Physiological and pathophysiological roles of
microvesicles
1.5.1 Microvesicles as signalling vectors
The promiscuous nature of microvesicle release raises the question of how the functions
of such ubiquitous structures can be controlled and fine-tuned. The protein, lipid and
nucleic acid content of microvesicles depends on the cell type from which they bud,
and also on the phenotype of that cell. For example, macrophages whose phenotype
has been polarised in vitro release microvesicles containing the mRNA of genes
associated with that phenotype115. Horizontal transfer of these mRNA transcripts
within microvesicles resulted in their translation into protein in receptive macro-
phages, conditioning their phenotype to that of the donor cells. After performing
transcriptomics on both the donor cells and their offspring microvesicles, the authors
noted that while the expression of many transcripts was comparable between the
two, some were enriched in the microvesicle fraction. This supports the view that
microvesicles take both a passive sample of the cell’s state, and are also selectively
packaged. While mechanisms of protein and lipid trafficking to the membrane have
been described116–118, how mRNA is stably packaged into these vesicles is unknown.
Another question raised by this mode of nucleic acid transfer is how the luminal
contents of the microvesicle are safely conveyed into the cytosol of the target cell. The
uptake mechanisms of microvesicles by different cell types is a much debated issue.
Several papers ascribe their internalisation by most cell types to be via endocytosis
and not phagocytosis (a process usually associated with larger objects)119, while others
suggest that vesicle uptake by macrophages and dendritic cells is phagocytic and
pinocytic, but not endocytic120. Either way, both pathways result in the formation of
lysosomes or, in the case of endocytosis, recycling to the plasma membrane121. While
the latter mechanism may explain the transfer of membrane proteins, how bioactive
lipids, mRNA and miRNA species escape lysosomal degradation is not described.
While passive fusion of the microvesicle and cell membranes has been proposed, the
protein-rich plasma membrane does not readily permit this form of assimilation122.
Nevertheless, microvesicles and exosomes represent the only mechanisms of long
distance RNA transfer, as they are stable in plasma whereas RNA itself is not123.
Not only do microvesicles transfer bioactive molecules to other cells, they partici-
pate in juxtacrine signalling by coming into direct contact with their target cells.
Ligands expressed on the surface of the microvesicle can bind their cognate receptors
and elicit a response independent of their uptake. In this situation, microvesicle in-
ternalisation may serve as a signal termination mechanism. Circulating microvesicles
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can also interact with plasma proteins, both sequestering and reducing bioavailability
of some, and modulating the function of others. For example, microvesicle-exposed
PtdSer activates the clotting cascade by allosterically modulating factors X(a) and
V(a), enhancing prothrombinase activity43. Indeed, for their surface area, microvesi-
cles are considerably more potent at inducing platelet aggregation than platelets
themselves, and are the main mechanism for the rapid induction of haemostasis.
This is supported by data from patients diagnosed with Scott syndrome, whose
impaired microvesicle release manifests most obviously as a severely diminished
clotting response124.
The most deeply studied population of microvesicles is platelet-derived. This is
due to their abundance in plasma (second only to erythrocyte-derived microvesicles1),
the fact they were the first population observed by Chargaff and West6, and perhaps
because their physiological (and pathophysiological) importance is so immediately
apparent. However, all cell types release these nanostructures into their respective
biological compartments and it stands to reason that all microvesicles, from every
cell type, in every tissue and microenvironment within the body elicit functions that
contribute in some way to health and possibly disease. While much progress has
been made in the role of these vesicles in oncology, cardiovascular, respiratory and
neurological health39, the role of microvesicles in inflammation and immunology will
be discussed below.
1.5.2 Microvesicles in adaptive immunity
One of the most exquisite mechanisms in adaptive immunity is the processing and
presentation of exogenous antigens on the surface of antigen-presenting cells (APC),
such as dendritic cells and macrophages. In the classical model of lymphocyte cell
activation, an APC must provide two activation signals: a major histocompatibility
complex (MHC)-mounted non-self antigen (which binds the T or B cell receptor),
and co-stimulatory molecule expression (CD80 and CD86 which activate CD28
expressed on the lymphocyte)125. While much of this process is mediated by direct
phagocytosis and processing of pathogens by APCs and the formation of a cell-cell
immune synapse, both antigen acquisition and presentation can be mediated by
vesicles. Vaccination of healthy mice with cell-free tumour-derived microvesicles
results in dendritic cells which are positive for tumour antigens, and able to induce
an antigen-specific adaptive response126. This supports a role of microvesicles in long
distance cross-presentation and acquisition of pathogenic antigens.
Once positive for an exogenous antigen, APCs (even weaker APCs like B cells)
activated by danger or pathogen-associated molecular pattern (PAMP)s, such as
LPS, release microvesicles and exosomes carrying the antigen on their surface101,127.
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In theory, provided these vesicles meet the same requirements as immunogenic
APCs (i.e. express high density MHC-mounted antigen and CD80/CD86), then they
will be able to induce lymphocyte activation in the absence of their donor APCs.
There is also evidence of vesicular antigen presentation which is independent of
MHC expression, although the role and importance of this mechanism in vivo is not
clear128.
Activated T cell-derived microvesicles express Fas ligand which induces NFκB
translocation in vascular endothelium and smooth muscle, upregulating nitric ox-
ide synthase and cyclooxygenase-2129,130. CD4+ microvesicles can activate B cells
similarly to APC vesicles, and CD8+ microvesicles may contribute to the killing of
infected cells131.
In addition to their physiological effects, inappropriate or modulated microvesicle
release and signalling can amplify disease processes. For example, ectocytosis can
be hijacked during viral infections. In the case of HIV, infected T cells release
virus-laden microvesicles which provide a protective vector for viral dissemination132.
HIV+ microvesicles in plasma also suppress dendritic cell activation by binding to
CD44133. Insufficient dendritic cell activation is a major hurdle in the development
of a HIV vaccine and so this represents a targetable mechanism.
1.5.3 Microvesicles in innate immunity
The cells that constitute the innate arm of our immune system are the sensors and
first responders to inflammatory stimuli like infection and damage. Tissue resident
macrophages, dendritic cells and mast cells express pattern recognition receptors,
such as toll-like receptors (TLR) and Nod-like receptors, to detect bacterial, viral
and fungal molecular patterns. Engagement of TLR4 by LPS in monocytes, macro-
phages or dendritic cells induces the transcription of pro-interleukin (IL)-1β134.
Engagement of the purinergic ligand-gated ion channel P2X7 by ATP (which is
released from cells undergoing necrosis and acts as a damage-associated molecular
pattern (DAMP) when extracellular) induces inflammasome activation and the
subsequent cleavage and release of bioactive IL-1β135. Unusually, however, IL-1β
belongs to a class of proteins which lack an N terminal signal peptide which targets
them to biological membranes and, as such, cannot be secreted from the cell via
the classical secretory pathway136. A number of “leaderless” proteins have been
identified including thioredoxin, macrophage migration inhibitory factor, galectins 1
and 3, fibroblast growth factors 1 and 2, IL-1α, IL-1β, IL-18 and annexin A1 (anxA1),
all of which are readily secreted137. How these leaderless proteins were released from
the cell remained a mystery until IL-1β was found to cofractionate with endosomes
and lysosomes in monocyte preparations, suggesting it was released via a vesicular
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pathway138. In 2001, MacKenzie et al. demonstrated the rapid release of IL-1β+
microvesicles upon inflammasome activation in LPS-primed monocytes32, and this
has since been shown to depend on other vesicular pathways as well139. The presence
of a number of leaderless proteins has since been confirmed within both exosomes
and microvesicles, suggesting vesicular export as a common secretory pathway for
these proteins140,141.
The uncoupling of IL-1β synthesis by mononuclear phagocytes from its release is
a biological safeguard against inappropriate inflammation. By limiting IL-1β release
to vesicles, an initial PAMP signal is usually insufficient to induce its secretion142.
Instead, primed cells must receive a temporally distinct second signal which induces
microvesicle release (such as ATP generated during tissue damage).
IL-1β+ microvesicles stimulate other tissue resident macrophages and dendritic
cells to release pro-inflammatory cytokines, such as IL-6 and tumour necrosis factor
α (TNFα) and chemokines, such as CCL2, CCL5, CCL22 and CXCL8, to activate
the local endothelium and create chemotactic gradients for neutrophils, monocytes
and lymphocytes143. Engagement of the IL-1 receptor on endothelial cells by these
microvesicles induces the release of IL-6, IL-8, GM-CSF and PAF, and expression
of P-selectin within minutes, E-selectin within ~4 hours and ICAM-1 and VCAM-
1 within ~6 hours144. Endothelial cells can also be activated by platelet-derived
microvesicles containing IL-1β35.
Changes to vascular adhesion allow circulating leucocytes to tether and roll
across the activated endothelium and eventually extravasate into the tissue. Typ-
ically, neutrophils are the first circulating cell type which capture and become
activated, upregulating their expression of CD11b and shedding L-selectin145. Acti-
vated neutrophils on the endothelium release microvesicles enriched in complexed
CD11b/CD18, and P-selectin glycoprotein ligand-1 which activate GPIba and P-
selectin, respectively on platelets, activating them to promote thrombus formation
and further endothelial cell activation82.
Despite their capacity to propagate inflammation and induce damage, activated
neutrophils release large numbers of microvesicles that are enriched in the potent
anti-inflammatory and pro-resolving protein anxA136. These anxA1+ neutrophil
microvesicles disrupt the interaction between endothelial cells and neutrophils both
in vitro and in vivo by ligating anxA1’s cognate receptor ALX/FPR2. The final step
during neutrophil paracellular transmigration is the elongation of a uropod which
fills the space through which the neutrophil is transmigrating146. The intravital
microscopy experiments performed in this paper show that when transmigrating
neutrophils finally retract this uropod, they often leave a microvesicle-like vesicle
behind on the luminal side of the vessel wall. Although the purpose of these vesicles
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and their similarity to ectocytic microvesicles is not fully known, they may restrict
further leucocyte transmigration through anxA1 and by sterically plugging loose
endothelial cell junctions.
Endothelium-activated monocytes release tissue factor+ microvesicles which
promote thrombus formation and haemostasis147. During monocyte transendothelial
migration, monocyte-derived CCR5 is transferred via microvesicles to endothelial
cells148. As CCR5 is one of the main receptors used by HIV for internalisation, this
process was shown to make inflamed endothelium more susceptible to infection.
In the case of infectious disease, neutrophils stimulated with opsonised bacte-
ria release microvesicles which are highly bacteriostatic compared to microvesicles
generated spontaneously or with phorbol myristate acetate149. Microvesicles from
opsonised Staphylococcus aureus-stimulated neutrophils contain functional myeloper-
oxidase and lactoferrin which may explain some of their antibacterial effect, although
blockade of microvesicle CD18 (β2 integrin) reverted the inhibition of bacterial
growth. The authors observed that these microvesicles formed Ca2+-dependent,
vesicle-bacteria aggregates via CD18 which prevented growth of Staphylococcus au-
reus and Escherichia coli (but not Proteus mirabilis) and made them available for
phagocytosis by myeloid cells (regardless of whether they were opsonised). This either
suggests that neutrophils release microvesicles relatively responsive to the pathogen
that stimulated them, or simply that Proteus mirabilis was resistant to their effects
in this system. In the same publication, the presence of these microvesicle-bacteria
aggregates was confirmed in patients with bacteraemia whereas they were absent
in healthy controls. These microvesicles therefore represent a novel bactericidal
mechanism in neutrophils. Whether other leucocytes, such as natural killer cells,
monocytes and macrophages, can generate pathogen-responsive microvesicles has
not been investigated.
In the inflammatory microenvironment, there is some evidence that neutrophil
microvesicles can modulate macrophage phenotype and dendritic cell activation.
Human monocyte-derived macrophages treated with microvesicles isolated from
TNFα-stimulated neutrophils expressed lower levels of IL-1β, IL-6, IL-8, IL-10, IL-
12p70 and TNFα in response to zymosan and LPS, suggesting a lower extent of
activation37. Macrophages treated with these microvesicles released TGFβ regardless
of zymosan or LPS which, along with PtdSer, appeared responsible for many of the
phenotypic effects seen. In similar experiments by the same group, monocyte-derived
dendritic cells matured more slowly in response to LPS when treated with neutrophil
microvesicles and expressed lower levels of CD86 and MHCII150. Macrophages
stimulated with neutrophil microvesicles also exhibit a greater efferocytic capacity151.
Dendritic cells stimulated with neutrophil microvesicles during maturation were
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also less phagocytic of zymosan particles and less able to induce allogenic T cell
proliferation. As with macrophages, microvesicle treatment induced TGFβ release
from dendritic cells regardless of other treatments, and some of these effects were
dependent on PtdSer. Microvesicle modulation of inflammatory cytokine and surface
protein expression was found to be mediated by the interaction between PtdSer on
the microvesicle, and the receptor tyrosine kinase Mer (most likely via the Protein
S and/or Gas6 scaffold proteins). Release of TGFβ was shown to be independent
of PtdSer, however150. The activation of platelets by pre-transmigrated neutrophil
microvesicles may explain their apparent shift between inducing and inhibiting
inflammation pre and post transmigration, respectively.
1.6 The resolution of inflammation
The functions served by inflammation are purely protective and have evolved in
response to selection pressure from pathogenic infection and tissue damage. Shortly
after detection of a noxious stimulus, local vascular permeability increases and innate
leucocytes infiltrate the affected site which typically becomes reddened, swollen, hot,
painful and may lose function. During the course of physiological inflammation, the
cellular infiltrate contains and removes the injurious stimulus before repairing the
damaged tissue, leaving the site and restoring it to its homeostatic condition. The
process of restoring inflamed tissue to its normal state is called the resolution of
inflammation, a term whose first documented usage was in 1838152.
A deprecated view of the transition between inflammation and resolution was
that removal of the initial stimulus leads to a transient decline in inflammatory
signalling, and passive deactivation of the infiltrated cells. A wealth of evidence
opposes this view, favouring the active resolution hypothesis which states that for
inflammation to resolve itself, a network of active cellular and signalling events must
occur to restore tissue homeostasis153. The majority of inflammatory events resolve
themselves appropriately. The situation where resolution is impaired or delayed is
termed chronic inflammation and can ensue as a result of excessive pro-inflammatory
and/or insufficient pro-resolution signals153. It is important to note here that the
terms anti-inflammatory and pro-resolving are not synonymous. Anti-inflammatory
signals directly counter inflammatory signals (IL-1 receptor antagonist for example).
Pro-resolution signals may do this, but also initiate active processes which result in
tissue homeostasis. Our understanding of these processes is reviewed below.
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1.6.1 Lipid class switching
The resolution of inflammation is programmed by early inflammatory events. When
granulocytes extravasate and become activated, they promote transient lipid class
switching of arachidonic acid products from the classical prostaglandins and leuko-
trienes to pro-resolving lipoxins154. Lipid class switching also involves the conversion
of the ω-3 polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic
acid (DHA) into E series resolvins, and protectins, maresins and D series resolvins,
respectively155. These pro-resolving lipid mediators collectively reduce vascular
permeability, inhibit further neutrophil transmigration, promote recruitment of non-
phlogistic monocytes, induce neutrophil apoptosis and promote their efferocytosis
by macrophages156–160.
1.6.2 Apoptosis and efferocytosis
Neutrophil apoptosis at the site of inflammation is considered one of the fundamental
checkpoints in inflammation resolution. Transmigrated neutrophils typically live 1
to 2 days before undergoing constitutive or induced (by macrophage-derived Fas
ligand for example) apoptosis161,162. As opposed to necrosis which releases cytosolic
DAMPs and is pro-inflammatory, apoptosing neutrophils expose PtdSer on their
surface, which signals them for efferocytosis (in the presence of adaptor proteins,
such as protein S or Gas6)163. Efferocytosis and contact with neutrophil apoptotic
bodies decreases expression of TNFα , IL-12, IL-1β and IL-6, and increases expression
of IL-10 and TGFβ in macrophages151. This switching of macrophage phenotype
also promotes their production of lipoxins, DHA products and E series resolvins
while decreasing their production of classical eicosanoids164. IL-10 and TGFβ further
alter macrophage phenotype, enhancing efferocytosis and conditioning them into a
“wound healing” phenotype which promotes matrix deposition, tissue remodelling
and repair165. Adenosine released from apoptotic and necrotic neutrophils also
induces macrophage vascular endothelial growth factor (VEGF) production which is
important for endothelial and epithelial repair166.
1.6.3 AnxA1
Neutrophils, monocytes and macrophages store large amounts of the pro-resolving
protein anxA1167. In neutrophils, the majority of anxA1 is stored in the tertiary
(gelatinase) granules which fuse rapidly with the membrane upon attachment to the
endothelium168. AnxA1 is also found in the cytosol, where it rapidly localises the
cytosolic leaflet of the plasma membrane at high intracellular Ca2+ concentrations
and binds PtdSer169–171. Surface expression of anxA1 facilitates juxtacrine signalling
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from neutrophils to other myeloid cells and endothelium which express ALX/FPR2,
while release of anxA1+ microvesicles allows for paracrine signalling. In addition to
inhibiting neutrophil recruitment to the inflamed site, anxA1 promotes neutrophil
apoptosis, the efferocytic capacity of macrophages (as well as regulating their TNFα
and IL-6 production) and downregulates the degranulation of mast cells172.
1.6.4 TAM receptors
Tyro3, Axl and MerTK form the TAM family of receptor tyrosine kinases. This
receptor family binds to PtdSer via the adaptor proteins Gas6 and Protein S, and
promotes the clearance of apoptotic moieties and regulation of the activation of
innate leucocytes173. All three members are expressed by macrophages, dendritic
cells, NK cells and platelets, with MerTK expression being absent in monocytes
before transmigration174, Tyro3 also being expressed in neuronal tissue175, and Axl
being expressed ubiquitously, but most highly in endothelium176.
Of the family, MerTK is the best characterised member, especially with regard to
macrophage function. Activation of MerTK in macrophages by PtdSer-Gas6/Protein
S conjugates induces signalling through two distinct pathways. The first is PI3 kinase-
linked and results in rac-mediated cytoskeletal rearrangement and the formation
of a phagosome177. The result of this is efferocytosis of apoptotic bodies and
cells, particularly neutrophils, by macrophages. The second pathway involves the
MerTK dimer complexing with the type I IFN receptor dimer173. This results in
phosphorylation and nuclear translocation of the STAT1 transcription factor, which
drives expression of SOCS1 and SOCS3 which suppress TLR and inflammatory
cytokine signalling. Activation of this pathway induces a wound-healing phenotype
in macrophages164.
The importance of MerTK in clearing self antigens and promoting resolution
is exemplified in data showing an accumulation of apoptotic cells and increased
infarct size post myocardial infarction in mice178. Similarly, in a model of pulmonary
fibrosis, mice deficient in MerTK experienced more severe lung damage in response
to bleomycin179. Indeed, loss of any one of the TAM family members in single,
double, or even triple knockout mice, results in impaired clearance of dead cells, and
supra-physiological inflammation180,181.
While Gas6 and Protein S are required for signalling, there are no data suggesting
this is limiting for PtdSer to achieve efficacy. This is likely attributable to their
autocrine secretion from TAM-expressing cells182.
The final stage of resolution is the intravasation of macrophages into the lymphat-
ics where they travel to draining lymph nodes and restore the number of resident
leucocytes to pre-inflammation numbers183.
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1.7 Diversity of the mononuclear phagocyte
system
1.7.1 Monocytes and tissue macrophages
Dendritic cells, monocytes, monocyte-derived macrophages and tissue-resident mac-
rophages form the mononuclear phagocyte system (deprecated: reticuloendothelial
system where fibroblasts and endothelial cells were included in the same classification).
Under homeostatic conditions, tissue resident macrophages, which are present in
most tissues, such as alveolar macrophages, Kupffer cells, histiocytes, Langerhans
cells, microglia and osteoclasts, perform janitorial functions, such as the removal of
cellular and exogenous debris, erythrocyte recycling and iron homeostasis184. In the
context of inflammation and infection these tissue macrophages, along with resident
dendritic cells, are the first sensors of injurious stimuli, responding to PAMPs and
DAMPs, and recruiting the initial wave of blood leucocytes185. While tissue macro-
phage pools were previously thought to be maintained by circulating monocytes, a
series of papers suggest this is largely not the case and that these cells are derived
from the yolk sac and proliferate locally185–188. On the other hand, there is evidence
of exceptions to this, such as Langerhans cells in the skin, splenic macrophages and
some tissues following severe inflammation where local proliferation is supplemented
by monocyte infiltration189,190.
The most prevalent population of circulating monocytes are CD14high, CD16−,
CCR2+, CX3CR1
low and termed “classical monocytes”191. Upon detection of in-
flammation, these cells extravasate into the tissue, promoting inflammation and
pathogen-killing before differentiating into macrophages or dendritic cells to serve
higher functions. In 1989, a second population of circulating monocytes was discov-
ered in humans found to be CD16+ and represented ~10% of circulating monocytes192.
These “non-classical monocytes” are smaller than classical monocytes, are found
to preferentially crawl along the apical face of the endothelium and are CD14low,
CD16high, CCR2−, CX3CR1
high (see Table 1.2 for a summary of the most commonly
used markers)193. Non-classical monocytes are considered to be patrolling cells that
monitor the integrity of the endothelium, inducing the recruitment of neutrophils
to sites of endothelial damage190. These cells are sometimes referred to as “non-
phlogistic” monocytes owing to their perceived inability to contribute significantly to
tissue inflammation, although in some circumstances this is a misnomer194. Indeed
the mouse orthologue of the non-classical monocyte (the Ly6C−monocyte) has been
shown to be required for the development of a model of autoantigen-induced arthritis
whereas classical cells (Ly6C+) were not195. In this model Ly6C− monocytes matured
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into inflammatory macrophages to drive the disease, and then transitioned to a
pro-resolving macrophage phenotype required for the disease model to spontaneously
resolve.
A third population of circulating monocytes are described as “intermediate” as
they form a continuous bridge between classical and non-classical cells for all the
major phenotypic markers used to separate the two196. The general consensus is that
these cells represent classical monocytes transitioning into a non-classical phenotype,
although it remains possible that these cells may have distinct functions from the
two canonical populations.
Table 1.2: Monocyte subsets in human and mouse
Monocyte Subset
Antigen Classical Intermediate Non-classical
Human
CD14 ++ + +
CD16 - + ++
Mouse Ly6C ++ + -
Both
CCR2 ++ + -
CX3CR1 + ++ +++
CD64 ++ + -
- not expressed; +/++/+++ relative expression within row
1.7.2 Macrophage plasticity
Macrophages are renowned for exhibiting remarkable plasticity and generate a wide
spectrum of responses to a wide spectrum of stimuli. Initially described by Élie
Metchnikoff in 1882 (who was awarded the Nobel prize with Paul Ehrlich 26 years
later), macrophages were the first described professional phagocytes (“macrophage”
translating roughly as big eater)197.
Their sensitivity to pg/mL levels of LPS and the pro-inflammatory Th1 cytokine
interferon gamma (IFNγ) earned them credence as pro-inflammatory, pathogen-killing
cells198,199. In response to these stimuli in vitro (in isolation or in combination),
macrophages undergo oxidative burst, generating reactive oxygen species (ROS)
and reactive nitrogen species (RNS) such as superoxide, hydrogen peroxide and
peroxynitrite. They also shift to favour macropinocytosis over phagocytosis, release
pro-inflammatory cytokines, such as TNFα, IL-6, IL-1β, IL-12p70, IL-23 and type
I interferon, and upregulate proteins involved in antigen presentation, such as
CD86 and MHCII200. In 1992, however, Stein et al. from Siamon Gordon’s group
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demonstrated that the Th2 cytokine IL-4 (and the related IL-13) potently induces a
distinct macrophage phenotype201 which promotes Th2 immunity and is evolutionarily
conserved for the killing of helminth and fungal infections202,203. With the view
that these were discrete and mutually exclusive macrophage phenotypes, they were
named classically activated and alternatively activated, or M1 and M2 macrophages,
respectively to conform to the Th1 and Th2 nomenclature. M2 macrophages express
higher levels of scavenger receptors (such as the CD206 mannose receptor and
the CD163 haemoglobin-haptoglobin receptor), arginase, IL-10 and the IL-1 decoy
receptor204. While initially described as anti-inflammatory, IL-4-polarised macro-
phages are more correctly thought of as anti-inflammatory only in the context of
Th1-driven inflammation, but themselves promote a type 2 response.
The understanding that macrophages could exhibit such disparate phenotypes
to regulate as well as promote inflammation led to the observation that the anti-
inflammatory cytokine IL-10 invokes a macrophage phenotype that is regulatory (for
both Th1 and Th2-driven inflammation), and promotes matrix deposition and tissue
remodelling205. These “wound healing” macrophages secrete their own IL-10, TGFβ
and deposit matrix components, such as versican and pentraxin 3, and α antitrypsin,
to promote anabolism206. A highly similar phenotype is induced by TGFβ. A third
seemingly distinct macrophage phenotype was identified in response to co-exposure
to immune complexes and TLR activation207. These cells seem in vitro to share
properties of both M1 and IL-4/IL-13-stimulated macrophages, at the same time
releasing large quantities of IL-10, TNFα, IL-1β, IL-6 and expressing MHCII and
CD86. The role of these cells is not fully understood but are suggested to be anti-
parasitic and to contribute to the pathogenesis of rheumatoid arthritis (and likely
any inflammatory disease involving immune complex deposition)208. In an attempt
to reconcile these other alternatively activated macrophage phenotypes with the
M1/M2 paradigm, IL-4/IL-13, immune complex and TLR ligand, and IL-10-induced
macrophage phenotypes have been named M2a, M2b and M2c, respectively209. The
most recent addition to the M2 family (predictably named M2d) is the result of
exposing M1 macrophages to adenosine which results in an IL-10 and VEGF-releasing
phenotype166. The physiological purpose of this population is likely to aid resolution
and wound healing by promoting angiogenesis in response to adenosine, made
extracellular by necrosis and tissue damage. Indeed, this is one of many pro-resolving
functions of adenosine210.
In recent years, the M1/M2 convention has been heavily criticised as unrepresen-
tative of true macrophage biology209. Macrophages in complex in vivo environments
rarely exhibit the characteristics of a single in vitro phenotype, often displaying
mixed distributions of M1 and M2 markers. The discreteness of such populations
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has also been refuted; where such an M1/M2 dichotomy exists in the tissue, it exists
solely as a continuum and not as discrete populations.
The overenthusiastic compartmentalisation of different macrophage phenotypes is
further exemplified by the work done on macrophages within atherosclerotic plaques.
Exposure of macrophages to CXCL4 promotes a phenotype termed M4, the in vivo
analogue of which appears more prone to foam cell formation and plaque instability211.
Uptake of a large number of oxidised phospholipids induces a phenotype referred to
as Mox which expresses sulfiredoxin-1, thioredoxin reductase and haem oxygenase-1
and provides plaque-protective antioxidant functions and also immunoregulation by
the carbon monoxide they produce212. Finally, a distinct population of macrophages
appears to cluster proximal to the vasa vasorum in plaques which express IL-10,
carbon monoxide and high levels of the haemoglobin-haptoglobin complex receptor
CD163213. This population is induced by the haem-hapt complex and is referred to
as Mhaem (see Table 1.3 for a more comprehensive summary of reported phenotypes).
Many research groups are moving away from the M1/M2 nomenclature now that
its relevance to physiology has been brought into question. What seems apparent is
that the macrophage is a remarkably dynamic cell type, the phenotype for which is
a complex function of multiple stimuli, tissue, and disease context. Nevertheless, in
in vitro models of mono-stimulation, these phenotypes are stable and can be thought
of to represent extremes of several, multidimensional activation spectra, and act
as useful models in studying modulators of these phenotypes. The generalisation
of these phenotypes to physiology, however, should be done with extreme caution,
although the terms “M1-like” and “M2-like” are useful in describing relative changes
in phenotype only.
1.8 Rheumatoid arthritis
Rheumatoid arthritis is a systemic, chronic inflammatory condition whose prime
manifestation is symmetrical inflammation and destruction of cartilagenous joints.
The stereotypical form of the disease involves inflammation of the synovial membrane
of the metacarpophalangeal and interphalangeal joints of the hand, but over time
can progress into polyarthritis where joints of the feet, spine, shoulder and knee are
affected, as well as inflammation of the skin, kidneys, blood vessels, eyes, and fibrosis
of the lung.
The ætiology of rheumatoid arthritis is poorly annotated. While the molecular
basis for the timing of onset is obscure, environmental, genetic and epigenetic factors
are proposed to trigger loss of self tolerance214. The reason for the initial loss
of tolerance is not understood, but smoking represents the strongest associated
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environmental factor (with reported odds ratios of 1.8 to 1.3), the effects of which
synergise with expression of the HLA-DRB1 shared epitope and PTPN22 R620W
polymorphisms (individual odds ratios of 5.6 to 11.3 and 1.6 to 2.8, respectively)215.
Half of the risk of developing rheumatoid arthritis is associated with these and
other polymorphisms, which modulate lymphocyte activation, and although tissue
damage or infection are suggested to act as triggers for the manifestation of these
polymorphisms, no credible link between either has been demonstrated. Detection
and use of rheumatoid factor and more recently anti-citrullinated protein antibodies
(ACPA) as biomarkers for rheumatoid arthritis led to the realisation that proteins
in patient joints were highly citrullinated216. Whether this inappropriate post-
translational citrullination is triggered by an environmental stimulus is not known,
but the presence of citrullinated-protein specific lymphocytes producing antibodies
in secondary lymphoid organs suggest this is at least a terminal trigger for the loss
of tolerance217. The deposition of these antibodies as immune complexes on the
cartilage surface induces activation of synovial macrophages and dendritic cells which
recruit monocytes and neutrophils into the synovial membrane (and fluid)218,219.
Inflammation and excessive proliferation induce swelling and hyperplasia of the
synovial membrane, forming a pannus which causes pain and loss of function of the
joints affected. Recruitment of lymphocytes completes an inflammatory feedback
loop between innate and adaptive cells, the long term effect of which is cartilage
degradation, bone erosion and patient disability. While the roles of T and B cells
are important to the progression of rheumatoid arthritis, only the contributions of
neutrophils, monocytes and macrophages will be discussed here.
1.8.1 Neutrophils in RA
Recognition of immune complexes by Fcγ receptors on granulocyte-macrophage
colony-stimulating factor (GM-CSF)-primed neutrophils induces respiratory burst
and full degranulation220. In the pannus and synovial fluid, this increase in ROS
and cytotoxic enzymes, such as myeloperoxidase, promotes a cytotoxic and catabolic
environment, overcoming protective antioxidant and antiprotease mechanisms and
facilitating cartilage erosion. Granule proteins may inhibit chondrocyte proliferation
and potentiate synoviocyte proliferation221. Transmigrating neutrophils also release
IL-8 and leukotriene B4 (LTB4) which potently recruit subsequent waves of neutrophil
extravasation and MHCII-induced T cell activation222,223. The life of a neutrophil in
circulation is ~24 hours, but activation cues in an inflamed microenvironment can
extend this time to several days224. The timely induction of neutrophil apoptosis is a
critical checkpoint required for the resolution of inflammation, but its dysregulation
and prolonged neutrophil lifespan in rheumatic synovia results in perpetual inflam-
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mation, neutrophil necrosis and NETosis225. NETosis is a form of programmed cell
death where neutrophils extrude their DNA into the extracellular space as structures
called neutrophil extracellular traps (NET)226. NET are complex structures of chro-
matin, citrullinated histones and granule proteins released in response to prolonged
activation that immobilise and opsonise pathogens. Both circulating and synovial
fluid neutrophils from rheumatoid arthritis patients undergo NETosis more readily
than healthy neutrophils, and are thus thought to contribute to the loss of tolerance
to and processing of auto-antigens214.
At the cartilage-pannus junction, immune complex-primed neutrophils attempt
to phagocytose the cartilage face. Unable to internalise the large surface, neutrophils
secrete lysosomes onto the cartilage face, degrading it in a process termed “frustrated
phagocytosis”227. Secretion of receptor activator of nuclear kappa-B ligand by
activated neutrophils promotes intra-articular osteoclastogenesis of macrophages -
which subsequently erode the bone and contribute to loss of function228.
1.8.2 Monocytes and macrophages in RA
While synovial tissue macrophages, monocytes and monocyte-derived macrophages
do not appear causative to rheumatoid arthritis, the relative success of treatments
with macrophage-modulating efficacy demonstrates their core importance to disease
progression. At the earliest stages of the disease, tissue macrophages recruit CCR2−
monocytes into the synovium which in mouse models, are required for the initiation
of clinical arthritis195. This is striking for two reasons: firstly, that it is the monocyte
and not the archetypal neutrophil as the front-line of recruitment, and secondly that
the so-called non-phlogistic monocyte is required for disease progression and not the
inflammatory monocyte. Recruited monocytes then differentiated into macrophages
resembling an M1-like phenotype, promoting inflammation and worsening clinical
score, before transitioning into a more M2-like, pro-resolution phenotype which
promoted spontaneous resolution. Whether these processes are analogous in the
human is not clear, but an important critique of this model is that unlike the clinical
situation, it fully resolves.
Another contradiction to the traditional view that alternatively activated mac-
rophages are anti-inflammatory is the observation that M2 macrophages exposed
to immune complexes and TLR ligands, such as LPS and Pam3CSK4 (TLR4 and
TLR1/2, respectively), secrete high levels of TNFα, IL-1β and IL-6 and may promote
synovial inflammation208. Indeed monocytes and macrophages are the main source
of intra-articular TNFα and IL-1β, the latter of which is released in response to
inflammasome activation, and induces activation of the endothelium and chondrocyte
apoptosis229. Juxtacrine contact between macrophages and synovial fibroblasts
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induces IL-6 (mainly from the fibroblasts), IL-8 and GM-CSF230.
Monocytes and macrophages release matrix metalloproteinase (MMP)s, most
prominently MMP 9 and 12, in response to TNFα, IL-1β and prostaglandin E2 which
degrade the local matrix and cartilage231. Similarly to neutrophils, macrophages
can also undergo frustrated phagocytosis, but also osteoclastogenesis to create an
overwhelmingly catabolic environment232.
In light of the contributions of synovial monocytes/macrophages to rheumatoid
arthritis, it is not surprising that therapies modulating these cells (at least indirectly)
have met with moderate success in the clinic. In the biologic family of anti-rheumatic
drugs, etanercept, infliximab, adalimumab and certolizumab neutralise soluble TNFα
(much of which is monocyte/macrophage-derived) and induce reverse transmembrane
TNFα signalling in monocytes, inducing their apoptosis233. Abatacept, licensed
for the treatment of rheumatoid arthritis in the US, is an Fc-CTLA-4 chimera
which prevents CD80/CD86-mediated activation of T lymphocytes by macrophages
and dendritic cells, and impairs macrophage TNFα release234. The contribution
to rheumatoid arthritis pathology by monocytes/macrophages is therefore non-
redundant and represents a targetable aspect of the disease. Despite this, no
treatment currently offers permanent remission, and sub groups of patients remain
refractory to TNFα blockade235. While these therapies are anti-inflammatory, they
do not necessarily promote resolution of synovial inflammation or restore immune
tolerance. New approaches are therefore needed to drive active resolution in the local
environment. As such, the present project aims to explore and delineate the effects
of neutrophil-derived microvesicles on the phenotype and function of macrophages
in the context of rheumatoid arthritis.
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1.9 Project aims
1. The present project aims to optimise and characterise the production of
microvesicles from primary human neutrophils, including:
• measurement of their concentration
• measurement of their phenotype
• their stability over time under different storage conditions
2. Once protocols to produce and store microvesicles have been optimised, the
project aims to determine if neutrophil-derived microvesicles alter classical
macrophage activation, using a panel of phenotypic markers
3. If efficacy is observed, the project aims to identify the mechanisms responsible
4. The project will identify whether microvesicles from neutrophils given different
stimuli elicit similar effects
5. The project will identify if the effects observed are specific to microvesicles and
not exosomes
6. Following this, the project will examine whether any changes in macrophage
phenotype or activation induced by neutrophil microvesicles, have functional
consequences on cell function. Specifically, the project will test whether vesicles
alter the interaction between macrophages and:
• chondrocytes
• fibroblast-like synoviocytes
These functional studies have been chosen as soluble factors released by macro-
phages are able to modulate chondrocyte survival and cartilage deposition, and
the close proximity of both resident and infiltrating macrophages to synovial
fibroblasts in the pannus, facilitates intimate control of phenotype between
these cell types236
7. If the in vitro data supporting the above hypotheses are robust, the hypotheses
will be tested in two in vivo models of compartmentalised inflammation:
• zymosan-induced peritonitis
• K/BxN serum-transfer arthritis
8. Finally, to answer more experimental hypotheses, the project will aim to test in
vitro, the validity of microvesicles as therapeutics. This will test the hypotheses
that:
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• autologous vesicles from rheumatoid arthritis patients, and
• vesicles generated using engineered cell lines
have similar effects as those seen from healthy neutrophil vesicles. Generation
of the cell line will require:
• identifying a protein determinant of microvesicle activity
• achieving stable transfection of the cells with the protein
• confirming presence of the protein in secreted microvesicles
Chapter 2
Materials and Methods
2.1 Running sizing beads on flow cytometers
Fluorescent 0.02µm FluoSpheres (F-8782), 0.1µm (L1528-1ML), 0.5µm (L1403-1ML)
and 1µm (L1278-1ML) latex calibration beads (Sigma-Aldrich) were diluted 1:15,000
in double sterile-filtered (0.22µm; SLGP033RS, Millipore) phosphate-buffered saline
(PBS) after 5 minute sonication and vortexing to disperse aggregates. Individual
beads were acquired on the ImageStream and the LSRFortessa with all lasers turned
on, slow flow rate and 60x magnification (ImageStream only) using fluorescence
triggering on the beads’ brightest channel (the phycoerythrin channel).
2.2 Isolation of whole blood components
A graphical representation of this procedure is shown in Figure 2.1. All volun-
teers gave written, informed consent to blood collection and the procedure was
approved by the East London & The City Local Research Ethics Committee (Rec
Ref. 05/Q0603/34 ELCHA, London, United Kingdom) for healthy controls and The
East London & The City Research Ethics Committee (Rec Ref. 07/Q0605/29) for
arthritis patients, in accordance with the World Health Organization guidelines on
drawing blood. Whole blood was drawn from healthy volunteers using a 21G (or 19G
if platelets were used) butterfly needle with tourniquet applied and anticoagulated
with 0.32% w/v (final, in water) sodium citrate. All blood cells are from healthy
controls unless indicated otherwise in figure legends.
2.2.1 Collection of plasma
Platelet-rich and platelet-poor plasma were generated by centrifuging whole blood
at 130×g for 20 minutes to separate plasma and cells, then the platelet-rich plasma
recovered and, if needed, platelets depleted by a second centrifugation at 13,000×g
for 2 minutes.
41
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2.2.2 Removal of erythrocytes
For every 30mL of whole blood, erythrocytes were depleted by sequentially layering
10mL of PBS then 8mL of 6% w/v dextran (high molecular weight, 31392-250G,
Sigma-Aldrich, in PBS) onto the blood after removal of plasma as above. The blood
was gently inverted to mix the PBS and dextran, and left to sediment at room
temperature for 15 minutes.
2.2.3 Separation of neutrophils and PBMC
After dextran sedimentation of erythrocytes, the leucocyte-rich fraction from every
30mL of whole blood was carefully layered over 10mL Histopaque 1077 (10771, Sigma-
Aldrich) in a fresh 50mL tube and centrifuged for 30 minutes at room temperature
at 450×g to separate granulocytes from peripheral blood monouclear cells (PBMC).
Remaining plasma was aspirated, the PBMC were carefully collected with a
Pasteur pipette and transferred into a new 50mL tube. Remaining supernatant was
aspirated and the residual erythrocytes were lysed through hypotonic shock with 9
mL of ice-cold, ultra pure distilled water. Isotonicity was quickly restored by adding
1mL of 10x Hanks Balanced Salt solution (H4641, Sigma-Aldrich). Both granulocyte
and PBMC fractions were made up to 50mL with PBS and pelleted at 300×g for 10
minutes at room temperature. The supernatant of both fractions was aspirated, the
granulocyte pellet was resuspended in phenol red-free RPMI (11835-063, Gibco) and
their concentration adjusted as needed, and the PBMC fraction was resuspended in
50mL of PBS and centrifuged at 120×g for 20 minutes to further remove platelets.
2.3 Generating monocyte-derived macrophages
The PBMC pellet generated in Section 2.2.3 was resuspended in RPMI (R8758,
Sigma-Aldrich) with 100U penicillin and 100µg/mL streptomycin (P4333, Sigma-
Aldrich) without serum at 1.8×106/mL and 500µL was seeded per well of a 24-well
suspension culture plate. Suspension plates were used to allow subsequent detachment
of otherwise extremely adherent macrophages. After incubation at 37oC for 1 hour,
PBMC were washed vigorously 3 times with PBS to deplete lymphocytes and
covered with RPMI with 100U penicillin and 100µg/mL streptomycin, 10% v/v
heat inactivated foetal bovine serum (FBS; 10500, Life Technologies, lot 08Q1150K)
and 50ng/mL macrophage-colony stimulating factor (M-CSF; 300-25, PeproTech;
referred to as “complete medium”). Cells were cultured at 37oC with 5% CO2 and
their medium was replaced on day 5. At day 7, macrophages were washed twice
with PBS and used as needed.
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Figure 2.1: Isolation of blood components. The procedure is shown for each
30mL of blood to isolate platelet-rich plasma (PRP), peripheral blood mononuclear
cells (PBMC) and a fraction containing neutrophils and erythrocytes, the latter of
which are subsequently removed by hypotonic lysis.
2.4 Microvesicle generation and storage
2.4.1 Inflammatory agonists
For fixed-time microvesicle generation, 2×107 neutrophils/mL were stimulated with
50ng/mL TNFα (T0157-10UG, Sigma-Aldrich), 50ng/mL IL-8 (200-08, Peprotech),
10nM LTB4 (20110, Cayman Chemical), 1µg/mL zymosan (Z4250, Sigma-Aldrich),
10ng/mL E. coli (EC1-5G, Sigma-Aldrich) or vehicle (PBS) for 20 minutes at 37oC
before placing on ice to arrest microvesicle production. Cell suspensions were then
either processed for ImageStream analysis or their neutrophils and large contaminants
(such as platelets) were pelleted by centrifugation at 4,400×g for 15 minutes at 4oC
followed by a second centrifugation at 13,000×g at 4oC for 2 minutes to remove
residual contaminants (such as smaller platelets, zymosan particles and E. coli).
Samples were resuspended in phenol-red free RPMI before proceeding to processing
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for ImageStream analysis. Microvesicles generated this way by TNFα are referred to
as MVTNFα.
For real-time microvesicle generation, freshly isolated neutrophils were resus-
pended at 1×106/mL in phenol red-free RPMI and labelled with boron-dipyrrometh-
ene maleimide (BODIPY maleimide), which has similar excitation and emission
spectra to fluorescein isothiocyanate (FITC), at 2.5 µM, 2 minutes prior to sample
acquisition, then the sample loader lowered. 50ng/mL TNFα or equal volume of
vehicle (PBS) was added immediately prior to loading the sample. Acquisition of
events was started as soon as the flow rate had equilibrated, and the events appearing
in the microvesicle population gate collected for 45 minutes (488nm and 785nm lasers
switched on).
2.4.2 Pre and post neutrophil transmigration
To optimise the generation of transmigrated-neutrophil-derived MV (MVPost) and
pre-transmigrated-neutrophil-derived MV (MVPre), cultures of human umbilical vein
endothelial cells (HUVEC) were generated from healthy human umbilical cords.
HUVEC were generated by cannulating the umbilical vein with a 21G butterfly
needle and flushing it twice with 30mL of PBS in a syringe. The PBS was expelled
by flushing the vein through with air, and replacing it with 0.2% w/v collagenase
D (in RPMI, 103586, Roche) until full. The non-cannulated end of the cord was
clamped with a haemostat, and more collagenase was pushed into the vein until no
more could be added. The cannulated end of the cord was clamped with a haemostat
and the entire cord was incubated at 37oC for 15 minutes. The non-cannulated
end of the cord was unclamped and the cell suspension was collected into a 50mL
tube containing 10mL of RPMI + 20% v/v human serum (H4522, Sigma-Aldrich).
Cells were pelleted at 300×g for 10 minutes, resuspended in 12mL of RPMI + 20%
human serum and seeded into a T75 flask, precoated with 5% w/v bovine gelatin
(G9391-500G, Sigma-Aldrich). Cells were washed with PBS 24 hours later, and
split 1 in 3 when ~80% conlfuent. HUVEC were seeded at P2 onto 6-well 3µm-pore
transwell inserts (a single T75 flask at ~80% confluency per 6 wells; 353091, Scientific
Laboratory Supplies), pre-coated for 24 hours with 5% w/v bovine gelatin with
10ng/mL fibronectin (341635, Calbiochem) for 2 hours and then washed with PBS
and transferred into fresh plates. After 48 hours, transwells were inspected to ensure
100% confluency and stimulated with 50ng/mL TNFα (under the transwell). 4 hours
later, transwells were washed twice (above and below) with PBS and 3×106 isolated
human neutrophils in 1mL were seeded per well in serum-free RPMI or RPMI with
10% v/v extracellular vesicle-free FBS (generated by centrifuging whole FBS at
100,000×g for 1 hour at 4oC and double filtering through 0.22µm filters), in the
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presence of 50ng/mL IL-8 (200-08, PeptroTech) or vehicle alone (PBS). 1mL of
matched-condition RPMI was added to the bottom of each well and plates incubated
for 90 minutes at 37oC. Transwells were removed to stop transmigration and the
suspensions above and below the transwell were collected and both the number of
neutrophils and microvesicles were collected.
2.4.3 From synovial fluid
Cell-free synovial fluid from 3 rheumatoid arthritis (aM011-fl-RA, Cambridge Bio-
science) and 3 osteoarthritis patients (aM011-fl-OA, Cambridge Bioscience) was
thawed at 37oC and treated with 40U/mL hyaluronidase with a sterile magnetic
stirrer at 37oC until viscosity was comparable to water (between 40 and 75 minutes).
Samples were centrifuged at 13,000×g for 2 minutes and the supernatant at 20,000×g
for 30 minutes to pellet platelets/apoptotic bodies and then microvesicles (which
were resuspended in RPMI and stored at -80oC). Microvesicle-free synovial fluid was
aliquotted and stored at -80oC until use.
To generate rheumatoid arthritis synovial fluid-induced MV (MVRA) and os-
teoarthritis synovial fluid-induced MV (MVOA), 2×107/mL human neutrophils were
treated with rheumatoid and osteoarthritis synovial fluid, respectively (1 in 10 for
comparison to TNFα and transmigration, 1 in 100 for all other assays). After 20
minutes at 37oC, samples were placed on ice to arrest microvesicle production, which
were isolated as in Section 2.4.1.
2.4.4 Storage
For storage longer than 24 hours, microvesicles were frozen slowly in a Mr. Frosty
unit (5100-0036, Thermo Scientific) at -1oC/minute to -80oC. All frozen microvesicle
samples were thawed quickly in a 37oC water bath. The same was performed for the
comparison of storage temperatures of between 37oC and -80oC.
For comparison between relative yield of microvesicle recovery between standard
microfuge tubes, and those made from a hydrophilic polypropylene polymer with
low protein binding (LoBind; Z666513, Sigma-Aldrich), MVTNFα were generated
and separated from cells as in Section 2.4.1. Each sample of vesicle suspension was
then split in equal volume between a standard polypropylene microfuge tube, and a
LoBind microfuge tube, labelled with 50µM BODIPY maleimide FL, and centrifuged
at 20,000×g for 30 minutes at 4oC to pellet the vesicles. After aspiration of the
supernatant, pellets were resuspended in 30µL of PBS each, and acquired on the
ImageStream using the 488nm laser.
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2.5 Tsg101 western blot
Isolated human neutrophils (3×107) were stimulated with 50ng/mL TNFα for 20
minutes at 37oC before cells and platelets/apoptotic bodies were removed as pre-
viously described. The supernatant was split equally between tubes which were
centrifuged at 20,000×g for 30 minutes or 100,000×g for 1 hour at 4oC (in rotors
with kadjusted factors of 692.39 and 406.43, respectively). Pellets were resuspended in
lysis buffer (89900, Life Technologies) with protease inhibitor (1 tablet/50mL; 88266,
Life Technologies).
A confluent T25 flask of C28/I2 cells was also lysed to provide a positive control.
Total protein content in each sample was quantified using a BCA kit (23227, Life
Technologies) as per manufacturer’s instructions. 30µg of protein from each sample
was boiled for 5 minutes at 100oC in 1x Laemmli buffer containing 2% w/v sodium
dodecyl sulphate (436143, Sigma-Aldrich), 10% v/v glycerol (G5516, Sigma-Aldrich),
5% v/v 2-mercaptoethanol (M6250, Sigma-Aldrich), 0.002% w/v bromophenol blue
(114391, Sigma-Aldrich), 0.0625M Tris HCL (T3253, Sigma-Aldrich), before loading
into a 10% w/v sodium dodecyl sulphate polyacrylamide gel, including a molecular
weight ladder (26623, Life Technologies).
The 10% resolving gel was prepared by combining 3.3mL of ProtoFLOWGel
(H16996, Scientific Laboratory Supplies), 2.5mL of 4% w/v Resolving gel buffer
(EC-892, Scientific Laboratory Supplies), 4.1mL of deionised water, 100µL of
10% w/v ammonium persulphate (A3678, Sigma-Aldrich) and 10µL of N,N,N’,N’-
teteramethylethylenediamine (TEMED; T9281, Sigma-Aldrich). The stacking gel
was poured between glass plates and 500µL of isopropanol (I9516, Sigma-Aldrich)
was added to force the gel to set evenly. The resolving gel was prepared by com-
bining 650µL of ProtoFLOWGel, 1.25mL of Stacking gel buffer (EC-893, Scientific
Laboratory Supplies), 3.05mL of deionised water, 50µL of 10% w/v ammonium
persulphate, and 5µL of TEMED. The stacking gel was layered onto the resolving
gel, the comb was inserted, and the gel was left to solidify for 20 minutes. The gel
was run at 120V until the buffer front reached the end of the gel, and the protein
bands were transferred overnight at 50V onto a methanol-activated polyvinyldene
fluoride membrane (IPVH00010, Immobilon) at 4oC.
The membrane was blocked in 5% w/v milk (in TBST buffer: 50mM Tris, 150mM
NaCl, 0.1 % v/v Tween 20) for 1 hour at room temperature while shaking. The milk
was replaced with a polyclonal rabbit anti-Tsg101 antibody (1 in 250 in 5% w/v milk;
HPA006161, Atlas Antibodies, in TBST buffer) for an hour, before washing 3 times
and replacing the antibody with a polyclonal horseradish peroxidase-conjugated
goat anti-rabbit antibody (1 in 2,000; P0448, Dako, in 5% w/v milk in TBST).
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After an hour incubation, the membrane was washed 3 times and replaced with a
monoclonal mouse anti β-actin antibody (1 in 2,000; A5441, Sigma-Aldrich, in 5%
w/v milk in TBST). Finally, after an hour incubation, the membrane was washed 3
times, incubated for an hour with a polyclonal horseradish peroxidase-conjugated
goat anti-mouse antibody (1 in 5,000; P0447, Sigma-Aldrich, in 5% w/v milk in
TBST), before being washed 3 times more. Luminata forte substrate (WBLUF0500,
Millipore) was added to cover the membrane which was imaged using a FluorChem
R digital imager.
2.6 Fluorescent microvesicle labelling
Microvesicle labels BODIPY maleimide FL or Texas Red (B10250 and D6116,
respectively, Thermo Fisher), carboxyfluorescein succinimidyl ester (CFSE; C34554,
Molecular Probes) and PKH (MINI67, Sigma-Aldrich) were used at concentrations
indicated and incubated with microvesicles for 20 minutes at room temperature (5
min for PKH). To wash away unbound dye, 1mL of sterile, double-filtered (0.22µm)
PBS was added to each sample, which were then centrifuged at 20,000×g for 30
minutes to remove excess dye. It is important to remove excess generic vesicle dye, as
this significantly compromises the signal-to noise ratio and the detection of smaller
vesicles. Vesicles were then resuspended in the buffer and volume specified in figure
legends.
For identification of microvesicles in biological fluids, whole blood (diluted 1 in 10
with phenol red-free RPMI), platelet-rich plasma, platelet-poor plasma and isolated
neutrophils were stained with 50µM BODIPY maleimide FL or Texas Red.
For detection of outward PtdSer expression, vesicle preparations were resuspended
in 1x anxA5-binding buffer (51-66121E, BD Pharmingen) with 10µg/mL FITC-
conjugated anxA5 (640905, Biolegend), incubated at room temperature for 15
minutes in the dark, and acquired on the ImageStream using the 488nm laser.
2.7 Antibody labelling for cytometry
2.7.1 Cells
Antibody labelling of human cells was performed in 96-well, U-bottom plates after
blocking Fc receptors by resuspending the cells in 100µL of FACS buffer (PBS +
0.02% w/v bovine serum albumin (BSA)) containing 160µg/mL human IgG (G4386,
Sigma-Aldrich) and incubating them at 4oC for 15 minutes. 100µL of FACS buffer
was added to each well and cells were washed three times by centrifuging the plate
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at 300×g for 30 seconds, discarding the supernatant and resuspending in 200µL of
FACS buffer. Cell pellets were then resuspended in 50µL FACS buffer containing
antibodies raised against targets of interest, or appropriate staining controls, and
incubated at room temperature in the dark for 30 minutes. Concentrations and
details of antibodies used to label human neutrophils and macrophages are shown
in Table 2.1. Note that the antibody raised against “HLA-DR, DP & DQ” is a
monoclonal antibody which binds to all three major human MHC class II proteins
(DR, DP and DQ).
150µL of FACS buffer was added to each well and cells were washed three times
by centrifuging the plate at 300×g for 30 seconds, discarding the supernatant and
resuspending in 200µL of FACS buffer. Cell pellets were resuspended in 100µL of
1% v/v formaldehyde and incubated at 4oC for 15 minutes to fix them. 100µL of
FACS buffer was added to each well and cells were washed twice by centrifuging
the plate at 300×g for 30 seconds, discarding the supernatant and resuspending in
200µL of FACS buffer. Fixed cells were resuspended in between 200µL and 500µL
of FACS buffer (depending on cell numer) and acquired on either an LSRFortessa,
FACSCanto II or ImageStreamx MkII.
Antibody labelling of mouse cells was performed as above, but instead of blocking
with human IgG, Fc receptors were blocked with cell-free supernatant from 2.4G2
hybridoma cells containing anti CD16/32 IgG (produced in-house and kindly given
by Dr. Oliver Haworth). Details of mouse antibodies can be found in Table 2.2.
Biological negative populations were used to gate cells positive for CD45, CD11b,
CD66b and CD90, and a fluorescence minus one (FMO) control was used to gate cells
positive for F4/80. Isotype-matched control antibodies were used for all antigens
whose expression was of interest, to validate the effectiveness of Fc-mediated and
non-specific antibody binding (but were never used as gating controls).
2.7.2 Microvesicles
For identifying circulating populations of microvesicles, platelet-poor plasma was
generated from 5mL of blood from each healthy donors (as described in Section 2.2).
150µL of undiluted plasma was stained with 50µM BODIPY maleimide (Texas Red)
and washed as per Section 2.6, and split equally between three tubes. One tube was
stained with antibodies against CD41, CD45 and CD146, another with antibodies
against CD14, CD66b and CD3, and the last one with an anti-CD235 antibody (see
Table 2.3 for antibody details). All staining was performed at room temperature in
the dark for 30 minutes with antibodies resuspended in 0.22µm-filtered FACS buffer.
Remaining plasma was used for appropriate isotype and staining controls. Stained
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plasma was then acquired on the ImageStream (unwashed) with all lasers turned on
and at full power.
For comparing plasma microvesicle populations between healthy and rheumatoid
arthritis patients, 500µL of platelet-free plasma (generated as per Section 2.2) from
healthy donors and rheumatoid arthritis patients was stained with 50µM BODIPY
maleimide and split between 3 tubes. Each tube was stained with antibodies against
anxA1, then either with antibodies against CD66b, CD14 or CD41, and acquired
on the ImageStream. FMO controls were used to gate on all antigens labelled on
microvesicles.
2.7.3 AnxA1
AnxA1 staining on cells or microvesicles was carried out as above using a monoclonal
antibody produced in-house (clone 1B, 10µg/mL, mIgG1), followed by an additional
staining step after washing, with a secondary goat anti-mouse IgG F(ab’)2-FITC
(2µg/mL; M35001, Caltag Lab.), both for 30 minutes at 4oC. Where anxA1 was
being probed for, FACS buffer was supplemented with 3mM CaCl to prevent anxA1
dissociating from PtdSer. Where anxA1 staining was done in tandem with other
antibodies, anxA1 staining was performed first followed by a wash step, at which
point remaining antibody labels were added.
2.7.4 Compensation beads
Correct compensation of polychromatic cytometry data requires that compensation
samples meet three criteria: they must be at least as bright as any sample the
compensation matrix will be applied to, the fluorophore must be the same (and
handled the same) as those used in any sample the compensation matrix will be
applied to, and the autofluorescence of the positive and negative populations must be
equivalent. Cells are commonly used to generate single colour compensation controls,
most often successfully, but often do not satisfy the first criterion, do not provide
clear positive and negative populations, and may require reserving otherwise sparse
cells for the purpose. For rare antigens, it may be difficult to determine a positive
population of cells without acquiring large numbers of events.
To circumvent these caveats, all compensation for antibody conjugates was
performed using OneComp eBeads (01-1111, Invitrogen) which are a suspension of
two bead populations: positive beads, which bind mouse, rat and hamster antibodies,
and negative beads which do not bind antibody. The positive beads can bind enough
antibody to achieve a larger separation between positive and negative peaks than
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generally seen with cells at appropriate PMT voltages, and their use negates the
need for reserving cells purely for compensation.
To prepare the beads, the antibodies used in each experiment (from the same lot)
were diluted in 100µL of FACS buffer to the concentration used in the experiment
for cells, or 1/4 this for microvesicles, and added to 20µL of bead suspension.
Antibody-bead suspensions were incubated in the dark at room temperature for
30 minutes before adding 1.5mL of FACS buffer and centrifuging a 500×g for 5
minutes. The supernatant was aspirated and the bead pellet was resuspended in
300µL of FACS buffer and acquired on the instrument (used for both standard and
imaging cytometers). To generate compensation values for non-antibody fluorophores
(BODIPY maleimide or anxA5 for example), vesicles/cells were used instead.
2.7.5 Intracellular staining
Where total antigen expression was of interest (plasma membrane and intracellular),
cells were fixed and permeabilised prior to Fc receptor blockade by resuspending
them in 100µL of IC Fixation Buffer (00-8222, Invitrogen) and incubating at 4oC for
15 minutes (in a U-bottom 96-well plate). Cells were centrifuged at 300×g for 30
seconds to pellet cells, the supernatant was discarded and the pellet was resuspended
in 100µL Permeabilization Buffer (00-8333, Invitrogen). After incubation at 4oC
for 15 minutes, cells were washed, Fc receptor blocked and antibody stained as per
Section 2.7.1.
2.8 Analysing microvesicles by ImageStream
Microvesicles were acquired on the ImageStream in volumes of between 30µL and 50
µL at slow flow rate, 60x magnification with any excitation lasers required for the
fluorophores being used and the 785nm (scatter) laser, turned on and at full power.
The “Remove beads” setting was turned off upon loading each sample, and sample
acquisition was started only once the flow rate had stabilised. Microvesicle-free
samples (processed and “stained” as through they contained vesicles) were run as
controls to ensure there was no contribution to the vesicle gate from particulate
matter present in staining reagents. A storage gate was set to all events, and the
stopping gate was set to the vesicle population which is characterised by low SSC
and low to mid fluorescence of the generic label. At least 10,000 objects in the
vesicle gate, and at least 2 seconds of acquisition were acquired per sample to ensure
stability of fluorescence and concentration estimates. A schematic of the optical
path and main features of the ImageStream platform is shown in Figure 2.2.
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To determine the concentrations of microvesicle populations, IDEAS software
was used. A scatter plot showing Channel 02 fluorescence intensity plotted against
scattering intensity of Channel 12 was generated and a microvesicle gate re-applied
and inspected visually to exclude inappropriate events. The gate was adjusted where
necessary and sub-gated to identify lineage-specific populations. The objects/mL
statistic was applied to each population (and total microvesicles).
Unlike traditional flow cytometers, the ImageStream does not give the option
of an explicit trigger channel and instead triggers on any channel in which a signal
above background is sufficient. As such, vesicles were detected using fluorescence
triggering when using a generic fluorescent label, without the need to alter instrument
configuration.
Fluorescence channels are more sensitive at triggering on microvesicles than the
brightfield as significant haloing contributes to the sample fluorescence, augmenting
the signal to noise ratio. Microvesicles smaller than the minimum wavelength of
visible light (~400nm) cannot be seen in a brightfield image.
Table 2.1: Human neutrophil and macrophage antibodies
Antigen Clone
Concentration
used (µg/mL) Conjugate Isotype
Cat#,
source






























APC allophycocyanin; FITC fluorescein isothiocyanate; mIg murine immunoglobulin;
PB Pacific Blue; PE phycoerythrin; PE/Cy5 phycoerythrin cyanine 5
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Table 2.2: Mouse antibodies
Antigen Clone
Concentration
used (µg/mL) Conjugate Isotype Cat#, source
F4/80 BM8 2 BV650 rIgG2a
123149,
Biolegend















CD90 778053 2 AF488 rIgG2a
FAB7335G,
RnD Systems










CD45 30-F11 1 PerCP rIgG2b
103130,
Biolegend
CD11b M1/70 0.125 BV785 rIgG2b
101243,
Biolegend
AF Alexa Fluor; APC allophycocyanin; BV Brilliant Violet; PE phycoerythrin;
PE/Cy7 phycoerythrin cyanine 7; PerCP peridinin chlorophyll;
rIgG rat γ immunoglobulin
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Table 2.3: Plasma microvesicle antibodies
Antigen Clone
Concentration
used (µg/mL) Conjugate Isotype Cat#, source



































APC allophycocyanin; FITC fluorescein isothiocyanate;
mIg murine immunoglobulin; PB Pacific Blue; PE phycoerythrin;
PE/Cy phycoerythrin cyanine; PerCP/Cy peridinin chlorophyll cyanine
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Figure 2.2: Schematic of the ImageStream Optics. Aerial schematic of the
optics of the ImageStreamx MkII, where the sample flow is perpendicular to the page.
Each laser is facing upwards and is reflected into the optical path by a dichroic mirror.
A series of light-emitting diode (LED)s combine to produce white light illumination
for brightfield images. Retro-reflectors reverse the optical path of laser light to
ensure maximal excitation of objects in the flow cell. The auto-focus and velocity
detection system monitors images of speed beads to make real-time corrections to
the focus (distance between the objective lens and the flow cell) and to monitor
flow speed. The multi-spectral decomposition units are each a series of band-pass
dichroic mirrors, each of which is set at a shallower angle than the last, such that
different band-passes of light are reflected onto one of six different regions of the time
delay integration charge-coupled device (TDI CCD). The layout of a TDI CCD chip
is shown top right, with channel images deconvoluted into an example cell. Image
adapted from the ImageStream System Software User’s Manual.
2.9 Blocking external PtdSer on microvesicles
PtdSer exposed on the outer membrane leaflet of microvesicles (generated as per
Section 2.4.1) was blocked by resuspending a sufficient number of vesicles for the
experiment in 1x anxA5-binding buffer containing 50µg/mL anxA5 (PK-CA577-
1005-100 , PromoKine). Control vesicles for these experiments were resuspended in
1x anxA5-binding buffer without anxA5. Control and anxA5-blocked microvesicles
were incubated at 4oC for 30 minutes before adding them to macrophage cultures
as per the experiment design. To control for any direct effects of soluble anxA5 on
macrophage phenotype, an additional control treatment was included which consisted
of 1x anxA5-binding buffer with 50µg/mL anxA5, but no vesicles (incubated under
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the same conditions).
2.10 Stimulation of monocyte-derived
macrophages
2.10.1 Classical and alternative activation
Classical or pro-inflammatory activation of macrophages was achieved by treating
näıve monocyte-derived macrophages on day 7 of differentiation (generated as per
Section 2.3) with 10ng/mL LPS from E. Coli 0111:B4 (L2630, Sigma-Aldrich) and
20ng/mL IFNγ (300-02, PeproTech) for 24 hours at 37oC. These concentrations were
chosen as they induce sub-maximal macrophage activation.
Alternative activation of macrophages was achieved by treating näıve monocyte-
derived macrophages on day 7 of differentiation with 20ng/mL IL-4 for 24 hours
at 37oC. For the IL-4 titration experiment, between 5 and 20ng/mL IL-4 was used
instead.
Näıve, control macrophages used in experiments were monocyte-derived macro-
phages on day 7 of differentiation, cultured in medium alone for 24 hours at 37oC.
2.10.2 Stimulation with vesicles
Microvesicle populations generated as per Section 2.4, were pooled between at least
3 donors and used to stimulate macrophages for 24 hours at 37oC at the same time
as activating stimuli described in Section 2.10.1, as well as any other treatments
described in figure legends. For each experiment, the number of vesicles used is
described in the figure legend, as is the number of donors whose vesicles were pooled
(the same preparation of vesicles was used within each experiment).
2.10.3 Nanoparticle tracking analysis
The chamber was flushed with double 0.22µm filtered, deionised water until clean,
and then 0.5mL of PBS was flushed through (filtered as above) and the absence of
particulate matter was confirmed. 400µL of microvesicle sample was loaded into a
1mL syringe and flushed through until vesicles were visible using the camera. The
focus and camera gain settings were optimised, and the sample was injected into the
flow cell at speed 50, before acquiring 3, 60-second recordings. Filtered PBS was
flushed through the system between samples until no particles could be seen. Data
plotted for each sample is the mean of the three technical replicates. The analysis
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was performed using an NS300 analyser, using a 488nm laser, high sensitivity camera,
and syringe pump.
2.11 Cytometric bead array
Once experimental treatments had concluded, supernatants were collected, cen-
trifuged at 300×g for 5 minutes to remove non-adherent cells, and split equally
between two microfuge tubes. One tube per sample was used to assay the concen-
tration of IL-10 (558274, BD Biosciences), and IL-12 p70 (558283, BD Biosciences)
by cytometric bead array, the other was acidified for 10 minutes at room tempera-
ture with 1N HCl to release latent TGFβ, and then neutralised with 1.2N NaOH
containing 0.5M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). This
was because the TGFβ kit could only be run in isolation (560429, BD Biosciences).
After collection of the supernatant, cells were covered with PBS with 1mM ATP
(A2383, Sigma-Aldrich) for 30 minutes to induce IL-1β release. This was made
cell free as above and the IL-1β was then quantified using a cytometric bead array
following the procedure below (558279, BD Biosciences).
The cytometric bead array assay (558264, BD Biosciences) was used to quan-
titatively measure the concentrations of these analytes, following manufacturers
instructions. The principle of this procedure is that the supernatant is incubated at
room temperature with beads coated with antibodies against the different antigens
of interest simultaneously. After 1 hour, PE-conjugated detection antibodies raised
against each antigen of interest are added and samples are incubated for a further 2
hours at room temperature. The beads were washed to remove unbound detection
antibody by centrifuging at 500×g for 5 minutes and resuspending in 300µL of Wash
Buffer. Beads which bind to different antigens have discrete APC and APC-Cy7 fluo-
rescence values and so can be resolved from each other on a flow cytometer. Protein
standards for each analyte are incubated with beads alongside experimental samples
to construct a standard curve of PE fluorescence from which the concentration of
unknowns could be interpolated. Beads from the IL-1β kit were combined with the
beads from the IL-12 p70 and IL-10 kits prior to acquisition.
2.12 Detachment of macrophages
After removal of supernatant, macrophages were detached by washing once with
PBS and replacing with Accutase (A6964, Sigma-Aldrich) with 0.5% w/v ethylene-
diaminetetraacetic acid (EDTA). After 20 minutes at 37oC, the plate was placed at
4oC for 30 seconds, and then each well was gently agitated with the rubber stopper of
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a 1mL syringe before flushing and collecting the cell suspension with a 1mL pipette
into microfuge tubes. Cells were centrifuged at 300×g for 5 minutes and, after
aspiration of the supernatant, were processed as required by the experiment.
2.13 Microvesicle internalisation assays
2.13.1 Comparing fluorescent labels
To compare the suitability of microvesicle dyes as indicators of internalisation by
macrophages, MVTNFα were generated from 2×107 neutrophils from 3 donors, pooled,
and stained with 5µM CFSE, 50µM BODIPY maleimide or 50µM PKH as per
Section 2.6 (including wash). 5×106/mL of each stained microvesicle population
was seeded onto monocyte-derived macrophages generated as per Section 2.3 and
incubated for 90 minutes at 37oC. Cells were washed twice with PBS and coated
with trypsin with 0.05% w/v EDTA (25300-062, Life Technologies) until the cells
started to detach, where they were flushed and collected in complete medium with a
1mL pipette. Macrophages were centrifuged at 300×g for 5 minutes, resuspended
in 1% v/v formaldehyde fixative (P/0840/53, Fisher Scientific) and acquired on
the ImageStream at 40x magnification with the 488nm laser turned on. A 75%
“Threshold” mask was applied to the Channel 02 images (setting the threshold higher
than the macrophages’ natural green fluorescence) to facilitate counting the number
of microvesicles per cell and to quantify the intensity of the fluorescent spots.
2.13.2 Blocking the PtdSer-Mer interaction
To assess the importance of PtdSer on microvesicle internalisation by macrophages,
MVTNFα microvesicles pooled from 3 donors were stained with 5µM CFSE as above
and seeded onto monocyte-derived macrophages at 5×106/mL after 15 minutes of
either PtdSer blockade, or vehicle control (as per Section 2.9). Treatments were
staggered such that macrophages treated for 5, 30, 60 and 90 minutes were all
processed at the same time as in Section 2.13.1 above. A separate experiment was
conducted as above, where macrophages were treated with a Mer receptor inhibitor,
UNC-569 (445835-10MG, Millipore) at 10nM or vehicle (0.1% v/v dimethyl sulfoxide)
for 15 minutes prior to addition of untreated MVTNFα.
2.14 The C28/I2 micromass culture system
C28/I2 pro-chondrocyte cells were cultured in monolayer in DMEM (D5796, Sigma-
Aldrich) diluted 1:1 with Ham’s F12 (N4888, Sigma-Aldrich) with 10% v/v non-heat
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inactivated FBS (10270-106, Invitrogen, lot 41A0940K) and 100U penicillin and
100µg/mL streptomycin (“Complete C28/I2 medium”).
To generate 3D micromass constructs, monolayers were detached with trypsin with
0.05% w/v EDTA and centrifuged at 300×g for 5 minutes. Cells were resuspended
in complete C28/I2 medium at 2.5×107/mL and 20µL of suspension was seeded
per 48-well cell culture plate as a spot in the centre, using a positive displacement
pipette. The outer wells were filled with PBS to maintain humidity, the plate was
incubated at 37oC for 2 hours, and 500µL of complete C28/I2 medium was carefully
added to each micromass. After 24 hours at 37oC, the medium was aspirated
and replaced with serum-free, phenol red-free DMEM/F12 (21041-025, Invitrogen)
supplemented with insulin (10µg/mL), transferrin (5.5µg/mL), selenium (6.7ng/mL)
solution (41400-045, Life Technologies), penicillin and streptomycin as above, to
induce chondrocytogenesis. After 24 hours at 37oC, micromasses were washed once
with PBS and covered with treatments for a further 24 hours at 37oC.
To quantify glycosaminoglycan production, the medium was aspirated, micro-
masses were washed once with PBS and fixed in 100µL of 4% v/v glutaraldehyde
(G-6257, Sigma-Aldrich) for 15 minutes at room temperature. Micromasses were
rinsed once with 200µL of 0.1N HCl (to acidify) which was aspirated and replaced
with 100µL of Alcian blue 8GS (which stains glycosaminoglycans at low pH; A-5269,
Sigma-Aldrich) and left on a rocker at room temperature overnight. Alcian blue
was aspirated and the micromasses washed once with 0.1N HCl and once with PBS
before adding 100µL of 6M guanidine HCl (50950-250G, Sigma-Aldrich). Plates
were left on the rocker overnight to extract the glycan-bound Alcian blue which was
quantified by constructing a standard curve and measuring absorbance of 630nm
light. To control for the variable number of cells in each micromass contributing to
glycan deposition, supernatant DNA concentration was quantified by staining with
1x SYBR Green (S7563, Invitrogen), constructing standard curves of genomic DNA
and quantifying fluorescence at 535nm (excitation at 485nm). Data are expressed as
the µg of Alcian blue per ng of DNA per mL of supernatant.
2.15 Macrophage-conditioned medium
To generate single treatment conditioned-medium, macrophages were treated with
complete medium alone, 50ng/mL IFNγ, 50ng/mL IL-4, rheumatoid arthritis synovial
fluid or osteoarthritis synovial fluid (both pooled from 3 donors, diluted 1 in 100)
for 24 hours at 37oC. Supernatants were centrifuged at 300×g for 5 minutes to
remove cells. To control for the effects of these stimuli residual in the conditioned
media, each condition had a mirrored “cell-free” conditioned-media condition, where
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wells of medium alone were treated with the above stimuli. Comparing the cell-
conditioned and cell-free-conditioned media allowed controlling for the effect of the
exogenously-added mediators on chondrocyte function.
To test the effect of anxA1 blockade on macrophage conditioned-medium, mac-
rophages were treated with vehicle (PBS) or 3×106/mL MVTNFα, MVRA or MVOA
in the presence of 10µg/mL neutralising anxA1 antibody (clone 1B) or 10µg/mL
control mIgG1 for 24 hours at 37oC. Supernatants were centrifuged at 300×g to
remove cells.
To test the effect of both TGFβ depletion and anxA1 blockade on macrophage
conditioned-medium, macrophages were treated with vehicle (PBS) or 3×106/mL
MVTNFα, in the presence of 10µg/mL 1B anxA1-neutralising antibody or 10µg/mL
mIgG1, and then incubated for 2 hours with 1 in 100 beads coated with either an
anti-TGFβ antibody (560429, BD Bioscience) or a control antibody (558279, BD
Bioscience) at 4oC. Supernatants were centrifuged at 300×g to remove cells.
For all experiments, supernatants were then centrifuged at 13,000×g for 2 minutes
to remove platelets/apoptotic bodies and at 20,000×g for 30 minutes to remove
microvesicles and beads. Microvesicles were removed as previous work from this lab
has shown direct effects of microvesicles on chondrocytes3. Supernatants were then
used as described.
2.16 Treatment of primary synovial fibroblasts
Primary synovial fibroblasts from osteoarthritis patients undergoing arthroscopy
were a gift from Dr. Trinidad Montero-Melendez (William Harvey Research Institute).
Cells were seeded at low passage numbers (<P10) onto glass coverslips in 24-well
plates and allowed to adhere for 24 hours in RPMI medium with 10% v/v non heat-
inactivated FBS, 2mM L-glutamine, 100U/mL penicillin, 100µg/mL streptomycin,
1mM sodium pyruvate (S 8636, Sigma-Aldrich) and 1x MEM non-essential amino
acid solution (M 7145, Sigma-Aldrich).
To establish an inflammatory phenotype in synovial fibroblasts, cells were cultured
with 1% v/v (in PBS) rheumatoid arthritis patient synovial fluid generated as in
Section 2.4.3, or vehicle (PBS) for between 0 and 72 hours. Treatments were staggered
such that all cells were processed for staining together.
For all experiments, 1x golgi block (4980-03, eBioscience) was added to the existing
culture medium of fibroblasts to facilitate cytoplasmic accumulation of cytokines, 6
hours prior to fixation. Fibroblasts were fixed by aspirating the supernatant, washing
the cells once with PBS, and fixing with 1% v/v formaldehyde for 15 minutes at
room temperature. After removal of fixative, cells were washed twice with PBS
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Table 2.4: Immunofluorescence antibodies
Antigen Clone Host species Concentration
used (µg/mL)
Cat#, source
CD55 (DAF) 28 Mouse 10
ABIN1995655,
antibodies-online
CD21 (C3dR) Bu32 Mouse 15
354902,
Biolegend
CD106 (VCAM-1) STA Mouse 5
305802,
Biolegend
MCP-1 2D8 Mouse 10
MA5-17040,
ThermoFisher
TNFα 28401 Mouse 15
MA5-23720,
ThermoFisher
IL-6 MP5-20F3 Rat 5
MA1-22531,
ThermoFisher
Mouse IgG / Goat 4
F-11021,
ThermoFisher
Rat IgG / Donkey 4
A-21208,
ThermoFisher
with 0.02% w/v BSA (staining buffer) and permeabilised by covering with 0.1%
v/v triton X-100 (X100-100ML, Sigma-Aldrich) in staining buffer for 15 minutes
at room temperature. After removal of triton X-100, cells were washed twice with
staining buffer and covered in the appropriate primary antibody or negative control
in staining buffer (one antigen per coverslip). After 30 minutes at 4oC, primary
antibody solutions were aspirated, cells washed twice in staining buffer, and covered
in appropriate secondary antibody. See Table 2.4 for details of all primary and
secondary antibodies.
2.17 Macrophage-fibroblast co-culture system
To model the close interaction between macrophages and fibroblasts in the syn-
ovial membrane, but still allow independent observation of fibroblast phenotype,
monocyte-derived macrophages were differentiated as in Section 2.2, on 6-well 3µm-
pore transwell inserts (353091, Scientific Laboratory Supplies). Following 24 hour
treatment of day 7 macrophages with medium alone, 20ng/mL IFNγ & 10ng/mL
LPS, 50ng/mL IL-4, 3×106 MVTNFα/mL or combinations thereof, transwells were
washed twice with PBS, placed into a 6-well plate containing glass coverslips of
CHAPTER 2. MATERIALS AND METHODS 61
synovial fibroblasts, such that the transwell membrane was in contact with both
fibroblasts and macrophages. The wells were incubated for a further 24 hours in
complete macrophage medium at 37oC, from which point fibroblasts were treated as
in Section 2.16 (including addition of golgi block 6 hours prior to fixation).
2.18 Culture of HL60, NB4 and HEK293 cells
HL60 (CCL-240, ATCC) and NB4 (ACC 207, DSMZ) cell lines are two, promyelo-
cytic, suspension cell lines derived from separate patients with acute promyelocytic
leukaemia. These cells have been used as surrogates for the study of certain processes
in monocytes and neutrophils, as they can be induced to differentiate into models
of these cell types experimentally237,238. Both HL60 and NB4 cells were cultured in
RPMI with 10% v/v FBS and 2mM L-glutamine between passages 10 and 35 from
origin. Both lines were maintained at between 0.25×105 and 2×105 cells/mL.
HEK293 human embryonic kidney cells (CRL-1573, ATCC) were used as a backup
transfection system in the event that neither HL60 or NB4 cells could be transfected.
HEK293 cells were cultured in DMEM with 10% v/v FBS and 2mM L-glutamine
between passages 64 and 75 from origin. Cells were maintained at between 30% and
80% confluency. All cells were cultured at 37oC, with 5% v/v CO2 in humidified
incubators.
2.19 Alamar blue viability assay
Alamar blue viability dye (DAL1025, Thermo Fisher) was used to optimise blasticidin
(R21001, Thermo Fisher) selection conditions for HL60, NB4 and HEK293 cell lines.
Alamar blue is a reagent which is reduced by metabolically-active cells to the
yellow/green-excitable fluorophore resorufin, and can be used to compare relative
viability of cell colonies.
2.19.1 Cell number titration
Initially, the optimal number of cells per reaction was determined by serially diluting
each cell line into a 96-well plate, from 0 to 7.5×104 cells/well, and staining for 1
hour with 10% v/v alamar blue at room temperature. The plate was then run on a
NOVOstar fluorescence plate reader with excitation at 560nm and emission read at
590nm, including a blank, alamar blue-only control. The background fluorescence
reading for the blank sample was subtracted from each experimental sample.
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2.19.2 Blasticidin titration
To determine the kinetics of blasticidin-induced cell death, HL60, NB4 and HEK293
cells cultured under conditions described above, in their respective growth medium
alone, or with between 5 and 20µg/mL of blasticidin. Every other day for 12 days
from 24 hours after seeding, cells from each line in medium alone were counted using
a haemocytometer. 3×104 of these cells and an equal volume of cell suspensions
treated with blasticidin were transferred into a 96-well plate, stained with alamar
blue for 1 hour and read as above.
2.20 Comparing activity of microvesicles and
exosomes on macrophages
MVTNFα were generated and pooled from 3 donors (2×107 human neutrophils from
each, as per Section 2.4.1). The microvesicle pellet was retained and the supernatant
further centrifuged at 100,000×g for 1 hour at 4oC. Both pellets were resuspended
in 100µL of RPMI and, along with the supernatant, were kept. Human monocyte-
derived macrophages were treated with medium alone, or 20ng/mL IFNγ & 10ng/mL
LPS for 24 hours, with the entire 20,000×g pellet, 100,000×g pellet, or supernatant.
Macrophages were detached, stained with antibodies against HLA-DR, DP & DQ,
CD86 and CD206, and analysed on a flow cytometer.
2.21 Zymosan-induced peritonitis model
A model of sterile, acute peritoneal inflammation can be induced in mice by in-
jecting zymosan A (Z4250, Sigma-Aldrich) intraperitoneally. This simple model
provides a convenient compartment in which potential modulators of inflammation
can be injected. Ten-week-old C57BL/6 mice (Charles River, UK) were injected
intraperitoneally with 0.5mL of 2mg/mL zymosan using a 29G needle. After 24
hours, mice were randomised and injected with 500µL PBS alone, or containing
a range of MVTNFα doses, pooled from equal numbers of vesicles from 5 human
donors, as indicated in each figure legend. Which mouse received which treatment
was blinded from its administration until the conclusion of the analysis.
After a further 24 hours, at the peak of macrophage presence in the peritoneum,
mice were euthanised with a rising concentration of CO2, and the skin above the
peritoneum washed with 70% v/v ethanol and removed. The peritoneal cavity was
lavaged by injecting it with 5mL of air, followed by 5mL of ice-cold PBS with 2mM
EDTA using a 25G needle. The mouse was agitated to detach as many cells as
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possible, and the lavage fluid collected with a 19G needle, avoiding blood vessels and
viscera.
The lavage fluid was centrifuged at 300×g for 5 minutes at 4oC to pellet cells
which were then processed and stained for F4/80, MHCII, CD86 and CD206 by
flow cytometry as per Section 2.7. The supernatant from the two group peritonitis
experiment was sent to Labospace to quantify the concentrations of TGFβ, IL-1β,
monocyte chemoattractant protein 1 (MCP-1), KC, IL-6 and TNFα by Luminex.
2.22 K/BxN model of autoantigen-induced
arthritis
2.22.1 Serum transfer and ankle injection
The K/BxN serum-transfer model allows the induction of a neutrophil-driven, acute
arthritis in mice by injecting näıve mice with serum from transgenic mice expressing
the KRN T cell receptor transgene and I-Ag7 MHCII variant239. These mice express
autoantibodies against the ubiquitously expressed glucose-6-phosphate isomerase,
which accumulate and form immune complexes in joints. The result is the systemic
and symmetrical manifestation of joint inflammation only 2 to 4 days after injection.
K/BxN arthritis was induced by injecting 8-week-old C57BL/6 mice intraperi-
toneally with 200µL of K/BxN mouse serum from a single batch, diluted 1 in 2 with
PBS, produced and kindly given by Dr. Dianne Lukes (William Harvey Research
Institute) who bred KRN mice with NOD mice, and collected the serum from the off-
spring at 10 weeks of age. This injection was repeated again 48 hours later. 24 hours
later, mice were anaesthetised with 3% v/v isofluorane, and injected intra-articularly
into the synovial space of each ankle. Each mouse was randomised to 10µL of either
3×106 MVTNFα (pooled from equal numbers of vesicles from 3 human donors) in the
left or right ankle, and vehicle (PBS) alone in the other. Injections were performed
with a Hamilton syringe with a 26G needle which was washed with ethanol and then
PBS following every injection. Which ankle received which treatment was blinded
from its administration until the conclusion of the analysis.
2.22.2 Ankle digest
Forty-eight hours after intra-articular injection, mice were euthanised with a rising
concentration of CO2, and the legs removed and placed in ice-cold RPMI for transport
between the in vivo facility and the tissue culture laboratory. As much soft tissue
was removed from the legs as possible, the femurs were removed, taking care not
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to damage the tibia, and the ankle synovium was cut with dissection scissors and
opened by mechanical force.
Each leg was placed in a separate Erlenmeyer flask containing 15mL digestion
buffer (RPMI + 0.5µg/mL collagenase D [11088866001, Sigma-Aldrich] and 40µg/mL
DNAse I [10104159001, Sigma-Aldrich]). Under vigorous agitation with magnetic
stirrers, the legs were incubated at 37oC for 30 minutes before collecting the cell
suspension through a 70µm cell strainer into a 50mL tube containing 10mL of ice-cold
RPMI with 10% v/v FBS (complete RPMI). The legs were covered with 15mL of
digestion buffer and incubated again at 37oC for 30 minutes under agitation. Once
the second round of cell suspension for each leg had been strained and combined
with the first round, the volume was made up to 50mL with ice-cold, complete RPMI
and the suspensions were centrifuged at 300×g for 10 minutes at 4oC.
The supernatant was aspirated and the cells were resuspended in 1x Zombie Aqua
fixable viability dye (423101, Biolegend) to exclude dead cells, and incubated at 4oC
for 20 minutes. 2mL of FACS buffer (PBS + 0.02% w/v BSA) was added to each
tube to remove unbound dye from solution, and tubes were centrifuged at 300×g
for 10 minutes at 4oC. Cell pellets were processed for flow cytometry, including Fc
receptor blocking, and staining for CD45, CD11b, F4/80, CD86, MHCII, CD206,
CD90, VCAM-1, and CD55 as per Section 2.7.
2.23 Generating microvesicles from platelets
In confirming that platelets produce microvesicles in response to TNFα stimulation,
500µL of platelet-rich plasma was generated as described in Section 2.2 from 5
healthy donors and stimulated either with 50ng/mL TNFα or vehicle (PBS) for 20
minutes at 37oC. Platelets were removed by centrifuging at 13,000×g for 2 minutes
at 4oC, supernatant was stained with 50µM BODIPY maleimide, and centrifuged at
20,000×g for 30 minutes at 4oC to pellet microvesicles. Pellets were resuspended in
30µL of double sterile-filtered (0.22µm) PBS and enumerated on the ImageStream.
To generate MVTNFα from washed platelets, 2µg/mL of prostacyclin (P6188-1MG
Sigma-Aldrich) and 0.02U/mL apyrase were added to platelet-rich plasma and mixed
gently for 1 minute, to prevent platelet activation. The plasma was centrifuged at
1,000×g for 10 minutes at room temperature to pellet the platelets, the supernatant
was discarded, and the pellet was resuspended in MTH buffer (134mM NaCl, 2.9mM
KCl, 340µM Na2HPO3, 12mM NaHCO3, 20mM HEPES, 1mM MgCl2, 0.1% w/v
glucose, 0.35% w/v BSA and 0.02U/mL apyrase) with 2µg/mL of prostacyclin. The
platelets were pelleted by centrifuging at 1,000×g for 10 minutes at room temperature,
the supernatant was aspirated and the pellet was resuspended in MTH buffer. The
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platelets were counted using a haemocytometer, their concentration adjusted to
2×107/mL and were allowed to rest at room temperature for 30 minutes. Platelets
were stimulated with 50ng/mL TNFα for 20 minutes at 37oC, and their microvesicles
were isolated (and an aliquot from each donor was labelled and enumerated) as
above.
2.24 Cloning anxA1 into a bicistronic expression
vector
The expression vector chosen to carry the anxA1 open reading frame (ORF; SC1197-
13, OriGene) was the pIRESbsd2 vector. Once the anxA1 ORF is cloned into
the XhoI restriction enzyme site, the messenger RNA produced by the vector is
bicistronic, containing both the gene of interest, and a blasticidin resistance gene
(See Figure 2.3). This ensures that if a cell is expressing the resistance gene, it is
also expressing anxA1.
To clone the anxA1 ORF into the XhoI site, it first had to be used as the
template in a polymerase chain reaction (PCR) to produce an ORF product with
XhoI restriction sites, which would produce complimentary “sticky ends” after
digestion with the XhoI enzyme. This was performed by combining 1ng of cDNA
template, 0.5µM of forward primer, 0.5µM of reverse primer and 50% v/v of HotStart
PCR master mix (K1051, Thermo Fisher) in a total volume of 50µL (made up with
molecular biology grade water) per reaction. PCR primers and protocol are shown
in Tables 2.5 and 2.6, respectively. Different annealing temperatures were used
for different samples, between 50oC and 70oC (in steps of 5oC) but all resulted in
amplified ORF. The pIRESbsd2 vector, and the forward and reverse PCR primers
were designed and kindly provided by Dr. Graham Craggs (UCB). Amplification
was confirmed by loading 5µL of PCR product, 2µL of Green DNA Gel Loading
Dye (AG18, DNA Gdansk) and 18µL of molecular biology water into a lane of
a 1.8% w/v agarose gel (G501801, Thermo Fisher), with high and low kilobase
ladders to confirm size (N3231S & N3232S, New England Biolabs). Gels were imaged
using a FluorChem E chemiluminescent imager. The amplicon was purified by
running through a GenElute PCR Clean-Up Kit (NA1020, Sigma-Aldrich), following
manufacturer’s instructions.
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Figure 2.3: Plasmid maps of the pIRESbsd2 expression vector. Annotated
plasmid maps of the pIRESbsd2 expression vector before and after ligation of the
anxA1 and ORF into the XhoI site.
Table 2.5: PCR Primers
Primer Sequence
Forward 5’-actg ctcgag ccacc atggcaatggtatcagaattcc-3’
Reverse 5’-actg ctcgag ttagtttcctccacaaagagcc-3’
Table 2.6: PCR Protocol
Step Temperature (oC) Duration (sec)
Initial denaturation 98 30
Denaturation 98 5
Annealing 50 - 70 20
Extension 72 20
Final extension 72 120
Hold 4 -
Denaturation, annealing and extension sequence repeated for 30 cycles before
proceeding to final extension and hold.
CHAPTER 2. MATERIALS AND METHODS 67
The purified amplicon and pIRESbsd2 vector were separately digested by combining
2.5µg of DNA, 20U of XhoI restriction enzyme (R0146S, New England Biolabs) and
10% v/v of CutSmart buffer (B7204S, New England Biolabs) in a total volume of
50µL (made up with molecular biology grade water). Each reaction was incubated
at 37oC for 30 minutes, before adding 20U more XhoI enzyme, and incubating for a
further 30 minutes. The digested and undigested vectors were run on an agarose
gel (as above) to confirm the absence of supercoiled and nicked DNA bands, and
the presence of a single, linear DNA band. The digested amplicon was not run as
the difference in size between digested and undigested fragments was too small to
resolve. To prevent self-ligation of the plasmid, its ends were dephosphorylated by
combining 5µL of digested vector, 25U of Antarctic phosphatase (M0289S, New
England Biolabs) and 5µL of Antarctic phosphatase reaction buffer (B0289S, New
England Biolabs), and incubating at 37oC for 30 minutes. Both the digested amplicon
and vector fragments were purified separately through a GenElute PCR Clean-Up
Kit as above.
To ligate the complimentary ends of the anxA1 amplicon and vector, ligation and
control reactions were formulated as in Table 2.7 and incubated at room temperature
for 5 minutes. Competent E. coli (C2987I, New England Biolabs) were thawed
on ice, and 2µL of each ligation or control reaction was added to separate vials of
bacteria. The bacteria were heat shocked at 42oC for 30 seconds to facilitate uptake
of ligated plasmids, and incubated at 4oC for 5 minutes. To each vial, 950µL of SOC
outgrowth medium (B9020S, New England Biolabs) was added and mixed vigorously
at 37oC for 1 hour. From each vial, 400µL was added to agar plates (containing
50µg/mL carbenicillin C1613-1ML, Sigma-Aldrich), spread with a spreader, allowed
to soak in for 10 minutes, and incubated upside down at 37oC overnight.












Vector only 1 0 0 10 9
Vector + ligase 1 0 1 10 8
Vector + ligase + amplicon 1 5 1 10 7
Ligase: T4 ligase (M0202T, New England BioLabs);
Buffer: 1x T4 DNA Ligase Reaction Buffer (B0202S, New England BioLabs)
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2.25 Picking and identifying correctly ligated
clones
After confirming a small number of colonies on the control plates, 24 transformed
E. coli colonies were picked from the full ligation plate and seeded into individual
cultures of 3mL of LB broth with 50µg/mL carbenicillin. Colonies were incubated
on a shaker at 37oC overnight. From each culture, 1.8mL was used in a QIAprep
Spin Miniprep Kit (27106, Qiagen) to isolate plasmid DNA, following manufacturer’s
instructions. The remaining volume of cultures was kept. A diagnostic restriction
digest with EcoRI enzyme (R3101S, New England Biolabs) was performed for each
clone by combining 2µL of plasmid, 20U of EcoRI enzyme and 10% v/v CutSmart
buffer in a total volume of 50µL (made up with molecular biology grade water).
Each reaction was incubated at 37oC for 30 minutes, before adding 20U more EcoRI
enzyme, and incubating for a further 30 minutes. Each plasmid clone was run on
an agarose gel as above to confirm diagnostic DNA bands. Two of the retained
E. coli colonies with EcoRI digest bands diagnostic of anxA1 ORF ligation in the
correct orientation, were seeded with an inoculating loop onto agar plates containing
50µg/mL carbenicillin as above, and incubated at 37oC overnight.
A single clone from each plate was picked and seeded into 3mL of LB broth with
50µg/mL carbenicillin and incubated on a shaker at 37oC overnight to form a starter
culture. Each 3mL culture was seeded into 3L of LB broth in an Erlenmeyer flask
and incubated on a shaker at 37oC overnight to bulk up the bacterial colonies. Each
colony was passed through a GenElute HP Endotoxin-Free Plasmid Maxiprep Kit
(NA0400, Sigma-Aldrich), following manufacturer’s instructions.
Isolated plasmid DNA was concentrated by adding 0.1 volumes of 3M sodium
acetate and 0.7 volumes of isopropanol, mixing by inversion, and centrifuging at
15,000×g for 30 minutes at 4oC. The supernatant was aspirated and the pellet was
resuspended in 70% v/v ethanol and centrifuged at 15,000×g for 30 minutes at 4oC
again. The supernatant was aspirated, the pellet allowed to air dry and resuspended
in 200µL of molecular biology grade water. Each DNA preparation was assayed
for concentration and purity using a Nanodrop 2000 (Thermo), and adjusted to
1µg/µL. An additional diagnostic restriction digest was performed for each clone by
combining 1µg of plasmid, 20U of HindIII enzyme (R3104S, New England Biolabs)
and 10% v/v CutSmart buffer in a total volume of 50µL (made up with molecular
biology grade water). Each reaction was incubated at 37oC for 30 minutes, before
adding 20U more HindIII enzyme, and incubating for a further 30 minutes. Each
plasmid clone was run on an agarose gel as above to confirm diagnostic DNA bands.
A single clone was used only from this point on.
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2.26 Linearising pIRESbsd2-AnxA1 expression
vector and transfection
To linearise the pIRESbsd2-AnxA1 expression vector to increase the efficiency of
stable transfection, a restriction digest of an AdhI restriction site at position 5495
in the ampicillin resistance gene was performed. This was performed by combining
100µg of plasmid, 10U of AhdI enzyme (R0584S, New England Biolabs) and 10%
v/v CutSmart buffer in a total volume of 50µL (made up with molecular biology
grade water). Each reaction was incubated at 37oC for 30 minutes, before adding
10U more AhdI enzyme, and incubating for a further 60 minutes. The digested and
undigested vectors were run on an agarose gel (as above) to confirm the absence of
supercoiled and nicked DNA bands, and the presence of a single, linear DNA band.
The linearised DNA was purified and concentrated by adding 0.1 volumes of 3M
sodium acetate and 2 volumes of ethanol, mixing by inversion, and centrifuging at
15,000×g for 30 minutes at 4oC. The supernatant was aspirated and the pellet was
resuspended in 70% v/v ethanol and centrifuged at 15,000×g for 30 minutes at 4oC
again. The supernatant was aspirated, the pellet allowed to air dry and resuspended
in 200µL of molecular biology grade water. Each DNA preparation was assayed for
concentration and purity using a Nanodrop 2000, and adjusted to 1µg/µL. The DNA
was stored at -20oC until use.
2.27 Transfection of HL60, NB4 and HEK293
cell lines
HEK293 cells were transfected with the linear pIRESbsd2-AnxA1 expression vector
by incubating the DNA in ViaFect reagent (E4981, Promega) at 1µg/4µL for 20
minutes at room temperature, and then adding this solution onto HEK293 cells in a
6-well plate at ~70% confluency.
Transfection of HL60 and NB4 cells was attempted with the above method twice
(the second time titrating the DNA:ViaFect ratio), and also using Lipofectamine
3000 (L3000008, ThermoFisher) and nucleofection (VACA-1003, Lonza), following
manufacturers’ instructions.
For all three cell lines, a control well was included which was subjected to the
same reagents and/or procedures, but was not given any exogenous DNA. At 48 hours
post transfection, all three cell lines were washed once with PBS and cultured in
their standard medium, with 10µg/mL blasticidin. Blasticidin medium was removed
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and replaced every other day for 5 days (for HEK293 cells) of for 7 days (for HL60
and NB4 cells).
AnxA1 expression was confirmed by immunolabelling cells as described in Section
2.7, and acquiring the samples on a FACSCanto II cytometer.
2.28 Software and statistical analysis
ImageStream data was collected and analysed using the Inspire and IDEAS 6
software, respectively (Amnis). Flow cytometry data was collected and analysed
using FACSDiva (BD Biosciences), and FlowJo 10 (FlowJo) and R 3.3.4, respectively.
Light scatter phase function simulation was performed using Mie Simulator 1.05.
Schematic figures created using Inkscape 0.91. Manuscript prepared in LATEX (Tex
Live 2016 distribution) using TeXstudio 2.10.8.
Statistical and graphical analysis was performed with R 3.3.4. Normality of
residuals was evaluated for all models fit. Repeated-measures data was fitted using
mixed general linear models (instead of the more traditional repeated measures
ANOVA). A major caveat of biological research, where a single donor’s cells are
split between multiple treatments, is violation of the assumption of independence.
In such situations, correlations between residuals were tested for and removed by
normalising to a control treatment, or modelled using a mixed model approach.
For post-hoc pair-wise comparisons, multiplicity-adjusted p values are shown.
Tukey (Kramer) was chosen when all comparisons were of interest in single factor
models and Holm-S̆idák was chosen when select comparisons were of interest or in
factorial models, as indicated in figure legends. All variables used to build linear
discriminant models were first standardized by their mean and standard deviation.
2.29 In vivo group size calculations
A pilot peritonitis experiment was performed to establish a range of vesicle doses
which could elicit a change in macrophage phenotype. A Monte Carlo simulation
was performed to determine the minimum number of mice per group needed to
achieve the same effect size as seen with the 2x107 MV dose (assuming a coefficient
of variance of 20% , as seen in other peritonitis experiments), with 80% power, at an
alpha level of 5%. A separate Monte Carlo simulation was performed to determine
the minimum number of mice per group needed to detect a 30% decrease in median
fluorescence intensity of measured antigens, assuming a 20% coefficient of variation,
a power of 80%, and alpha of 5%.
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The Monte Carlo simulations were performed by simulating 2 normal distributions,
each with 1000 observations, with means and standard deviations corresponding
to the estimated variability and effect size considered to be biologically significant.
Each distribution was sampled (with replacement) for a range of group sizes, from 3
to 100, and at each iteration, a p value for a t test between each pair of samples was
calculated. This process was repeated 10,000 times, and the minimum group size
which achieved p values smaller than 0.05 at least 80% of the time were chosen as
the required group sizes.
Chapter 3
Results
3.1 Optimisation of microvesicle preparation,
storage and analysis
3.1.1 Comparing lower limits of detection between
cytometers
To compare the ability of the ImageStreamx MKII and an LSRFortessa at resolving
small, fluorescent particles, poly-fluorescent latex beads ranging from 1µm to 0.02µm
in diameter were acquired on both machines (Figure 3.1). While the LSRFortessa was
able to fully discriminate 0.5µm and 1µm beads, the 0.1µm bead population almost
completely overlapped with the machine noise in all parameters, and the 0.02µm
beads were wholly undetectable. The ImageStream was able to fully resolve all
beads larger than 0.1µm, and most of the 0.02µm population based on fluorescence,
area and diameter parameters. It is important to note that while area and diameter
parameters can be plotted for the beads, they are vastly overestimated for particles
under 10µm. Much of the 0.02µm bead population is estimated to be larger than
the other bead populations, partly because they are brighter (at least compared to
the 0.1µm and 0.5µm populations) and produce a larger fluorescent halo, and partly
because there is greater measurement error for small particles, where a single pixel
difference equates to a change of 0.3µm2.
3.1.2 Detecting microvesicles in complex biological fluids
To test if the ImageStream was therefore capable of resolving fluorescent microvesicles,
isolated human neutrophils, platelet poor/rich plasma and whole blood (1 in 10) were
stained with 50µM BODIPY maleimide and acquired on the ImageStream (Figure
3.2). In all fluid samples, a low scatter, low/medium fluorescent population was
detected which, when interrogated, consisted of single, uniformly-rounded objects
which could be removed when pelleting at 20,000×g for 20 minutes.
72
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Figure 3.1: Small particle resolution of the ImageStreamX MkII and
LSRFortessa. Poly-fluorescent latex beads of 1.0µm, 0.5µm, 0.1µm and 0.02µm
were run individually on an ImageStreamX MkII and an LSRFortessa cytometer.
Upper panels show dot plots of right angle light/side scatter (SSC) intensity against
A each bead’s brightest channel fluorescence intensity (Channel 2 for the 0.02µm
and 0.1µm beads, and channel 3 for the 0.5µm and 1µm beads), area and diameter
parameters on the ImageStream, and B phycoerythrin (PE) intensity, forward
angle light scatter (FSC) area and FSC width on the LSRFortessa (with marginal
histograms). C Representative ImageStream images of the three largest bead
populations showing the two brightfield channels (set here as Ch01 and Ch09), the
“PE channel” (Ch03) and the SSC channel (set here as Ch12) where scale bars apply
to all images.
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Figure 3.2: Detection of microvesicles in different biological fluids. A Dot
plots showing right angle light/side scatter (SSC) against FITC fluorescence for
platelet poor plasma, platelet rich plasma, whole blood and isolated neutrophils
stained with 50µM BODIPY maleimide. B Representative brightfield, BODIPY
maleimide and SSC images of events inside dot plot gates.
3.1.3 Comparing fluorescent labels for microvesicle
triggering
As a major hurdle in identifying microvesicles is distinguishing them from electronic
noise in the cytometer (including the ImageStream), a dye is needed which will label
all membrane-bound objects as anxA5 is not a reliable marker for microvesicles84.
BODIPY maleimide, CFSE and PKH67 are dyes which bind to cysteine residues,
intracellular/luminal lysine residues or lipid bilayers, respectively. These dyes were
titrated in technical replicates of a single MVTNFα preparation, pooled from 5 donors,
to compare relative labelling efficiency (Figure 3.3). When enumerating the detectable
microvesicles, CFSE and BODIPY maleimide fully labelled the microvesicles from
4µM and 40µM, respectively, whereas PKH67 did not achieve full labelling.
3.1.4 Freeze-thaw stability of microvesicles and their labels
Microvesicles have previously been shown to be resistant to freeze-thaw cycles, and
so can be re-used without aliquotting87. To test whether fluorescently labelled































































Figure 3.3: Titration of pan-microvesicle labels. A single MVTNFα prepara-
tion, pooled between 5 neutrophil donors (2×107 cells each), was stained separately
with BODIPY maleimide, PKH67 or CFSE in the range 10-7M - 10-4M, and acquired
on the ImageStream. Individual technical replicates are shown with model fits by
non-linear regression.
microvesicles can be frozen and re-used, a single MVTNFα preparation, pooled from 3
donors, was labelled with 5µM CFSE, 50µM BODIPY maleimide or 50µM PKH67
or left unstained. The stained samples were either run immediately, or freeze-thawed
between -80oC and 20oC once, twice or three times (one freeze-thaw cycle per day;
Figure 3.4). The unlabelled samples were freeze-thawed 3 times, then labelled
with each dye separately to control for any loss of vesicles. On enumerating the
microvesicles in each sample, there was no difference between the numbers in non-
freeze-thawed samples and the samples which underwent 3 cycles and were then
labelled. While CFSE was most resistant to loss of fluorescence on freeze-thawing,
all three dyes reported fewer positive microvesicles when frozen and re-used.
3.1.5 Comparing microvesicle yields between microfuge
tubes
Maximising the yield of microvesicles is important to facilitate efficient experimenta-
tion and generate as much data from a single isolation as possible. To optimise mi-
crovesicle recovery during the 20,000×g centrifugation step, individual supernatants
from TNFα-stimulated neutrophils were labelled with 50µM BODIPY maleimide FL,
split between standard and LoBind tubes and pelleted at 20,000×g for 30 minutes at
4oC. Vesicles were resuspended in 30µL of sterile 0.22µm-filtered PBS and counted
using an ImageStream(Figure 3.5). The recovery from LoBind tubes was, on average,
1.83 fold higher compared to standard tubes for each sample (p = 0.054) although
half of samples acquired saw little change or even a small decrease in yield. As this






































































Figure 3.4: Freeze-thaw stability of pan-microvesicle labels. A single
MVTNFα preparation, pooled between 3 donors (2×107 each), was stained sepa-
rately with 50µM BODIPY maleimide, 50µM PKH67 or 5µM CFSE and enumerated
on the ImageStream after successive freeze-thaw cycles between -80oC and 20oC. The
x axis shows the number of freeze-thaw cycles. To control for loss of microvesicles
during freeze thaw, one group from each dye was freeze-thawed 3 times prior to
staining. Individual technical replicates are shown with bars at group means.
data suggested that yield was either slightly higher or roughly equivalent compared
to standard tubes, LoBind tubes were used for all future microvesicle isolations.
3.1.6 Exosomes are not enriched for in the 20,000×g pellet
As their size distribution overlaps with that of microvesicles, exosomes are the most
problematic contaminant in microvesicle preparations. While platelets are reasonably
easy to identify using the ImageStream, exosomes are indistinguishable from the
microvesicle population. To confirm the absence of important numbers of exosomes in
the microvesicle preparations, microvesicles were pelleted at 20,000×g for 20 minutes
or 100,000×g for 1 hour at 4oC, lysed (along with C28/I2 cells as a positive control),
run on a sodium dodecyl sulphate polyacrylamide gel and probed for Tsg101 and
β-actin as a house-keeping gene (Figure 3.6). Tsg101 is a protein required for the
formation of multivesicular bodies whose only vesicular compartment is exosomes.
The protein was present in the C28/I2 and 100,000×g lysates but not the 20,000×g
(10 minute exposure).
3.1.7 Microvesicles are stable at -80oC
Experimental use of microvesicles on the day of isolation is not always possible, and
so short to mid-term storage is necessary. To evaluate the stability of microvesicles
across different temperatures and times, MVTNFα pooled from 3 neutrophil donors




























Figure 3.5: Comparison of mi-
crovesicle yield recovered after pel-
leting in standard and LoBind-
coated microfuge tubes. 5×106 hu-
man neutrophils were isolated from
whole blood and stimulated for 20 min
with 50ng/mL TNFα at 37oC. After re-
moval of cells and small contaminants
by centrifugation, vesicles were labelled
with 50µM BODIPY maleimide, split
equally between standard and LoBind-
coated microfuge tubes and pelleted
at 20,000×g for 30 min at 4oC. Af-
ter aspiration of the supernatant, pel-
lets were resuspended in 30µL of sterile-
filtered PBS and counted using the Im-
ageStream. Data analysed with paired t
test and lines connect data from a single
donor.
Figure 3.6: Microvesicle preparation is negative for Tsg101. Neutrophil
microvesicles were generated with 50ng/mL TNFα and (following removal of cells
and platelets/apoptotic bodies), were centrifuged at 20,000×g for 20 minutes or
100,000×g for 1 hour at 4oC (in rotors with kadjusted factors of 692.39 and 406.43,
respectively). Microvesicle preparation lysates (30µg of protein) and a control
lysate of C28/I2 cells were probed for Tsg101 and β-actin. Representative blot of 3
independent experiments with separate biological replicates.
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were incubated at 37oC, room temperature, 4oC, -20oC and -80oC for 1 week, 72
hours, 48 hours, 24 hours or processed immediately (Figure 3.7). Samples were
labelled with BODIPY maleimide and enumerated on the ImageStream. Samples
incubated at 4oC and above lost around a third of their microvesicles after 24 hours,
and none were detected at 1 week. Samples stored at -20oC gradually declined
in number with ~50% remaining after 1 week. The only samples to retain their
microvesicle numbers were those stored at -80oC.
3.1.8 Neutrophil microvesicles express antigens of their
parent cells
To test whether microvesicles can be immunophenotyped in tandem with their
parent cells using the ImageStream and whether neutrophil microvesicles express
neutrophil antigens, TNFα-stimulated neutrophils were labelled with BODIPY
maleimide and fluorescent antibodies against CD66b (a reliable human neutrophil-
restricted marker), CD62L and CD11b (Figure 3.8). Neutrophils and microvesicles
were gated separately based on their scatter and BODIPY maleimide fluorescence
and interrogated for antibody staining. All neutrophils were positive for the three
antigens, showing varying degrees of activation (as indicated by CD62L and CD11b
expression). Microvesicles were largely positive for all three antigens although were
considerably dimmer than the cells.
3.1.9 ImageStream concentrations decline linearly with
sample dilution
While evaluating the accuracy of the ImageStream in enumerating microvesicles, it
was important to confirm the estimation of concentration was linear with sample
dilution. To test this, MVTNFα were generated from 3 donors, labelled with BODIPY
maleimide and enumerated on the ImageStream either as they were, or following
dilutions of 1 in 2, 1 in 4 and 1 in 8 (Figure 3.9). Microvesicle concentration estimates
showed excellent linearity with dilution with Pearson correlation coefficients ≥ 0.992.
3.1.10 Profiling populations of circulating microvesicles
To confirm the ability of the ImageStream to phenotype isolated microvesicle pop-
ulations, plasma microvesicles were generated from 6 healthy donors, dyed with
BODIPY maleimide Texas Red, split between separate staining reactions and im-
munolabelled separately (i.e. one antibody per reaction) for CD235 (erythrocyte),
CD41 (platelet), CD45 (leucocyte), CD146 (endothelial cell), CD14 (monocyte),









































































Figure 3.7: The effect of storage temperature on microvesicle stability.
MVTNFα were generated from 3×107 neutrophils from each of 3 donors, split between
5 groups and stored at a range of temperatures, for different lengths of time up to
a week. Stored microvesicles were stained with 50µM BODIPY maleimide (after
thawing if necessary) and enumerated on the ImageStream. Individual biological
replicates are shown, where solid lines connect group means and dashed lines connect
data from each donor.
CD66b (neutrophil) and CD3 (lymphocyte). Microvesicles were acquired on the
ImageStream and the number of microvesicles from each population was expressed as
a percentage of all BODIPY maleimide+ microvesicles and as their absolute number
per mL of plasma (Figure 3.10 and Table 3.1). The most abundant population was
erythrocyte-derived (37.5% ± 6.9; mean ± standard deviation), followed by platelet
(24.3% ± 3.6), leucocyte (12.0% ± 5.1) and endothelial cell (6.6% ± 2.0), although
11.5% of BODIPY maleimide+ microvesicles were negative for all these antigens.
Of the leucocyte populations, monocyte and neutrophil-derived vesicles represented
3.4% ± 2.5 and 3.6 ± 3.1 of the total, respectively, while thymocyte-derived vesicles
constituted only 0.9% ± 0.9. A small number of CD45+ vesicles did not express
CD14, CD66b or CD3.
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Figure 3.8: Simultaneous phenotyping of neutrophils and their microvesi-
cles. Neutrophils were stimulated with 50ng/mL TNFα for 20 min, stained with
50µM BODIPY maleimide and antibodies against CD66b, CD62L and CD11b, and
acquired on the ImageStream. Microvesicles and neutrophils were gated separately.
A Overlay histograms showing the intensity of antigen staining for neutrophils,
microvesicles and isotype controls. B Representative brightfield, fluorescence (with
merged images) and SSC images for gated neutrophils and microvesicles.













Donor 1 rS= 1.00; rP= .996
Donor 2 rS= 1.00; rP= .992














Figure 3.9: Accurate concentra-
tion estimates across linear dilu-
tion. MVTNFα were generated from
three donors, stained with 50µM BOD-
IPY maleimide, diluted up to 1 in 8 with
sterile-filtered PBS and enumerated on
the ImageStream. Individual samples
and linear regression lines shown for each
donor. rS - Spearman correlation coeffi-
cient; rP - Pearson correlation coefficient.
3.1.11 Comparing inflammatory stimuli for inducing
microvesicle release
To study the effects of neutrophil microvesicles in vitro, model stimuli needed to
be characterised for their ability to induce ectocytosis. To this end, a panel of
pro-inflammatory stimuli (TNFα, IL-8, LTB4, zymosan and E. coli) were use to treat
isolated neutrophils for 20 minutes, and the number of vesicles was quantified. Data
were represented as the number of microvesicles per neutrophil, and all treatments
induced a comparable ≥ 2-fold increase over the vehicle-treated neutrophils (Figure
3.11 A).
3.1.12 TNFα induces rapid and persistent ectocytosis
To assess how the rate of ectocytosis changes upon stimulation, isolated neutrophils
labelled with BODIPY maleimide were stimulated with TNFα or vehicle and im-
mediately acquired. Data are shown as objects/second in the microvesicle gate
over time for each donor (normalised to vehicle baseline; Figure 3.11 B). TNFα
induced a modest increase in rate among all donors (an average increase of 0.57 ± 0.4
microvesicles/cell/second; mean ± standard deviation), but most notably induced a
considerable increase in the number of microvesicles in the latent period between
treatment and acquisition (from 18.5 ± 6.5 microvesicles/second in vehicle-treated
samples to 65.98 ± 28.24 microvesicles/second in TNFα-treated samples at 2 minutes
post stimulation; mean ± standard deviation).
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Figure 3.10: Circulating microvesicle populations. Platelet-poor plasma
(PPP) was obtained from healthy volunteers, stained with 50µM BODIPY maleimide
and antibodies against CD235, CD41, CD45, CD146, CD14, CD66b and CD3, and
acquired on the ImageStream. The percentage of BODIPY maleimide+ microvesicles
positive for each A lineage and B leucocyte marker are shown, with representative
brightfield, BODIPY maleimide, fluorescence and SSC images.
Table 3.1: Concentrations of microvesicle subsets in human plasma
Antigen









































2.5 1.06 0.71 0.35 0.18 0.10 0.10 0.02
SD 0.98 0.37 0.32 0.22 0.05 0.10 0.07 0.02
Mean and standard deviation of absolute concentrations of microvesicle lineages per
mL of platelet-poor plasma for 6 healthy donors.
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Figure 3.11: Neutrophils release large numbers of microvesicles upon
stimulation. A 1×106 neutrophils from 4 healthy donors were stimulated with
50ng/mL TNFα, 50ng/mL IL-8, 10nM LTB4, 1µg/mL zymosan, 10ng/mL E. Coli
or vehicle alone for 20 min at 37oC. Microvesicles were isolated, stained with 50µM
BODIPY maleimide FL and enumerated on the ImageStream. Individual biological
replicates (connected by grey lines) are shown with bars at group means. Analysed
with a mixed model ANOVA (treating donor as a random factor) with Tukey post-hoc
test. B 2×107 neutrophils from 3 healthy donors were each split between two tubes,
stained with 50µM BODIPY maleimide and treated with 50ng/mL TNFα or vehicle
alone. Immediately after treatment, each tube was acquired on the Imagestream
and the rate of microvesicles passing through the flow cell was tracked as a function
of time, with traces shown for each donor (with TNFα traces normalised to vehicle
baseline at time 0). C Brightfield, images of neutrophils from donor 2. Boxes are
magnified x3 in the right-hand images. Arrows indicate outward membrane blebs
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3.2 Microvesicles modulate phlogistic
macrophage activation
3.2.1 MVTNFα restrict classical activation
To test the hypothesis that neutrophil microvesicles can modulate M1 macrophage
polarisation, human monocyte-derived macrophages were treated with increasing
concentrations of MVTNFα during LPS and IFNγ-stimulation for 24 hours (Figure
3.12). Microvesicles induced a concentration-dependent decrease in HLA-DR, DP
& DQ and CD86 expression, returning levels to those of unstimulated cells at
3×106 MV/mL. A concentration-dependent increase in CD206 expression was also
observed, returning levels to those of unstimulated macrophages at 1×106 MV/mL
and continuing to rise at 3×106 MV/mL.
3.2.2 Efficacy is microvesicle (and not exosome)-dependent
To confirm that this efficacy was solely attributable to microvesicles and not exosomes,
neutrophils were treated with TNFα to induce vesicle release and, after removal of
the cells, supernatants were sequentially centrifuged at 20,000×g and then 100,000×g
to differentially enrich for microvesicles and exosomes, respectively. Macrophages
undergoing classical activation were concomitantly treated with the microvesicle
pellet, exosome pellet, or the remaining supernatant (Figure 3.13). While treatment
of macrophages with the 20,000×g pellet restricted upregulation of HLA-DR, DP &
DQ and CD86 expression during classical activation, and increased CD206 expression,
treatment with either the supernatant or 100,000×g pellet did not.
Nanoparticle tracking analysis of the 20,000×g pellets showed that these prepa-
rations of vesicles had median diameters of between 110nm and 140nm, and while
most of the samples contained vesicles under 100nm in size (exosomes), the majority
of vesicles were larger than 100nm (Figure 3.14).
As it is has historically been used as a marker of microvesicles, the expression
of PtdSer was compared between vesicles in the 20,000×g and 100,000×g pellets
(Figure 3.15). Exosomes were negative for PtdSer while only ~60% of vesicles in the
microvesicle-enriched fraction were positive. Expression of the proresolving protein
anxA1, which is known to be exported via microvesicles, was also compared between
the fractions. Again while exosomes were negative, ~20% of neutrophil microvesicles
were anxA1+.

















































HLA DR/DP/DQ CD86 CD206



























Figure 3.12: Neutrophil microvesicles modulate macrophage polarisation.
Human monocyte-derived macrophages from 4 separate donors were classically
activated over 24 hours alone, or with increasing concentrations of MVTNFα (pooled
from 3 donors, the same preparation for each macrophage donor). Cells were detached,
stained for HLA-DR, DP & DQ, CD86 and CD206 expression and analysed by
flow cytometry. Data from individual biological replicates are shown as median
fluorescence as a percentage of näıve macrophages. Data analysed with separate







































































































Figure 3.13: Comparison of microvesicle and exosome pellets. From 2×107
human neutrophils (each from 3 donors), MVTNFα were produced and differentially
isolated from exosomes by sequential centrifugation and 20,000×g and 100,000×g.
Both pellets from each neutrophil donor were pooled between donors by resuspending
in 100µL of RPMI and, along with the supernatant, were kept. Human monocyte-
derived macrophages from 4 separate donors were classically activated for 24 hours,
in the presence of the entire 20,000×g pellet, 100,000×g pellet, or supernatant.
Macrophages were detached, stained with antibodies against HLA-DR, DP & DQ,
CD86 and CD206, and analysed on a flow cytometer. Data are median fluorescence
as a percentage of untreated macrophages, of biological replicates, with bars at group
means. Data analysed with separate one-way ANOVA with Tukey post-hoc test for
each antigen.


























































































Figure 3.14: Nanoparticle Tracking Analysis of MVTNFα. MVTNFα were
generated and isolated from 5 human donors (1×107 neutrophils each), and pelleted
at 20,000×g. Each vesicle pellet was resusended in 500µL of sterile-filtered PBS and
acquired under flow, after optimising the focus and capture settings. Concentration
of particles at each diameter are shown by the density histogram, and the cumulative
density function shows the proportion of particles in each sample below each diameter.
Median particle diameters for each sample is shown in the plots.
3.2.3 MVTNFα efficacy is partly PtdSer-dependent
In order to further interrogate the effect of these microvesicles on macrophage pheno-
type and to determine whether the effects observed were dependent on PtdSer (as for
apoptotic bodies151), monocyte-derived macrophages were treated with combinations
of LPS and IFNγ, standard MVTNFα (3×106/mL) and those pre-coated with anxA5
as per Section 2.9 (and IL-4 as a positive M2 control) for 24 hours (Figure 3.16).
The expression of HLA-DR, DP & DQ, CD86 and CD206 was compared as above,
and supernatants were also assessed for IL-12p70, TGFβ, IL-10 and IL-1β expression.
MVTNFα had no effect on the expression of HLA-DR, DP & DQ, CD86, CD206,
IL-12p70, IL-10 or IL-1β, but did cause ~20-fold increase in TGFβ release. LPS and
IFNγ-treatment induced ~2.5-fold increase in HLA-DR, DP & DQ and CD86 expres-
sion, a small but non-significant decrease in CD206 expression, 3.3-fold increase in
IL-12p70, a 3.75-fold increase in IL-1β, a small but non-significant increase in IL-10,
and no change in TGFβ levels. MVTNFα-treatment in the presence of LPS and IFNγ
decreased HLA-DR, DP & DQ, CD86 and IL-12p70, IL-10 and IL-1β expression
compared to LPS and IFNγ alone while inducing an increase in CD206. The effects
of microvesicles on all phenotypic markers were lost when pre-coated with anxA5,
except IL-12p70 which was partially restored in the coated microvesicle treatment,






















Figure 3.15: PtdSer and anxA1 expression in neutrophil vesicles. From
2×107 human neutrophils (each from 3 donors, labelled with 2.5µM BODIPY maleim-
ide Texas red), MVTNFα were produced and differentially isolated from exosomes
by sequential centrifugation and 20,000×g and 100,000×g. Both pellets were re-
suspended in 100µL of 1x anxA5-binding buffer (or Ca2+-free buffer to control for
non-specific anxA5-binding), labelled with anxA5-FITC or antibodies against anxA1
(or a secondary antibody only), and acquired on the ImageStream. “Gating control”
refers to secondary antibody-only or Ca2+-free conditions for anxA1 and PtdSer-
labelling, respectively. Kernel density plots of 10,000 microvesicles are shown for
each condition.
and TGFβ which was independent of PtdSer. To confirm that the microvesicles were
not, in fact, the source of the TGFβ, the same number of vesicles from the same
preparation was lysed using 0.02% v/v triton X-100 by gentle pipetting, centrifuged
at 13,000×g for 2 minutes to remove membrane fragments, and the concentration of
TGFβ measured by cytometric bead array. There was no detectable TGFβ in the
preparation (data not shown).
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3.2.4 MVTNFα do not modulate alternative activation
As microvesicles in isolation did not seem to induce an alternative activation phe-
notype, their effect on IL-4-mediated polarisation was tested by titrating IL-4 on
monocyte-derived macrophages in the presence of 3×106/mL MVTNFα or vehicle
alone for 24 hours (Figure 3.17). There was a concentration-dependent decrease in
HLA-DR, DP & DQ and CD86 expression and increase in CD206 expression with
IL-4 which was unaffected by microvesicle addition.
3.2.5 Internalisation of microvesicles depends on PtdSer
and MerTK
The phagocytosis of apoptotic moieties by macrophages is mediated in large part by
the receptor-tyrosine kinase MerTK, which is a member of the tyro-3/Axl/MerTK
family of receptors174,240. To determine whether blocking the interaction between
PtdSer and MerTK abrogated the uptake and subsequent efficacy of microvesicles on
macrophage phenotype, a vesicle internalisation assay was optimised. To compare
their suitability, BODIPY maleimide, CFSE and PKH67 dyes were used to label
microvesicles which were loaded onto macrophage cultures for 90 minutes. The
percentage of positive cells, the fluorescence intensity and detectable microvesicles
per cell for each dye was compared using the ImageStream (Figure 3.18). PKH67-
labelled vesicles were detected in more macrophages than CFSE and BODIPY
maleimide-labelled vesicles (the latter of which was detected in < 10%).
When masked, intracellular PKH67-labelled vesicles were > 3-fold brighter than
their CFSE and BODIPY maleimide counterparts (which were equivalent). The
median number of microvesicles detected per cell was higher for PKH67-labelled
samples (7 ± 1.5; median ± range) followed by CFSE (6 ± 1) and BODIPY maleim-
ide (2 ± 1.5). While PKH67 outperformed the other two dyes, it was noticed that
a considerable amount of lysis occurred when staining with this dye (possibly due
to its ethanol solvent), and that it contributes a number of fluorescent particles,
even in the absence of microvesicles. For this reason, CFSE was chosen as the most
appropriate label for internalisation assays.
To test the hypothesis that microvesicle internalisation by macrophages is PtdSer-
dependent, monocyte-derived macrophages were treated with 5×106/mL standard
MVTNFα or those pre-coated with 50µg/mL anxA5 (both labelled with CFSE), for
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p < 0.001
 p = 0.018
 p = 0.053
 p = 0.197
 p = 0.240
Figure 3.16: Macrophage polarisation is partially modulated via phospha-
tidylserine. Human monocyte-derived macrophages were treated with combinations
of 3×106/mL MVTNFα (pooled from 3 donors, with or without anxA5 blocking) and
10ng/mL IFNγ & 10ng/mL LPS or vehicle for 24 hours. Näıve macrophages were
used as negative controls and those treated only with IL-4 acted as positive controls
for alternative activation. A Cells were detached, stained for HLA-DR, DP & DQ,
CD86 and CD206 expression and analysed by flow cytometry. B Supernatants were
collected and levels of IL-12p70, TGFβ-1 and IL-1β were quantified using a Cytometric
Bead Array. Data are median fluorescence as a percentage of untreated cells for
surface proteins and absolute concentration for cytokines. Individual biological
replicates are shown with bars at group means. IL-12 p70 could not be detected
following IL-4 stimulation. Data analysed with separate one-way ANOVA with
Tukey post-hoc tests for each antigen.
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Figure 3.17: Neutrophil microvesicles do not promote M2 macrophage
polarisation. Human monocyte-derived macrophages were alternatively activated
with between 5ng/mL and 20ng/mL IL-4, with or without 3×106/mL MVTNFα
(pooled between 3 donors) for 24 hours. Cells were detached, stained with antibodies
against HLA-DR, DP & DQ, CD86 and CD206, and analysed using flow cytometry.
Data from individual biological replicates are shown as median fluorescence as a
percentage of untreated cells. Data analysed with separate ANCOVA for each






























































































Figure 3.18: Comparison of different labels for microvesicle internalisa-
tion. MVTNFα pooled from 3 donors were stained with 5µM CFSE, 50µM BODIPY
maleimide or 50µM PKH67, washed by pelleting, counted, and resuspended at
5×106/mL in sterile-filtered PBS. Human monocyte-derived macrophage supernatant
was aspirated and replaced with 1mL of MVTNFα suspension (9×105 macrophages
per well of 12-well plates; MV:cell ratio of 5.6:1) for 90 minutes. Cells were washed,
detached, fixed and acquired on the ImageStream. A Data showing the % of positive
cells, B the median fluorescence intensity of masked-fluorescence and C the median
and modal microvesicles per cell for each dye. Data are technical replicates with
bars at group means.
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5, 30, 60 and 90 minutes at 37oC (Figure 3.19). The percentage of macrophages
positive for microvesicles was significantly reduced from 30 minutes in samples treated
with anxA5-coated vesicles. To test whether this effect was related to MerTK, the
experiment was repeated, but instead of blocking PtdSer, macrophages were treated
with a small molecule inhibitor of MerTK auto-phosphorylation, UNC-569, or vehicle.
Blockade of MerTK auto-phosphorylation significantly reduced microvesicle uptake
from 60 minutes compared to vehicle.
3.2.6 PtdSer-dependent effects are mediated through
MerTK
As blockade of the PtdSer-MerTK interaction was shown to be responsible for
microvesicle uptake, it was hypothesised that this may also be the mechanism by
which microvesicles condition macrophage phenotype. To test this, macrophages
were classically activated in the presence of 3×106/mL MVTNFα or vehicle, with
10nM UNC-569 or vehicle in a 2x2 factorial design (Figure 3.20). Protection against
classical upregulation of HLA-DR, DP & DQ, CD86 and IL-10 by MVTNFα was lost
in cells treated UNC-569, as was the upregulation of CD206. There was a similar,
though not significant, loss of protection against classical upregulation of IL-12 p70
and IL-1β with UNC-569 . Conversely, TGFβ secretion was independent of UNC-569
treatment (an experiment which was conducted both during classical activation and
in näıve macrophages, due to increased secretion in the latter).
3.2.7 Efficacy of microvesicles generated by activated
endothelium
Interactions between neutrophils and macrophages in vivo occur post transmigration
through the endothelium. It was therefore desirable to compare whether microvesicles
generated in response to trans-endothelial migration exerted similar control of
macrophage phenotype compared to those generated in suspension with TNFα. This
is especially important as microvesicles generated by TNFα in suspension have been
shown to have a different proteome to those generated on endothelial monolayers82.
In order to generate microvesicles released in response to trans-endothelial mi-
gration from neutrophils, an in vitro transmigration system had to be established
and optimised. As serum contains large numbers of exosomes and microvesicles, and
complement induces microvesicle release, serum-free transmigration was attempted,
either on its own or with IL-8 under the transwell to provide a chemotactic gradient
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Figure 3.19: Microvesicle internalisation is phosphatidylserine and
MerTK-dependent. MVTNFα microvesicles (pooled from 6 donors) were stained
with 5µM CFSE, washed by pelleting, counted, and resuspended at 5×106/mL in
sterile-filtered PBS. Human monocyte-derived macrophage supernatant was aspirated
and replaced with 1mL of MVTNFα suspension (9×105 macrophages per well of 12-well
plates; MV:cell ratio of 5.6:1). A Macrophages were treated with anxA5-blocked
MVTNFα or vehicle, and 10nM UNC-569 or vehicle. Cells were washed, detached and
fixed at 5, 30, 60 and 90 minutes post microvesicle addition and acquired on the Im-
ageStream to quantify microvesicle internalisation. AnxA5 and UNC-569 blockades
were performed as two separate experiments, each with 4 biological replicates (lines
connecting group means). Data analysed with two-way ANOVA and S̆idak post-hoc
tests comparing treatments at each time point. B Representative brightfield (Ch01),
CFSE (Ch02) and overlay images for macrophages gated as CFSE+.
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Figure 3.20: Phosphatidylserine-dependent efficacy is mediated by
MerTK. Human monocyte-derived macrophages were classically activated in the
presence of 3×106/mL MVTNFα (pooled between 3 donors) or vehicle, and with
10nM UNC-569 (a small molecule inhibitor of MerTK) or vehicle for 24 hours.
Supernatants were collected and levels of A IL-12p70, IL-1β, IL-10 and B TGFβ-1
were quantified using a Cytometric Bead Array. Cells were detached, stained for
HLA-DR, DP & DQ, CD86 and CD206 expression and analysed by flow cytometry.
Data are median fluorescence as a percentage of untreated cells for surface proteins
and absolute concentration for cytokines. Individual biological replicates are shown.
Data analysed with separate two-way (three-way for TGFβ-1) ANOVA with S̆idák
post-hoc tests for each antigen.
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(Figure 3.21). The yield of transmigrated cells after 90 minutes was poor under
both conditions but was ~2-fold greater in the presence of IL-8. To test whether
serum could improve the yield of transmigrated cells, the experiment was repeated
in the presence of 10% v/v extracellular vesicle-depleted FBS. Although there was
no change in the percentage of cells between serum-free and 10% FBS in the absence
of IL-8, the presence of serum allowed the neutrophils to chemotax with considerably
more efficiency towards the IL-8 (~2.5-fold more than IL-8 alone). When comparing
the total number of microvesicles under the transwell post transmigration, there
was a significant effect of IL-8 treatment on the number of microvesicles, but the
presence of serum had a limited and non-significant effect.
Immunophenotyping the microvesicles below the transwell at 90 minutes in the
serum and IL-8-treated wells showed that 78% ± 9.3 were CD66b+, 19% ± 3.4 were
CD146+ and 3% negative for both (n = 3, mean ± standard deviation). Above
the transwell the microvesicles were 89% ± 4.9 CD66b+, 10.2% ± 2.1 CD146+ and
0.8% negative for both. The proportion of neutrophil-derived microvesicles under
the transwell treated with IL-8 in the absence of serum was only 67% ± 7.8, where
CD146+ microvesicles made up 31%.
Although a mixed population of neutrophil and endothelial cell vesicles, microvesi-
cles collected from above (MVPre) and below (MVPost) the transwell after 90 minutes
of transmigration were compared to MVTNFα for their ability to affect macrophage
phenotype (Figure 3.22). Macrophages were treated with LPS and IFNγ as before,
alone or in the presence of 3×106/mL MVTNFα, MVPre or MVPost for 24 hours. All
three microvesicle populations reduced HLA-DR, DP & DQ and CD86 and increased
CD206 expression to a similar degree with no significant differences between the
three.
3.2.8 Arthritis-relevant stimuli induce vesicle release
To test whether more arthritis-relevant stimuli induced microvesicle release, and
whether these microvesicles were enriched in the pro-resolving mediator anxA1 (as
has been previously reported36), isolated neutrophils were treated with RPMI alone,
TNFα (as a positive control), 1 in 10 rheumatoid arthritis patient or osteoarthritis
patient synovial fluid (made microvesicle-free by centrifuging at 20,000×g as per
Section 1.3) for 20 minutes, or transmigrated in the presence of 10% v/v vesicle-free
serum (generated as per Section 2.4.2) towards IL-8 for 90 minutes. Microvesicles were
isolated, immunolabelled for anxA1 and acquired on the ImageStream (Figure 3.23).
All stimuli induced the release of similar numbers of microvesicles per neutrophil
and higher percentage of anxA1+ microvesicles compared to control. TNFα and
transmigration-induced microvesicles were similarly enriched in anxA1 (16% ± 2.8
























































Figure 3.21: Optimisation of in vitro neutrophil transmigration. Isolated
human neutrophils were seeded onto HUVEC-coated 3µm-pore, 6-well transwells at
3×106/well, after 4 hours of HUVEC stimulation with 50ng/mL TNFα. Neutrophils
were allowed to transmigrate for 90 minutes at 37oC with or without 10 % v/v
extracellular vesicle-depleted FBS (in PBS), and with or without 50ng/mL IL-8
stimulation. Neutrophils and total microvesicles were enumerated. A the percentage
of neutrophils that transmigrated and B the concentration of total microvesicles
under the transwell after transmigration. Individual biological replicates are shown
with bars at group means. Data analysed with separate two-way ANOVA and S̆idak
post-hoc tests for each dependent variable.
and 17.5% ± 5.1, respectively; mean ± standard deviation), while rheumatoid and
osteoarthritis synovial fluid-induced microvesicles were the most positive (26% ± 2.8
and 30% ± 5.2, respectively).
3.2.9 Induction of TGFβ release by MVTNFα is
anxA1-dependent
While most of the phenotypic effects of MVTNFα studied appeared PtdSer and MerTK-
dependent, the mechanism for the induction of TGFβ was still not described. As
activated neutrophil microvesicles were enriched in the pro-resolution mediator anxA1
and that this has been shown to contribute to vesicle-induced TGFβ release from
chondrocytes3, the role this protein may have in this mechanism was tested. Human
monocyte-derived macrophages were treated with 3×106/mL MVTNFα, MVRA or
MVOA in the presence of a neutralising anti-anxA1 antibody or a mIgG1 control for
24 hours (Figure 3.24). Quantification of TGFβ concentration in the supernatants
showed potent TGFβ release above control in all microvesicle-treated samples treated
with the isotype control, but ~1.71-fold reduction in samples treated with the
anti-anxA1 antibody.

















































































































Figure 3.22: Transmigration-induced microvesicles have similar efficacy
to MVTNFα. Human monocyte-derived macrophages were classically activated
alone or in combination with 3×106/mL MVTNFα, MVPost or MVPre (each pooled
between 3 donors) for 24 hours. Alternatively activated macrophages were used as
a positive control. Cells were washed, detached, stained for HLA-DR, DP & DQ,
CD86 and CD206 expression and analysed using flow cytometry. Data are median
fluorescence intensity of individual biological replicates with a bars at group means.



















































































































Figure 3.23: Activated neutrophils release large numbers of anxA1+ mi-
crovesicles. 2×106 human neutrophils were isolated and stimulated with 50ng/mL
TNFα, by transmigration through an activated HUVEC monolayer, or pooled
microvesicle-free synovial fluid diluted 1 in 10 from 3 rheumatoid arthritis or 3
osteoarthritis patients, for 20 minutes at 37oC. Samples were stained with BODIPY
maleimide and an antibody against anxA1 and analysed on the ImageStream. A
The number of microvesicles per neutrophil and B the % of microvesicles positive for
anxA1 are shown for each biological replicate with bars at group means. Data anal-
ysed with separate one-way ANOVA with Tukey post-hoc tests for each dependent
variable.
CHAPTER 3. RESULTS 97
3.2.10 Classically-activated macrophages express higher
levels of FPR2
Expression of the pro-resolving, cognate receptor for anxA1, FPR2, was confirmed
and compared across macrophage phenotypes (Figure 3.25). Classically-activated
macrophages expressed higher levels of FPR2 than alternatively-activated of näıve
macrophages, both in total (in fixed and permeabilised cells) and at the plasma
membrane. While all three phenotypes were comparable in the percentage of cells
positive for FPR2 in total, twice as many classically-activated macrophages were

























































Figure 3.24: Neutrophil microvesicle-induced TGFβ release is anxA1-
dependent. Human monocyte-derived macrophages were treated with vehicle,
MVTNFα, MVRA or MVOA (at 3×106/mL each) in the presence of 10µg/mL
neutralising-anxA1 antibody, or 10µg/mL of an isotype-matched control antibody,
for 24 hours. Supernatants were collected and analysed for TGFβ quantification
by Cytometric Bead Array. Individual biological replicates are shown with bars at
group means. Data analysed with two-way ANOVA and S̆idak post-hoc tests.


















































































Figure 3.25: Total and surface expression of FPR2 across macrophage
phenotypes. Human monocyte-derived macrophages were classically activated,
alternatively activated or left näıve for 24 hours, detached, and stained with an
antibody against FPR2 either with or without prior fixation and permeabilisation.
Cells were analysed by flow cytometry and data are A percentage of cells positive
for FPR2 and B median fluorescence for each donor, with bars at group means.
3.3 Interactions between macrophages, and
chondrocytes and fibroblasts
While the data thus far demonstrate phenotypic control of macrophage activation
by MVTNFα, it was important to determine whether this translates into a functional
effect. The ability to modulate chondrocyte and fibroblast function by macrophages
was chosen as an arthritis-specific functional readout, as these are two ways in which
macrophages may drive inflammation and joint destruction236.
3.3.1 Interaction with chondrocytes
To explore the role macrophage phenotype may play in the deposition of sulphated
glycosaminoglycans by chondrocytes, the C28/I2 3D micromass culture system was
employed. This system, developed and validated in detail by Greco et al.241, involves
seeding a high density, 3D colony of C28/I2 cells and inducing chondrocytogenesis
with serum-starvation and insulin, from which point the cultures begin to deposit
cartilage-associated glycosaminoglycans. To validate this system for the present
project, micromasses were first treated with 10ng/mL TGFβ or vehicle alone and
the amount of glycans deposited after 24 hours was quantified with alcian blue and
normalised to DNA content, to control for variable numbers of cells per micromass
(Figure 3.26). Micromasses treated with TGFβ deposited ~1.8-fold more glycans
than vehicle-treated.
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Macrophages within the rheumatic synovium are known to contribute to cartilage
degradation242. To test whether soluble mediators released from different macrophage
phenotypes could differentially control cartilage deposition/degradation, micromasses
were treated for 24 hours with the conditioned medium of macrophages treated
with complete medium alone, IFNγ, IL-4, rheumatoid or osteoarthritis synovial
fluid diluted 1 in 100 (made microvesicle-free by centrifuging at 20,000×g as per
Section 1.3; Figure 3.27). To control for the direct effects of these stimuli on the
chondrocytes, micromasses were also treated with identical “conditioned” medium
from cell-free cultures. IFNγ, IL-4 and rheumatoid synovial fluid on their own did
not alter glycan deposition/degradation, whereas osteoarthritis synovial fluid reduced
these levels (p = 0.059). Although there was a trend for a decrease in glycan levels
in micromasses cultured with medium, IFNγ and rheumatoid synovial fluid-treated
macrophage-conditioned medium, these differences were not significant. The only
conditioned-medium to increase glycan levels above that of the mediator alone was
from IL-4-treated macrophages.
To determine whether conditioned-medium from microvesicle-treated macro-
phages could affect glycosaminoglycan deposition by chondrocytes, and whether this
was dependent on anxA1, macrophages were treated with complete medium alone,
MVTNFα, MVRA or MVOA for 24 hours in the presence of an anxA1-neutralising
antibody or mIgG1 (Figure 3.28). Conditioned-medium from all microvesicle-treated
macrophage cultures increased the amount of glycans present by ~2-fold, an effect
lost in the presence of the anti-anxA1 antibody.
A similar experiment was performed to test the hypothesis that this cartilage-
protection conferred by the microvesicles to the macrophages was a result of anxA1-
induced TGFβ release (Figure 3.29). Macrophages were treated with complete
medium or with MVTNFα, in the presence of the neutralising anxA1 antibody or the
mIgG1 control for 24 hours. These supernatants were incubated with beads coated
with an anti-TGFβ antibody, or control beads for 2 hours in order to adsorb soluble
TGFβ. After depletion of TGFβ and microvesicles by centrifugation, micromasses
were treated with the supernatants for a further 24 hours. In the absence of
microvesicles, there was no effect of the anti-anxA1 antibody, and a small but non-
significant decrease in glycan deposition with TGFβ-depletion. In samples treated
with MVTNFα, there was a significant increase in glycans compared to vehicle in
the control group; an effect completely lost upon blockade of anxA1 (p = 0.049) or
depletion of TGFβ (p = 0.006).
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Figure 3.26: The C28\I2 chondrocyte model of cartilage deposition. A
Graphical scheme of the C28/I2 chondrocyte micromass culture system. Photographs
show the edge of the micromass at day 0 (x20) and the micromass pre and post alcian
blue staining (at 72 and 96 hours, respectively). B Micromasses were treated with
vehicle or 10ng/mL TGFβ for 24 hours before quantification of glycosaminoglycans
(by alcian blue staining and extraction) relative to DNA content/mL. DNA and
alcian blue standard curves with standards and interpolated unknowns are shown,
as well as the final normalisation of technical replicates treated with vehicle (n = 5)
and TGFβ (n = 6).
































































































Figure 3.27: Polarised macrophage-conditioned media modulates carti-
lage deposition. Human monocyte-derived macrophages or wells containing no
cells were treated with medium alone, 50ng/mL IFNγ, 50ng/mL IL-4, rheumatoid
arthritis synovial fluid or osteoarthritis synovial fluid (both pooled from 3 donors,
diluted 1 in 100 and microvesicle-free) for 24 hours. Supernatants were collected,
made cell and microvesicle-free and used to treat C28/I2 chondrocyte micromasses
for a further 24 hours. Glycosaminoglycan quantification relative to DNA content are
shown for each biological replicate (n = 7/8). Data analysed with two-way ANOVA

























































Figure 3.28: AnxA1+ microvesicles stimulate release of chondrogenera-
tive factor(s). Human monocyte-derived macrophages were treated with vehicle, or
3×106/mL MVTNFα, MVRA or MVOA in the presence of 10µg/mL neutralising-anxA1
antibody or 10µg/mL isotype-matched control antibody for 24 hours. Supernatants
were collected, made cell and microvesicle-free and used to treat C28/I2 chondrocyte
micromasses for a further 24 hours. Glycosaminoglycan quantification relative to
DNA content are shown for each biological replicate. Data analysed with two-way
ANOVA with S̆idák post-hoc tests.














































Control beads p = 0.049
Figure 3.29: TGFβ is the chondrogenerative factor induced by anxA1+
microvesicles. Human monocyte-derived macrophages were treated with vehicle,
or 3×106/mL MVTNFα in the presence of 10µg/mL neutralising-anxA1 antibody
or 10µg/mL isotype-matched control antibody for 24 hours. Supernatants were
collected, made cell-free and incubated with beads coated with an anti-TGFβ-1
antibody (to capture soluble TGFβ-1), or an isotype-matched control for 2 hours.
Supernatants were centrifuged to remove beads and microvesicles, and used to
treat C28/I2 chondrocyte micromasses for a further 24 hours. Glycosaminoglycan
quantification relative to DNA content are shown for each biological replicate. Data
analysed with three-way ANOVA with Holm-S̆idák post-hoc tests.














































































































































































Figure 3.30: Establishing an inflammatory phenotype in synovial fibrob-
lasts. Primary synovial fibroblasts from patients with osteoarthritis were seeded onto
glass coverslips and allowed to attach overnight. Fibroblasts were then stimulated
with synovial fluid pooled from 3 other rheumatoid arthritis patients for varying
lengths of time. Six hours prior to fixation, fibroblasts were treated with golgi block,
before fixation with 1% v/v formaldehyde, permeabilisation with triton-X 100 and
antibody staining for immunofluorescence (one antigen per coverslip). Individual
biological replicates shown, with LOESS fits to each group (span = 1).
3.3.2 Interaction with fibroblasts
Macrophages and synovial fibroblasts interact within the synovium to condition
each other’s phenotypes. To study this interaction in vitro, a panel of phenotypic
markers had to be defined which could discriminate an inflammatory phenotype in
synovial fibroblasts. Primary synovial fibroblasts were stimulated with synovial fluid
from rheumatoid arthritis patients for varying lengths of time and the expression of
a range of antigens reported to respond to inflammatory stimuli243 was quantified
by fluorescence microscopy (Figure 3.30). While an increase in expression could
be detected in VCAM-1, CD55, IL-6, MCP-1 and TNFα after 24 hours in synovial
fluid, CD21 remained unchanged. These responsive markers were therefore used as
indicators of fibroblast phenotype in future experiments.
To model the close proximity of synovial macrophages and fibroblasts in vitro, a
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co-culture system was devised where macrophages are cultured and polarised on tran-
swell inserts, and placed on top of coverslips of fibroblasts to initiate co-culture. In
determining whether, in this artificial system, monocyte-derived macrophage pheno-
type can condition fibroblast phenotype, classical, alternative, and näıve macrophages
were co-cultured with fibroblasts for 24 hours. After quantifying the expression
of fibroblast phenotypic markers by fluorescence microscopy, it was observed that
VCAM-1, CD55, IL-6 and TNFα were all increased in fibroblasts cultured with
classically activated macrophages compared to those cultured with näıve and alter-
natively activated macrophages (whose expression level was comparable; Figure 3.31
A). MCP-1 expression was highest in fibroblasts cultured with alternatively-activated
macrophages, followed by those cultured with classically-activated macrophages, and
finally those with näıve macrophages.
To compare overall similarity of these three fibroblast populations across the
antigens studied, and to compare which antigens best discriminated between them,
data were used to construct a linear discriminant model (Figure 3.31 B & C). The first
discriminant factor accounted for 84.5% of the variability between groups, primarily
separating groups by their MCP-1 expression, which correlated positively with it.
The second discriminant factor accounted for 15.5% of the variability between groups
and primarily separates fibroblasts cultured with alternatively-activated macrophages
from the other two populations, by their expression of VCAM-1, CD55, IL-6 and
TNFα which all correlated negatively with it.
In order to test whether treating macrophages with MVTNFα during classical
activation affected their modulation of fibroblast phenotype, macrophages were given
MVTNFα or vehicle during classical activation, or to näıve cells, before co-culture
with fibroblasts for 24 hours. For all antigens studied, co-culture with classically
activated macrophages (devoid of MVTNFα treatment) increased their expression as
previously demonstrated (Figure 3.32 A). This upregulation was not induced by
co-culture with macrophages given MVTNFα during their activation, where expression
levels for all antigens was comparable to when fibroblasts were cultured with näıve
macrophages treated with MVTNFα.
To compare overall similarity of these four fibroblast populations across the
antigens studied, and to compare which antigens best discriminated between them,
data were used to construct a linear discriminant model (Figure 3.32 B & C). The first
discriminant factor accounted for 99.2% of the variability between groups, primarily
separating fibroblasts cultured with classically activated macrophages by all antigens,
which correlated positively with it. The second discriminant factor only accounted
for 0.8% of the variability between groups, primarily separating fibroblasts cultured
with completely näıve macrophages, from the other three populations by their TNFα






















































































































































Figure 3.31: Macrophage phenotype controls fibroblast phenotype in co-
culture. Human monocyte-derived macrophages differentiated in 6-well transwell
inserts were classically activated, alternatively activated, or left näıve for 24 hours.
Macrophage transwell inserts were then washed and placed on top of primary synovial
fibroblasts from osteoarthritis patients cultured on glass coverslips, and co-cultured
for a further 24 hours. Six hours prior to fixation, fibroblasts were treated with golgi
block, before fixation with 1% v/v formaldehyde, permeabilisation with triton X-100
and antibody staining for immunofluorescence (one antigen per coverslip). Individual
biological replicates shown (one macrophage donor to one fibroblast donor) with
A bars at group means for individual antigens, and B result of linear discriminant
analysis with 95% confidence ellipses for each group. C Standardized factor loadings
for both discriminant factors are tabulated.





















































































































































Figure 3.32: MVTNFα modulate macrophage control of fibroblast pheno-
type. Human monocyte-derived macrophages differentiated in 6-well transwell
inserts were classically activated or left näıve for 24 hours in the presence of 3×106
MVTNFα (pooled between 3 donors) or vehicle. Macrophage transwell inserts were
then washed and placed on top of primary synovial fibroblasts from osteoarthritis
patients cultured on glass coverslips, and co-cultured for a further 24 hours. Six
hours prior to fixation, fibroblasts were treated with golgi block, before fixation with
1% v/v formaldehyde, permeabilisation with triton X-100 and antibody staining
for immunofluorescence (one antigen per coverslip). Individual biological replicates
shown (one macrophage donor to one fibroblast donor) with A bars at group means
for individual antigens, and B result of linear discriminant analysis with 95% confi-
dence ellipses for each group. C Standardized factor loadings for both discriminant
factors are tabulated.
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3.4 Microvesicles modulate macrophage
phenotype in vivo
3.4.1 Zymosan-induced peritonitis
While MVTNFα-mediated control of macrophage phenotype in vitro could be demon-
strated, it was important to confirm whether the same phenomenon could be observed
in a living system. Zymosan-induced peritonitis was chosen as an initial model to test
vesicles in vivo as it is a simple model of sterile acute inflammation with a defined
compartment within which treatments can be administered and cells (particularly
macrophages) can be extracted244. Following intraperitoneal injection with 1mg
zymosan (a glucan polysaccharide component of fungal cell walls), tissue resident
peritoneal macrophages initiate an innate immune response, culminating in the
recruitment of neutrophils and monocytes to the cavity245. The peak of monocyte-
derived macrophage presence in the peritoneum is at 48 hours, at which point the
peritoneum can be lavaged and the macrophages immunophenotyped244.
To maximise the likelihood of observing efficacy of microvesicles in this model,
mice were randomised to a range of doses of human MVTNFα (or vehicle) injected
intraperitoneally 24 hours post zymosan, before lavage 24 hours later (Figure 3.33).
The cells were stained for F4/80, MHCII, CD86 and CD206 and acquired on a
flow cytometer. Singlet, F4/80+ cells’ MHCII and CD86 expression decreased with
MVTNFα dose, whereas CD206 increased with dose, although the absolute changes in
median fluorescence were relatively small. No adverse effects of injecting the mice
with human material was observed.
To repeat the model but with replicate treatments, the same model was performed
except that mice were randomised to receive intraperitoneal injection of either vehicle,
or 2×107 MVTNFα (the maximum number of vesicles which could realistically be
generated for the experiment, which still showed efficacy in Figure 3.33). As shown
in Figure 3.34, in support of the previous peritonitis data and the in vitro data
generated thus far, macrophages isolated from mice injected with MVTNFα expressed
lower MHCII and CD86, and higher CD206. The cell-free lavage fluid was sent to
Labospace for cytokine profiling by luminex. While there were no differences in KC
(CXCL1), IL-1β or TNFα expression (the latter of which was mostly below the limit
of detection), mice injected with MVTNFα expressed lower levels of MCP-1 (p =
0.009) and increased expression of TGFβ (p = 0.006). The was a non-significant
decrease in IL-6 expression in mice injected with MVTNFα (p = 0.109).

















































Figure 3.33: In vivo titration of MVTNFα on macrophage phenotype.
Six, 10 week-old C57BL/6 mice were injected with 500µL of 2mg/mL zymosan
intraperitoneally. After 24 hours, mice were randomised to a range of doses of human
MVTNFα (pooled between 6 donors) injected intraperitoneally in 500µL. A further 24
hours later, mice were culled and a peritoneal lavage performed with 2mM EDTA.
Cells were stained with antibodies against F4/80, MHCII, CD86 and CD206, and
analysed by flow cytometry. Data are median fluorescence of each antigen of F4/80+
cells, for each mouse. Data analysed with linear regression for each antigen, where
least square lines are shown. Both treatment and analysis were blinded.
3.4.2 K/BxN arthritis
While the data from both peritonitis models supported the data generated in vitro,
the absolute effect sizes of vesicle treatment were small, possibly due to the large
surface area and volume of the peritoneal cavity relative to the number of vesicles
administered (whose production is rate limiting). Therefore, to examine the effects
of MVTNFα in a smaller compartment relative to their number, and in a model which
is more relevant to arthritis, the K/BxN model of acute arthritis was chosen.
Mice injected with K/BxN serum on days 0 and 2, develop an acute, neutrophil-
driven model of systemic and symmetrical arthritis. As the model is symmetrical,
intra-articular injection of an experimental agent can be given into one joint, and its
control treatment administered to the contralateral joint. To maximise the number
of cells recovered, the ankle synovia were chosen as these undergo the greatest
swelling and cell infiltration during the model. 24 hours after the second K/BxN
serum injection, mice were randomised to receive intra-articular injection of 3×106
MVTNFα in one of their ankles, and vehicle in the other. After a further 24 hours,
all soft tissue was removed from the ankle, the synovium was digested and the cells
immunophenotyped for flow cytometry (Figure 3.35). In support of data presented
thus far, singlet CD45+, CD11b+, F4/80+ macrophages isolated from ankles which
received MVTNFα expressed lower (but not significantly) MHCII (p = 0.006) and
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CD86 (p = 0.117), and higher CD206 (p = 0.001) compared to their contralateral
controls. Antibodies raised against CD90, CD55 and VCAM-1 were also included in
the panel to immunophenotype synovial fibroblasts (CD45-, CD11b-, CD90+), but
not enough could be acquired from individual joints.
3.5 MVTNFα from RA patients are protective
3.5.1 RA patient neutrophils release anxA1+ microvesicles
Microvesicles with protective properties could represent a novel form of autologous
therapy. If such vesicles can be generated from a patient’s cells, isolated, and
administered, they may achieve efficacy with minimal side effects (being of the
patient’s own tissue) and represent the ultimate personalised therapy. To consider
this as an application for MVTNFα in the treatment of rheumatoid arthritis, it was
first important to address the question of whether blood neutrophils from rheumatoid
arthritis patients produce microvesicles in response to TNFα, and if so, whether
these MVTNFα are protective.
To address the first question, blood neutrophils were isolated from 5 rheumatoid
arthritis patients and stimulated with 50ng/mL TNFα or vehicle for 20 minutes at
37oC. Microvesicles were isolated, labelled with BODIPY maleimide and a primary-
secondary antibody combination to label anxA1, and acquired on the ImageStream
(Figure 3.36). TNFα induced a 2.42-fold mean increase in vesicle release over vehicle
(p = 0.044) and a 1.67-fold mean increase in anxA1 expression (p = 0.049). While
the fold change in vesicle release was comparable to data observed in healthy controls
(Figure 3.11), the fold increase in anxA1 expression was smaller, owing to the higher
expression of anxA1 at baseline.
The number of microvesicles isolated per starting neutrophil was plotted and
compared between healthy controls and rheumatoid arthritis patients (Figure 3.37).
Overall, the number of vesicles recovered per cell increased with the starting number
of neutrophils. While the relationship appears shallower for preparations from
rheumatoid arthritis patients, it was difficult to isolate large enough numbers of
neutrophils to make a like-for-like comparison, and there are too few data to conclude.


















































































































































Figure 3.34: Confirmatory, two group peritonitis. Ten week-old C57BL/6
mice were injected with 500µL of 2mg/mL zymosan intraperitoneally. After 24 hours,
mice were randomised to intraperitoneal injection of 2×107 human MVTNFα (pooled
between 6 donors) or vehicle alone (both 500µL). A further 24 hours later, mice were
culled and a peritoneal lavage performed with 2mM EDTA. A Cells were stained
with antibodies against F4/80, MHCII, CD86 and CD206, and analysed by flow
cytometry. B Cell-free lavage fluid was sent to Labospace for Luminex cytokine
profiling. Data are median fluorescence of each surface antigen of singlet F4/80+ cells,
or absolute concentration of cytokine, for each mouse. Data analysed with separate
two-tailed t tests for each antigen, with bars at group means. Both treatment and
analysis were blinded.
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Figure 3.35: Intra-articular efficacy of MVTNFα in K/BxN arthritis. Four,
8 week-old C57BL/6 mice were injected with 200µL of K/BxN serum, diluted 1 in
2 with PBS, intraperitoneally on days 0 and 2. After 24 hours, mice were given
intra-articular (ankle) injections of 3×106 human MVTNFα (pooled between 3 donors)
in one ankle, and an equal volume of PBS in the contralateral ankle (which ankle
received each treatment was randomised for each mouse). After 48 hours, mice
were culled, ankles were made skin and muscle-free, and digested with 0.5µg/mL
collagenase D and 40 µg/mL DNAse I for 1 hour at 37oC. Cell suspensions were
stained with Zombie Aqua, and antibodies against CD45, CD11b, F4/80, MHCII,
CD86 and CD206, and analysed by flow cytometry. Data are median fluorescence
of each antigen on CD45+, CD11b+, F4/80+ macrophages for each mouse. Lines
connect ankles within each mouse. Data analysed with paired, two-tailed t tests for
each antigen.






























Figure 3.36: Blood neutrophils from RA patients produce anxA1+
MVTNFα. As many neutrophils as possible were isolated from the blood of 5
rheumatoid arthritis patients and split between two tubes for each. One tube was
treated with 50ng/mL TNFα and the other with equal volume of vehicle, for 20
minutes at 37oC. Neutrophils were removed by centrifugation, samples were labelled
with 50µM BODIPY maleimide and an anti-anxA1 antibody, and centrifuged at
20,000×g for 30 minutes at 4oC to pellet microvesicles. Pellets were resuspended in
30µL of PBS and enumerated on the ImageStream. Data are expressed as A the
concentration of BODIPY maleimide+ microvesicles and B the percentage of mi-
crovesicles positive for anxA1, with lines connecting each donor. Data were analysed
with separate paired, two-tailed t tests.









































Figure 3.37: Relationship between starting neutrophil number, and vesi-
cle yield. Blood neutrophils from healthy controls (HC) or rheumatoid arthritis
patients (RA) were stimulated with 50ng/mL TNFα for 20 minutes at 37oC. Cells
were removed, the supernatant was labelled with 50µM BODIPY maleimide and
microvesicles pelleted at 20,000×g for 30 minutes at 4oC and enumerated on the
ImageStream. Data are the number of vesicles recovered per cell against starting
number of näıve neutrophils for each donor. Non-linear regression lines are fit within
and between groups.
3.5.2 Plasma microvesicles in healthy donor and RA
patients
Due to the higher level of baseline anxA1 expression observed on MVTNFα from
rheumatoid arthritis patients compared to healthy controls, circulating microvesicles
from both populations were immunophenotyped to quantify anxA1 expression on
microvesicles from neutrophils, monocytes, and platelets (as a negative control;
Figure 3.38). In this small sample, the levels of circulating neutrophil, monocyte
and platelet microvesicles was comparable between healthy controls and rheumatoid
arthritis patients. The percentage of total anxA1+ microvesicles was 11.3% higher
in rheumatoid arthritis patients than in healthy controls, although when stratifying
anxA1 expression by cell type, no differences were observed between the groups.










































































Figure 3.38: Phenotype of healthy and RA plasma microvesicles. 500µL
of platelet-free plasma from healthy donors and rheumatoid arthritis patients were
stained with 50µM BODIPY maleimide and split between 3 tubes. Each tube was
stained with antibodies against anxA1, then either with antibodies against CD66b,
CD14 or CD41, and acquired on the ImageStream. Data are the percentage of
BODIPY maleimide+ vesicles which were A positive for each lineage antigen, or
B double positive for each lineage antigen and anxA1 for each donor, with bars at
group means.
3.5.3 RA and healthy neutrophil MVTNFα have similar
efficacy
To test whether MVTNFα generated from rheumatoid arthritis patient neutrophils
had similar efficacy to those from healthy controls, monocyte-derived macrophages
(generated from rheumatoid arthritis patient monocytes) were classically activated
in the presence of 3×106/mL MVTNFα (pooled from 3 donors) from healthy controls
or rheumatoid arthritis patients, or vehicle alone (Figure 3.39). Supernatants were
processed for Cytometric Bead Array, and cells were immunophenotyped by flow
cytometry. MVTNFα from healthy controls and rheumatoid arthritis patients had
similar effects on macrophage phenotype across all antigens assayed. Linear discrim-
inant analysis showed that macrophages treated with either MVTNFα preparation
separated from vehicle-treated macrophages by all antigens, most strongly HLA-DR,
DP & DQ, CD86 and TGFβ, along the first discriminant factor (which accounted
for 88.2% of the variability between groups). Macrophages treated with the two
MVTNFα populations had very similar expression profiles, separating along the second
discriminant factor (which accounted for 11.8% of the variability between groups)
by IL-12 p70, IL-10, and TGFβ. IL-12 p70 and IL-10 were more highly expressed in
macrophages treated with rheumatoid arthritis MVTNFα, whereas TGFβ (the antigen
which varied the greatest between them) was more highly expressed by macrophages
treated with healthy control MVTNFα.
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Figure 3.39: MVTNFα from healthy and RA blood neutrophils have simi-
lar efficacy. Monocyte-derived macrophages were classically activated for 24 hours
alone or in combination with 3×106/mL MVTNFα from healthy controls (HC) or
rheumatoid arthritis patients (RA; each pooled between 3 donors). Supernatants
were collected and the concentration of IL-12 p70, IL-1β, IL-10 and TGFβ was mea-
sured by a Cytometric Bead Array. Cells were detached and stained with antibodies
against HLA-DR, DP & DQ, CD86 and CD206, and analysed by flow cytometry. A
Data are median fluorescence as a percentage of untreated cells for surface antigens,
and absolute concentration of cytokines for each donor, with bars at group means
for each antigen. B Results of linear discriminant analysis with 95% confidence
ellipses for each group. Standardised factor loadings for both discriminant factors
are tabulated.
CHAPTER 3. RESULTS 116
3.5.4 Platelets release pro-inflammatory MVTNFα
The rheumatoid synovium contains large numbers of microvesicles, the majority
of which are pro-inflammatory246. For an autologous, vesicle-based therapy to be
viable, it must be shown that exogenously-administered microvesicles are able to
achieve efficacy, even in the presence of a large number of endogenous vesicles with
potentially opposing effects. The ratio of exogenous to endogenous vesicles required
to achieve efficacy can also aid in determining effective doses.
To address this, platelet microvesicles were first used as a model, pro-inflamm-
atory microvesicle population. To compare microvesicles generated by platelets and
neutrophils generated by the same stimulus, it was desirable to generate vesicles
from platelets using TNFα. To test whether platelets released microvesicles in
response to TNFα (not a typical platelet agonist) platelet-rich plasma was stimulated
with 50ng/mL TNFα or vehicle alone for 20 minutes at 37oC and the number of
microvesicles quantified using the ImageStream (Figure 3.40). TNFα induced a
mean 3.6-fold increase in the number of microvesicles over vehicle (p = 0.066),
demonstrating that platelets release MVTNFα, although a single donor produced
fewer vesicles post TNFα stimulation.
To determine the effects platelet MVTNFα have on macrophage phenotype, macro-
phages were treated with 1×106, 2×106, 3×106 platelet MVTNFα/mL or vehicle alone
for 24 hours (Figure 3.41). Supernatants were processed for Cytometric Bead Array,
and cells immunophenotyped by flow cytometry. There was a weak but positive
relationship between the number of platelet MVTNFα and macrophage expression of
HLA-DR, DP & DQ (p <0.001) and CD86 (p = 0.008) but no change in CD206,
IL-12 p70, IL-1β, IL-10 or TGFβ. Although the p value of the slope for IL-12 p70
was <0.05, the effect was not biologically significant.
3.5.5 The effects of platelet MVTNFα can be outcompeted
To confirm whether neutrophil MVTNFα from rheumatoid arthritis patients can
outcompete the effects platelet MVTNFα have on macrophage HLA-DR, DP & DQ
and CD86 expression, macrophages were treated with a fixed concentration of platelet
MVTNFα (3×106/mL) alone, or with increasing ratios of neutrophil MVTNFα (Figure
3.42). Neutrophil MVTNFα were able to abrogate platelet MVTNFα-mediated increases
in HLA-DR, DR & DQ and CD86, and increase release of TGFβ. Neutrophil MVTNFα
completely reversed the effects of platelet MVTNFα from a ratio of 5:1.



























Figure 3.40: Platelets produce mi-
crovesicles in response to TNFα.
Platelet-rich plasma was generated from 5
donors and split into two tubes. One tube
was treated with 50ng/mL TNFα and the
other with equal volume of vehicle, for 20
minutes at 37oC. Platelets were depleted
by centrifuging at 13,000×g for 2 minutes
at 4oC, samples were labelled with 50µM
BODIPY maleimide and centrifuged at
20,000×g for 30 minutes at 4oC to pellet
microvesicles. Pellets were resuspended
in 30µL of PBS and enumerated on the
ImageStream. Data are expressed as the
number of microvesicles per mL of start-
ing plasma, with lines connecting each
donor. Data analysed with a paired, two-
tailed t test.
3.5.6 Total RA synovial fluid microvesicles are
pro-inflammatory
Once the principle had been demonstrated that neutrophil MVTNFα can outcompete
the effects of a model inflammatory microvesicle population, the same was repeated
but using the total population of microvesicles isolated from the synovial fluid of
patients with rheumatoid arthritis. Macrophages treated with increasing concentra-
tions of total synovial fluid microvesicles demonstrated a similar increase in HLA-DR,
DP & DQ and CD86 as seen with the platelet MVTNFα (Figure 3.43). There were
small but variable increases in IL-12 p70, IL-1β, and TGFβ with increased vesicle
treatment, but no change in CD206 or IL-10.
3.5.7 The effects of synovial fluid microvesicles can be
outcompeted
In a similar experiment as was performed with platelet MVTNFα, to confirm whether
rheumatoid arthritis patient neutrophil MVTNFα can outcompete the effects synovial
fluid microvesicles have on macrophage HLA-DR, DP & DQ and CD86 expression,
macrophages were treated with a fixed concentration of synovial fluid microvesicles
(3×106/mL) alone, or with increasing ratios of neutrophil MVTNFα (Figure 3.44).
Neutrophil MVTNFα were able to abrogate synovial microvesicle-mediated increases
in HLA-DR, DR & DQ and CD86, and increase release of TGFβ. A higher ratio of
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Figure 3.41: Platelet MVTNFα are pro-inflammatory for macrophages.
MVTNFα were generated from washed platelets from 5mL of platelet-rich plasma each
from 3 donors and pooled together. Monocyte-derived macrophages were treated
with medium alone, or increasing concentrations of platelet MVTNFα for 24 hours
at 37oC. Supernatants were analysed by a Cytometric Bead Array for IL-12 p70,
IL-1β, IL-10 and TGFβ, and cells were detached and stained for HLA-DR, DP & DQ,
CD86 and CD206 expression and analysed by flow cytometry. Data are expressed as
median fluorescence as a percentage of untreated cells for surface antigens, or absolute
concentration of cytokines for each donor. Data analysed with linear regression for
each antigen, with least square lines.
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Figure 3.42: Neutrophil and platelet MVTNFα have opposing efficacy. Hu-
man monocyte-derived macrophages were treated for 24 hours at 37oC with medium
alone, or 3×106 platelet MVTNFα/mL alone, or in combination with increasing ratios
of neutrophil MVTNFα. Supernatants were collected and TGFβ concentration was
measured with a Cytometric Bead Array, and cells were detached and stained with
antibodies against HLA-DR, DP & DQ and CD86. Data are median fluorescence as
a percentage of untreated cells for surface antigens, and absolute concentration of
TGFβ for each donor. Data analysed with non-linear regression,where least squares
lines are shown in blue and p values compare the full fits shown to intercept-only
fits.
neutrophil MVTNFα to synovial fluid microvesicles was required to completely reverse
the effects of synovial microvesicles, than for platelet MVTNFα.
3.6 Generating a cell line to produce anxA1+
microvesicles
While using autologous vesicle preparations is attractive as a novel form of therapy,
it does present the issues of volume of production, and of preparation quality control.
An alternative which deals with these issues is the prospect of engineering a cell
line to produce vesicles with desirable properties, and produce large-scale vesicle
batches which can be quality control checked prior to administration. As a simple
proof of principle, and based on the observed relationship between vesicular anxA1
and macrophage TGFβ expression, it was determined that a cell line(s) would be
generated to produce anxA1+ microvesicles. Once generated, the effects of wild type
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p < 0.001 p < 0.001 p = 0.945



















































































Figure 3.43: Total RA synovial fluid microvesicles are pro-inflammatory.
Synovial fluid from 3 rheumatoid arthritis patients was digested with 20U/mL
hyaluronidase for 30 minutes at 37oC, depleted of cells, and centrifuged at 20,000×g
to pellet microvesicles. Monocyte-derived macrophages were treated with medium
alone, or increasing concentrations of synovial fluid microvesicles for 24 hours at
37oC. Supernatants were analysed by a Cytometric Bead Array for IL-12 p70, IL-1β,
IL-10 and TGFβ, and cells were detached and stained for HLA-DR, DP & DQ,
CD86 and CD206 expression and analysed by flow cytometry. Data are expressed as
median fluorescence as a percentage of untreated cells for surface antigens, or absolute
concentration of cytokines for each donor. Data analysed with linear regression for
each antigen, with least square lines.
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Figure 3.44: Neutrophil and synovial fluid microvesicles have opposing
efficacy. Human monocyte-derived macrophages were treated for 24 hours at 37oC
with medium alone, or 3×106 synovial fluid microvesicles/mL (pooled between 3
rheumatoid arthritis patients) alone, or in combination with increasing ratios of
neutrophil MVTNFα. Supernatants were collected and TGFβ concentration was
measured with a Cytometric Bead Array, and cells were detached and stained with
antibodies against HLA-DR, DP & DQ and CD86. Data are median fluorescence as
a percentage of untreated cells for surface antigens, and absolute concentration of
TGFβ for each donor. Data analysed with non-linear regression, where least squares
lines are shown in blue and p values compare the full fits shown to intercept-only
fits.
vs. anxA1+ microvesicles could be directly compared.
HL60 and NB4 cells were chosen as they are promyelocytic cell lines which can
be differentiated into monocyte and neutrophil-like cells experimentally237,247. The
HEK293 cell line was also included as it is more amenable to transfection than HL60
and NB4 cells (which have not been widely transfected successfully).
3.6.1 Optimising conditions for antibiotic selection
The vector selected to transfect the cell lines contained a blasticidin resistance gene,
blasticidin-S deaminase (bsd), and once transfected, cells expressing the bsd gene
(and therefore anxA1) would be selected for by culturing in blasticidin. To determine
a minimum concentration of blasticidin required to kill all cells after culture for 5-10
days, an assay was constructed to allow repeated sampling of cell viability over time.
Alamar blue is a non-cytotoxic, membrane-permeable substrate which is reduced by

















































Figure 3.45: Titration of cell num-
ber for alamar blue viability assay.
The number of HL60, NB4 and HEK293
cells per well was serially-diluted 1 in 2
in a 96-well plate and stained for 1 hour
with 10% v/v alamar blue. Fluorescence
at 590nm was measured upon excitation
at 560nm using a fluorescence plate reader.
Data are blank-subtracted fluorescence in-
tensity of an individual reading per cell
number, per cell line.
viable cells into a product which fluoresces red upon excitation with a yellow-green
laser. Labelling cells with alamar blue allows repeated viability measurements from
tissue culture samples without the need to perform a trypan blue exclusion count
for every sample.
To optimise the number of cells per well to achieve the greatest fluorescence
signal, HEK293, HL60 and NB4 cells were labelled with alamar blue, serially diluted
across a 96-well plate, and read using a fluorescence plate reader (Figure 3.45). While
HEK293 cells generally required fewer cells per well to achieve a higher fluorescence
reading, all three cell lines produced the greatest fluorescence reading at 3.75×104
cells/well, with fluorescence values dropping upon further increase of cell number.
To determine the optimal concentration and length of blasticidin incubation,
the three cell lines were cultured in 5, 10, 15 or 20µg/mL blasticidin, or vehicle
for 13 days. Every other day, the untreated cells of each line were counted using a
haemocytometer, and 3×104 (just below the saturation of the alamar blue signal) of
these cells and an equal volume of the cells in culture with blasticidin were labelled
with alamar blue and their fluorescence read on a plate reader (Figure 3.46). This
facilitated the quantification of viable cells, relative to the number in the vehicle-
treated wells. Blasticidin treatment induced cell death in all three cell lines, in a
concentration-dependent manner. HEK293 cells were most sensitive to blasticidin,
followed by NB4 and then HL60 cells which were least sensitive. 5 days of selection
for HEK293 cells, and 7 days for NB4 and HL60 cells in 10µg/mL blasticidin were
chosen as appropriate selection conditions post transfection.
After ligation of the anxA1 ORF into the pIRESbsd2 vector and transformation
of E. coli with the putative pIRESbsd2-AnxA1 construct, it was important to select
bacterial clones which contained plasmids containing anxA1 ORF, and in the correct
orientation. Plasmids were isolated for each clone by miniprep, digested with EcoRI
and separated by size using agarose gel electrophoresis (Figure 3.47). Clones A, H, I,
O, R, S, U, V, W and X displayed bands at 5368bp and 1031bp, diagnostic of the















































































































































Figure 3.46: Blasticidin titration on cell viability. HL60, NB4 and HEK293
cells were seeded at 2×105 cells in 1mL in 12-well plates in their complete media
containing increasing concentrations of blasticidin antibiotic as shown in panel
headings (or were untreated). Every other day, the untreated cells were counted
using a haemocytometer, and 3×104 cells were transferred to a 96-well plate. The
same volume of cells was transferred to the plate from every other condition, and
all wells were stained with 10% v/v alamar blue for 1 hour and their fluorescence
read at 590nm upon excitation at 560nm. The fluorescence intensity as a percentage
of untreated cells is shown for each technical replicate, with non-linear regression
curves plotted for each group.
pIRESbsd2-AnxA1 vector (with AnxA1 in the correct orientation).
Bacterial clones W and X were selected for outgrowth and maxiprep isolation
of enough plasmid for purification and transfection. As an additional round of
confirmation, plasmids isolated by miniprep were digested with HindIII and separated
by size using agarose gel electrophoresis (Figure 3.48). Both clones displayed bands
at 4394bp, 1186bp, 471bp and 348bp, diagnostic of the pIRESbsd2-AnxA1 vector
(with AnxA1 in the correct orientation).
After transfection, NB4 and HL60 cells did not survive antibiotic selection,
whereas HEK293 cells did. After repeating the transfection multiple times with
the NB4 and HL60 cells, and achieving no antibiotic resistance each time, only the
HEK293 cells were used from here on. To confirm their expression of anxA1, HEK293
cells were fixed, permeabilised, and immunophenotyped for anxA1 expression by
flow cytometry (Figure 3.49). Despite being antibiotic resistant, only 14.7% of cells
were positive for anxA1.
To generate lines of cells which was 100% positive for anxA1, this polyclonal
population of cells was serially diluted and seeded at ~1 cell per well of several 96-well
plates, in order to grow up clonal colonies. Once expanded enough, each colony was
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Figure 3.47: Diagnostic EcoRI restriction digest. Individual colonies of E.
coli transformed with the pIRESbsd2 vector were picked, expanded and put through
a miniprep to isolate the plasmid DNA. Plasmid from each clone was digested with
EcoRI and run on agarose gels with DNA ladders to confirm insertion of the anxA1
gene in the correct orientation.
sampled, fixed, permeabilised and immunophenotyped for anxA1 expression by flow
cytometry (Figure 3.50). Clones 3, 11, 14, 23 and 32 were almost all completely
positive for anxA1 and so were expanded in order to generate microvesicles from
them.
To confirm the presence of anxA1 on the microvesicles of each HEK-AnxA1 clone,
each clone was washed twice with PBS, and treated with serum-free RPMI containing
1µM ionomycin (I3909, Sigma-Aldrich) for 30 minutes at 37oC. Untransfected HEK293
cells were also stimulated to generate biological-negative vesicles, and MVTNFα were
generated from a single donor’s primary neutrophils to act as a positive control.
Microvesicles were labelled with BODIPY maleimide and immunophenotyped for
anxA1 expression using the ImageStream (Figure 3.51). Despite almost all HEK-
AnxA1 cells expressing anxA1, on average, only 3.4% of vesicles from each clone
expressed detectable levels of the protein on their surface.
Monocyte-derived macrophages treated with microvesicles isolated from HEK-
AnxA1 cells stimulated with 1µM ionomycin as above, did not secrete higher levels
of TGFβ than those treated with microvesicles generated in the same way from
untransfected HEK293 cells (Figure 3.52). The levels of TGFβ in the supernatant
was also independent of anxA1 blockade under these conditions. MVTNFα from
primary human neutrophils were included as a positive control, which induced TGFβ
production in the presence of the isotype-matched control antibody only, supporting
previous results.
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Figure 3.48: Diagnostic HindIII re-
striction digest. Plasmid DNA from
clones W and X, isolated by miniprep,
were digested with HindIII and run on
an agarose gel with DNA ladders to con-
firm with an additional restriction digest
that the anxA1 gene was inserted into
the pIRESbsd2 vector in the correct ori-
entation.
0.12% 14.70%
Secondary only Primary + secondary












Figure 3.49: Screening transfected HEK293 colony for anxA1 expression.
HEK293 cells after transfection and blasticidin selection were fixed, permeabilised and
immunolabelled for total anxA1 expression, and acquired on a Canto II cytometer.
Hexagon bin plots shaded by density of gated singlet cells labelled with primary and
secondary antibodies, or just the secondary as a gating control.
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Figure 3.50: Screening HEK293 colonies for anxA1 expression. Transfected
HEK293 cell colonies were stained for total anxA1 expression and acquired on a
Canto II cytometer. Hexagon bin plots shaded by density of gated singlet cells for
each clone, secondary antibody-only and unstained cells are shown, with polygon
gate drawn against the secondary-only population.
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Figure 3.51: Low expression of anxA1 on HEK-AnxA1 microvesicles.
HEK-AnxA1 clones and wild type (WT) HEK293 cells were stimulated with 1µM ion-
omycin for 30 min at 37oC in serum-free medium before isolation of their microvesicles.
Microvesicles were labelled with BODIPY maleimide and immunophenotyped for
anxA1 expression using the ImageStream. MVTNFα from a single, primary neutrophil

























































Figure 3.52: HEK-AnxA1 clones do not induce macrophage TGFβ pro-
duction. Human monocyte-derived macrophages were treated with 3×106/mL
ionomycin-induced microvesicles from HEK293 cells (WT) or HEK-AnxA1 clones,
or the same concentration of MVTNFα from a single primary neutrophil donor. Stim-
ulations from each source of vesicles were performed in the presence of 10µg/mL
neutralising anti-anxA1 antibody, or 10µg/mL of an isotype-matched control anti-
body for 24 hours. Supernatants were collected and analysed for TGFβ quantification




4.1 Microvesicle analysis is robust
Flow cytometry remains one of the most widely used methods of analysing microvesi-
cles due to its high throughput and mutliparameter output. When comparing the
modern LSRFortessa cytometer to the ImageStreamx MKII, the latter was able to
resolve fluorescent particles as small as 20nm in diameter where the former was
unable to detect 100nm particles. As the Imagestream bases its detection and
analysis on the collection of light by its CCDs, it seems surprising that its limit
of detection is not ≥ 400nm, the shortest wavelength of light at which most light
microscopy techniques are limited. This limitation is in fact in effect; the instrument
cannot detect brightfield signals of particles smaller than this threshold, but instead
relies on the fluorescent haloing of a labelled particle to make it appear larger than it
actually is. The advantage of this is that it allows particles <100nm in diameter to be
detected and analysed provided they are appropriately labelled, allowing detection of
microvesicles and possibly exosomes (although this application has not been tested).
This platform provides four advantages over traditional cytometry: firstly its limit
of detection for fluorescent particles is considerably lower, secondly (and related to
the first) with appropriate labelling these particles can completely separate from
the noise population (which is less considerable), thirdly the concentration of any
population is given without the need for additional beads, and finally each event can
be visually interrogated to ensure correct gating and exclusion of doublets (which are
very rare given the instrument’s flow rate of 40nL/sec). These benefits have allowed
the simple identification and enumeration of microvesicles in different biological
fluids. The major drawback of this instrument compared to the LSRFortessa, is
smaller dynamic range of fluorescence detection which impacts its ability to separate
vesicle populations by antigen expression. Nevertheless, microvesicles from plasma
and isolated neutrophils can be phenotyped with optimisation of antibody labelling.
In comparing the relative efficiency of CFSE, BODIPY maleimide and PKH in
labelling a concentrated preparation of microvesicles, CFSE achieved full labelling
at a 10-fold lower concentration than BODIPY maleimide. PKH did not achieve
full labelling because across all concentrations used, the ethanol solvent lysed a
128
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proportion of the vesicles after the 5 minute incubation. Additionally, even in the
absence of microvesicles, PKH contained a number of fluorescent particles which
overlapped with the microvesicle gate. These are likely to be micelles given the
lipophilic nature of this class of dyes248. While both CFSE and BODIPY maleim-
ide were deemed appropriate as pan-microvesicle dyes, BODIPY maleimide was
considerably cheaper, even at the higher concentration needed, and so was used for
most assays. As microvesicles can be freeze-thawed multiple times with no injurious
effect on structure or function, it would be useful to store fluorescently labelled
microvesicles to reuse at a later date. Although CFSE was the most resistant label
to freeze-thaw, all three dyes used lost fluorescence and therefore underestimated
microvesicle number, prohibiting the long term storage of fluorescent microvesicles.
Centrifugation at 20,000×g is widely accepted as too low a force to pellet
significant numbers of exosomes in several hours, let alone 20 minutes. The absence of
important numbers of exosomes was demonstrated by the lack of Tsg101 expression in
a 20,000×g pellet, where considerable expression was detected in a 100,000×g pellet.
While generating a pure population of any vesicle is as yet impossible, this suggests
that this protocol generates vesicle preparations highly enriched in microvesicles.
While their resilience to freeze-thaw allows storage of microvesicles, it was im-
portant to know how stable they were for prolonged periods of time and at which
temperatures. Storage at temperatures greater than -20oC are not appropriate,
resulting in rapid vesicle loss, and while stable for 48 hours at -20oC preparations
stored longer than this need to be stored at -80oC. Although the exact mechanisms
by which microvesicles expire in storage are not known, a large proportion of them
are reported to contain mitochondria and can generate superoxide82,249. The presence
of ROS may damage the membrane, even in those stored at -20oC, where subsequent
thawing causes membrane rupture.
While neutrophil-derived microvesicles can be immunophenotyped without the
need to remove their maternal neutrophils, the neutrophils themselves act as an
antigenic sink, reducing the fluorescent intensity of the microvesicles in the absence
of a saturating concentration of antibody. For this reason microvesicles were always
subsequently phenotyped in isolation (where stronger separation from isotype controls
was observed).
The fluidics system of the ImageStream differs from most standard cytometers
in that the sample is aspirated and syringe-driven into the flow cell by motors. A
consequence of this is that the volume of sample acquired is accurately estimated
to the nearest 10nL. The number of events in a population detected within this
volume is used to estimate the concentration of those objects in the sample. The
instrument showed linearity of estimates of microvesicle concentration with sequential
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sample dilution, demonstrating the reliability of this method to estimate microvesicle
concentration. It is important to note, however, that sample acquisition must take
more than ~2 seconds, or the instrument is unable to measure the volume injected,
and therefore concentration cannot be estimated.
The profile of circulating erythrocyte, platelet and leucocyte microvesicle pop-
ulations in healthy human plasma largely correlates with the abundance of each
cell type, as may be expected. The level of endothelial cell-derived microvesicles
was surprisingly low, although may demonstrate a relative absence of ectocytosis
of these cells in the resting state. The abundance follows erythrocyte > platelet >
leukocyte > endothelial cell. Monocyte and neutrophil-derived microvesicle levels
also do not represent the difference in circulating numbers of these cells, where far
higher neutrophil-derived microvesicles may have been expected. For the leukocyte
subsets, the abundance follows neutrophil ~ monocyte > lymphocyte.
It is important to note that ~10% of the total microvesicles remain unidentified.
The reason for this may lie in fringe populations of microvesicles, as well as variability
and error in labelling/acquisition. Until more powerful methods are developed,
full identification of the remainder of “unknown” microvesicles is likely to remain
asymptotic. An additional caveat to this experiment is that it was not possible to
conduct all immunolabelling in a single reaction but instead was split into 3 separate
reactions. Regardless, this data demonstrates the ability of this platform to type a
patient’s vesicle profile, and could therefore facilitate their use as biomarkers.
4.2 Inflammatory stimuli induce ectocytosis in
neutrophils
While constitutively occurring, ectocytosis is a regulated process and efficacy of
microvesicles is conceptually dependent on both their contents and density within
a tissue compartment. For this reason, and for the purpose of producing sufficient
numbers of vesicles for experimentation, different model stimuli were applied to
human neutrophils to quantify the number of vesicles they release. Increased
ectocytosis in neutrophils was induced by all inflammatory stimuli tested, sugesting
the universal nature of this process in response to activating stimuli. The observation
that “unstimulated” neutrophils released ~2×107 microvesicles/mL after 20 minutes
would seem to indicate constitutive microvesicle release from resting cells. While
this is likely (although in vivo all cells are always receiving stimulation in one form
or another), the procedure of isolating cells (neutrophils in particular) from whole
blood does cause partial activation.
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Interestingly, the number of microvesicles released in response to various stimuli
did not vary as much as expected. While this could be ascribed as a coincidence,
this was observed repeatedly with different classes of stimuli and may suggest a
limitation in the number of microvesicles released, equilibrium between release and
re-uptake, or more likely be related to the initial release and trivial change in rate of
release described below.
Although important, the increase in the rate of microvesicle release upon TNFα
stimulation is not sufficient to explain the rise in total microvesicle number at 20
minutes. Surprisingly, there is a large initial burst of microvesicle release within
2 minutes of stimulation (before the ImageStream was able to start enumerating
them). This would suggest that a number of primed sites for ectocytosis exist in the
resting cell which bud off rapidly. One limitation of this experiment is that the rate
of microvesicles/second flowing through the flow cell is both a function of the number
of neutrophils and the flow rate, and so is not a direct measure of microvesicle release
from the cells. However, given that neutrophils were suspended at 1×106/mL and
therefore flowing at 40 cells/40nL/second, it can be estimated that TNFα caused a
mean increase in rate from 0.59 to 1.16 microvesicles/second/cell. This, however,
does not take into consideration the loss of neutrophils to waste as the sample was
run.
While this experiment demonstrated a continual increase in the rate of ectocytosis,
20 minutes was chosen as an optimal length for subsequent neutrophil stimulation
to provide as many microvesicles as possible while avoiding the initiation of NETosis.
An experiment performed in collaboration with Dr. Elisa Corsiero (William Harvey
Research Institute) showed that NETs were abundant after 60 minutes of stimulation
with TNFα (these data are not shown in the thesis as I did not produce them, but
are published in reference 3).
4.3 MVTNFα inhibit classical activation of
macrophages
MVTNFα microvesicles inhibited classical activation in monocyte-derived macro-
phages, completely restoring the expression of HLA-DR, DP & DQ and CD86 to
control levels at 3×106/mL. On their own, microvesicles did not seem to affect
macrophage phenotype, suggesting that they inhibit classical activation rather than
imparting alternative activation (supported by their lack of effect on IL-4-mediated
polarisation). The exception to this is in the presence of LPS and IFNγ where they
actually increased CD206 expression (an effect seen in neither treatment alone).
3×106 microvesicles/mL was chosen for all future treatments (except where specified),
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although both the concentration and the ratio of microvesicles:macrophage seem
important for the magnitude of their effects, where in a 24-well format, the ratio is
~3:1.
Due to differences in isolation protocol and insufficient sensitivity of analysis
techniques, which population of vesicles is responsible for a reported efficacy is often
ambiguous. While more sophisticated methods of enriching for a populations of
exosomes are becoming more widespread (such as size exclusion chromatography250),
the differential centrifugation of the activated neutrophil supernatant allowed for
the relative enrichment of microvesicles and exosomes. The data indicate clearly
that the regulation of classical macrophage activation imparted by the MVTNFα
preparations was attributable to the microvesicle-enriched fraction, and was not
imparted by the exosome-enriched fraction. While theoretically the lack of efficacy
from the 100,000×g pellet could merely be due to a smaller number of exosomes
released during the 20 minute timescale, it nevertheless shows that for the MVTNFα
preparations used in this project, exosomes were not responsible for the effects
seen. As subsequent data demonstrates that the effects on macrophage phenotype
were PtdSer and anxA1-dependent (and exosomes do not express either), it seems
unlikely that exosomes contribute to this phenomenon. Even if exosomes contribute
to the conditioning of an aspect of macrophage phenotype not studied, the release
of microvesicles in response to a stimulus is a much more rapid process251 and may
exert more immediate control.
The dis-inhibition of HLA-DR, DP & DQ, CD86 and CD206 upregulation by
coating and making PtdSer unavailable for binding with anxA5, suggests these effects
are similar to those imparted by apoptotic bodies which also present PtdSer. A
similar effect is seen with IL-1β, although the initial decrease with MVTNFα treatment
is less striking and not significant. A much larger decrease in IL-12p70 was induced
by MVTNFα, but which was only partially restored by blocking PtdSer, suggesting
other factors may also mediate this effect. Perhaps the most striking effect of these
microvesicles was their induction of TGFβ release regardless of other stimulation. In
the presence of LPS and IFNγ this effect was diminished, but was independent of
PtdSer blockade, suggesting that these microvesicles modulate macrophage phenotype
by at least two separate pathways: one which is PtdSer-dependent, and one which
is PtdSer-independent and culminates in the release of TGFβ. A caveat of this
experiment is that an MVTNFα + anxA5 in the absence of LPS and IFNγ was
not included. Overall, these data are supported by work from the Schifferli lab
demonstrating that control of macrophage activation and dendritic cell maturation
is mediated, in part, by PtdSer exposed by neutrophil microvesicles37,150,252.
These observations suggest a similarity between neutrophil microvesicles and
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apoptotic bodies in the conditioning of macrophage phenotype. The tethering
and phagocytosis of apoptotic bodies by macrophages depends on the interaction
between PtdSer and a plethora of PtdSer receptors, including TAM receptors such
as MerTK253. Uptake of apoptotic bodies and cells promotes a pro-resolving, wound-
healing phenotype in macrophages which secretes TGFβ254. However, while it is
tempting to make the assumption that neutrophil microvesicles and apoptotic bodies
are acting in an identical manner on macrophages, apopotic bodies induce the
secretion of IL-10 and even small amounts of IL-12 p70, whereas microvesicles
reduced expression of both255. While they may share an uptake mechanism and
perhaps some signalling pathways, the reduction of both IL-10 and IL-12 p70 by
microvesicles suggest they achieve a net reduction in NFκB activation. It seems
unlikely therefore that PtdSer is the only or even the primary signal in both cases and
that the downstream effects depend on other mediators contained within the vesicles.
This seems especially so as it was anxA1 and not PtdSer which was responsible for
TGFβ release in response to neutrophil microvesicles.
The effects on cell phenotype that are mediated directly by PtdSer can be
distinguished from those related to other mediators by treating macrophages with
empty, PtdSer-exposing lipsomes. In fact, this has been performed both in vitro and
in a model of myocardial infarct256. In this study, PtdSer was shown to be directly
responsible for decreasing CD86 and increasing CD206 expression in the presence of
LPS, but that it also strongly induces IL-10 secretion, and that it did not induce
TGFβ release in vitro (although it did once administered in vivo). Taking these
reported findings and the observations herein together, would suggest that PtdSer is
both important for tethering, uptake, and signalling, but that the other components
are also at work. For example, the reduction in IL-10 production despite PtdSer
strongly inducing its secretion is interesting.
It is important to consider whether induction of TGFβ from macrophages is benefi-
cial in the context of the rheumatic joint. In addition to being anti-inflammatory/pro-
resolving, TGFβ is pro-fibrotic, and has been shown to drive pathological fibrosis in
several disease settings257–259. Nevertheless, arthritides are diseases of destruction
and catabolism, and supplementation has been shown to provide joint protection in
models of osteoarthritis260.
In light of the contribution of PtdSer to the pharmacodynamic effects of these
microvesicles, the question was raised whether this is purely a signalling event, or
whether it relies on the internalisation of the microvesicle to elicit the effect, due to
PtdSer’s role as an “eat me” signal. When comparing microvesicle labels, although
PKH appeared the best detected and brightest fluorescent dye, it caused microvesicle
lysis, making it difficult to tell whether membrane fragments or intact vesicles were
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inside the cells. Additionally, this increased brightness may be attributable to the
fluorescent particles present in this label. As such, CFSE was chosen as the most
appropriate internalisation label instead.
The internalisation assay demonstrated that microvesicles are indeed quickly
taken up, and that the process is dependent on both PtdSer on the microvesicle
and its cognate receptor Mer expressed on the macrophages. As of yet, the question
of whether internalisation or merely juxtacrine contact are required for the PtdSer-
dependent effects on phenotype is not known, but future work where microvesicles
are allowed to bind, but not enter the macrophages may answer this. This may also
be addressed by selectively blocking the PI3 kinase and STAT1-mediated pathways
from the receptor. This is relevant, as while PtdSer is important for internalisation,
other components of the vesicles may be exerting control over phenotype, such
as miRNA species. It also is not clear whether the primary uptake mechanism is
endocytosis or phagocytosis-dependent. This could be addressed in future by using
specific inhibitors of each process, although existing publications argue for both
cases119,120.
The presentation of apoptotic moeities, prominantly apoptotic neutrophils, at
a site of acute inflammation is considered a critical checkpoint for resolution155.
The expression of PtdSer receptors by macrophages facilitates both the removal of
dead and dying cells (to prevent the release of DAMP during secondary necrosis)
and the transition from a pro-inflammatory to an pro-resolving phenotype255. That
MerTK, the best studied member of the TAM receptor family, is responsible for
the PtdSer-mediated effects of MVTNFα is suggestive that in some ways, neutrophil
microvesicles mimic apoptotic bodies. In the context of acute inflammation, this
process may serve to balance macrophage activation in a way that primes them for
the resolution phase. The other TAM receptor family members, Tyro3 and Axl also
bind PtdSer via Gas6 and Protein S, but as inhibition of MerTK signalling was
sufficient to fully attenuate vesicle efficacy, these were not examined.
There are, however, two issues with this mechanism. The first is that not all
neutrophil microvesicles express PtdSer, which begs the questions: are only the
PtdSer+ vesicles able to restrict activation in this way; and what, if any, effect do
PtdSer- impart? The second issue is that most cell types have been reported to
release a subset of PtdSer+ microvesicles, and yet largely induce a pro-inflammatory
phenotype in macrophages261,262. The only other cell type reported to release vesicles
which restrict classical macrophage activation are those derived from mesenchymal
stem cells263.
MerTK was responsive to vesicle-presented PtdSer, despite the absence of exoge-
nously added Gas6 or Protein S, the adaptors required for signalling to occur. While
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one or both of these adaptors may be present in the culture medium (bovine Gas6
and Protein S share 81% and 82% sequence homology, respectively with the human
proteins [BLAST accession numbers NP 000811.1, XP 005214103.1, NP 000304.2 &
NP 776863.1]), it seems more likely that they are secreted in an autocrine fashion
by the macrophages in culture themselves, as Gas6 in particular has been shown to
be secreted from macrophages174.
The proteome of microvesicles released from neutrophils stimulated in suspension
with TNFα is different from those exposed to an activated endothelium82. Microvesi-
cles produced in suspension induced a less inflammatory gene expression profile in
näıve endothelium, while those activated by endothelium induced an inflammatory
gene signature. While not fully explored, this may represent a dichotomy in func-
tionality of neutrophil microvesicles produced pre and post extravasation, where
intravascular vesicle release may serve to recruit additional waves of leucocytes,
while their release in the inflammatory site promotes resolution. There was therefore
rationale for comparing the effect of vesicles released from neutrophils before and
after transmigration.
The transmigration of isolated neutrophils across HUVEC-coated transwells
is a useful in vitro system to study extravasation and the phenotypic changes it
induces. If only studying the number of cells which transmigrate, low yields of
transmigration are still sufficient to see changes in response to different stimuli. The
purpose of this system in the present study however, was to generate large numbers
of microvesicles in response to transmigration and for this reason, microvesicles
generated in the presence of serum (made extracellular vesicle-free and confirmed
using the ImageStream) and a gradient of IL-8 were used for future study. IL-8
on its own induced a modest increase in neutrophil transmigration, but acted in
synergy with serum (which on its own had no effect). Although this increase in
transmigrated neutrophils did not raise the total yield of microvesicles below the
transwell (paradoxically), it did raise the proportion of vesicles of neutrophil origin.
Perhaps unexpectedly, microvesicles collected from this system, both above and
below the transwell, imparted similar effects on macrophage phenotype as MVTNFα.
This might suggest that endothelial microvesicles share the pro-resolving properties
of their neutrophil counterparts (for which there is evidence264), or simply that
their presence was inconsequential and overcome by the neutrophil majority (as
pro-inflammatory roles of endothelial microvesicles are also documented34).
When comparing the number of microvesicles per neutrophil (below the transwell)
at collection, again the numbers were similar to those generated with TNFα or with
synovial fluid from rheumatoid and osteoarthritis patients. As reported previously,
microvesicles generated in response to these model stimuli were enriched in anxA1
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where diluted synovial fluid induced the highest expression (although it is possible
that the fluid itself contains soluble anxA1 which bound to the microvesicle PtdSer).
The induction of TGFβ by microvesicles generated from TNFα and synovial fluid
(and likely any inflammatory stimulus) is at least partially dependent on anxA1
expressed on the microvesicle surface, despite only ≤20% of MVTNFα expressing it
on their surface. While this is not a response typically associated with the anxA1-
ALX/FPR2 axis, it may be related to a general shift in the macrophages’ phenotype
towards M2a/c, which produce TGFβ and are classically induced with IL-4 or IL-10
(or glucocorticoids), respectively. AnxA1 also positively regulates TGFβ-signalling
in breast cancer cells and may play a similar role in macrophages265. A similar effect
has been reported in the induction of TGFβ release from chondrocytes induced by
neutrophil MVTNFα
3, and anxA1+ microvesicles derived from the gut epithelial cells
have been shown to resolve tissue damage in the gut via activation of FPR22.
While FPR2, the cognate receptor for anxA1, was expressed in classical, alterna-
tive and näıve macrophages, its upregulation in classically activated macrophages
may represent a negative feedback mechanism to regulate a pro-inflammatory pheno-
type. Interestingly, the percentage of FPR2+ macrophages was comparable between
phenotypes in permeabilised cells, suggesting that FPR2 may be stored in the cells
and translocate to the plasma membrane in classical macrophages. De novo synthesis
must also occur, as even in permeabilised cells, the relative expression values were
higher than in alternative and näıve cells.
4.4 Microvesicle-treated macrophages are
chondroprotective
The increase in glycosaminoglycan deposition by C28/I2 chondrocyte micromasses in
response to TGFβ (known to be chondroprotective266) demonstrated the sensitivity
of the model to anabolic stimuli. The lack of catabolic activity of IFNγ and IL-4
shows they have no direct effects on the chondrocytes themselves. Osteoarthritis
synovial fluid was highly catabolic, likely due to the presence of metalloproteinases
and cytokines, such as IL-1β. Surprisingly, rheumatoid arthritis synovial fluid
showed only a trivial and non-significant reduction in matrix although this may
reflect osteoarthritis as being the more overtly degradative disease267. IFNγ and
rheumatoid synovial fluid-treated macrophage-conditioned medium was modestly
catabolic, likely due to the induction of proteinases and/or IL-1β. Even medium from
resting “M0” macrophages appeared catabolic, despite these cells appearing similar
to M2 cells in culture. The anabolic effects of M2 macrophages may be related to
decreased release of proteinases and/or an increase in TGFβ.
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MVTNFα, MVRA and MVOA caused macrophages to release an anabolic mediator(s)
into their medium, an effect which was wholly dependent on microvesicle-anxA1 and
produced similar results to IL-4 treatment. As microvesicle delivery of anxA1 had
already been shown to induce TGFβ release, it was only a small step to demonstrate
in a single experiment that this is the primary mediator induced by the microvesicles
to confer chondroprotection. This set of experiments demonstrates a long-lasting
effect of MVTNFα, which are able to educate the macrophages.
4.5 Microvesicles affect the
macrophage-fibroblast interaction
Synovial fibroblasts participate in disease progression during rheumatoid arthritis268.
While during homeostasis, fibroblasts provide structure to the intimal lining of the
synovium and facilitate movement of cells in and out of the synovial space, following
onset of rheumatoid arthritis, they respond to the inflammatory synovium and adopt
an activated phenotype. Once activated, synovial fibroblasts secrete proteinases,
such as MMP1, MMP3, MMP13, cathepsins and aggrecanases, which degrade the
extracellular matrix and cartilage surface269–271.
Activated synovial fibroblasts contribute to the inflammatory milieu by releasing
cytokines and growth factors, such as MCP-1269, VEGF272, IL-6273 and GM-CSF274,
supporting leucocyte recruitment, delaying neutrophil apoptosis and propagating
pannus hyperplasia. As the synovial lining is comprised of fibroblasts and macro-
phages, whether microvesicle stimulation could promulgate an anti-inflammatory
phenotype from macrophages to fibroblasts was examined.
Responding to arthritic synovial fluid as a model stimulus, the increased expres-
sion of VCAM-1, CD55, IL-6, MCP-1 and TNFα was indicative of an inflammatory
phenotype in primary synovial fibroblasts, although CD21 expression didn’t increase
as reported243. Incubation of otherwise näıve fibroblasts with classically activated
macrophages resulted in a pro-inflammatory change in fibroblast phenotype. While
the change in each individual antigen was not as pronounced as in response to
synovial fluid, the combined change in antigen expression was sufficient to discrim-
inate these fibroblasts from those cultured with alternatively-activated or näıve
macrophages. Interestingly, alternatively-activated macrophages induced even higher
MCP-1 production from fibroblasts which appears counter-intuitive. A major caveat
of this co-culture system is that while the fibroblasts are derived from the inflamed
synovia of rheumatoid arthritis patients, the macrophages are not.
The ability of MVTNFα to abrogate the pro-inflammatory effect classically acti-
vated macrophages have on fibroblast phenotype is most likely due to the fact that
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Figure 4.1: Graphical summary of the working hypothesis. Stimulation of
neutrophils by pro-inflammatory mediators induces the release of microvesicles, a
proportion of which expose phosphatidylserine (PtdSer) and annexin A1 (AnxA1).
Vesicle-bound anxA1 induces the production of transforming growth factor β (TGFβ)
which stimulates the production of sulphated glycosaminoglycans (sGAG) by chon-
drocytes. The interaction between PtdSer and MerTK restricts macrophage response
to pro-inflammatory stimuli, and prevents the pro-inflammatory activation of synovial
fibroblasts.
the microvesicles prevent the classical activation in the first place. Nevertheless,
the data suggest that in an inflamed synovium, microvesicle-induced resistance to
classical activation has consequences for the influence macrophages exert on other
cell types.
The working hypothesis based on the data collected thus far is therefore that
within the synovium of rheumatoid arthritis patients, recruitment and activation of
neutrophils induces the release of microvesicles. These microvesicles, by interacting
with synovial macrophages, can deliver pro-resolving signals via engagement of the
MerTK receptor by exposed PtdSer, and regulate the pro-inflammatory polarisation
of these macrophages. Engagement of ALX/FPR2 by anxA1 and the subsequent
release of TGFβ could also modulate macrophage phenotype but may also directly
counter cartilage degradation (summarised in Figure 4.1). While these mechanisms,
if present, are clearly not sufficient to induce resolution, they may prolong cartilage
integrity. It must be noted that the approach taken in the project has not been
unbiased in selection of antigens to compare macrophage phenotype. As such, it is
possible and quite likely that many other antigens are modulated by MVTNFα that
were not probed for, and which may be dependent or independent of the PtdSer and
anxA1 mechanisms identified thus far. An unbiased approach, such as a microarray
or RNA sequencing of MVTNFα-conditioned macrophages, would provide a broader
view.
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4.6 Biological functions of MVTNFα are relevant
in vivo
The recapitulation of the efficacy seen in human macrophages in vitro in mice,
demonstrates that the efficacy observed is a real biological phenomenon. The
modulation of MHCII, CD86 and CD206 seen in mice completely reproduced the
trends seen in human cells. What is more interesting is that these effects are
observed despite the xenogeneic nature of the vesicle adoptive transfer, where human
neutrophil vesicles are administered to mice. This modus operandi was chosen as it
is difficult to generate large numbers of microvesicles from mouse neutrophils, and
has been demonstrated to be effective with no immunogenic response3. The increase
in TGFβ in the cavity in response to MVTNFα was particularly supportive of the
previous data, although it must be remembered that in this crude in vivo model,
microvesicles interact with more cell types than just macrophages, and that an array
of different cell types contribute to the overall cytokine profile of the lavage fluid.
It must be noted that despite the recapitulation of antigen expression changes in
the peritonitis model, the absolute changes in relative expression were much smaller
than observed in vitro. This is likely partially due to the complex nature of an in vivo
compartment, containing many competing signals and generating a larger amount of
noise above which the signal must rise, but also because the ratio of microvesicles to
macrophages would be considerably smaller than in the in vitro setting. Indeed, the
peritoneal cavity of a mouse has a large surface area, and even after the injection of
5×107 MVTNFα, the change in macrophage phenotype observed was small, despite
being statistically significant.
To address this second issue, and to test this effect in a more arthritis-relevant
setting, a smaller inflammatory compartment was chosen: the synovial space in the
ankles of mice undergoing K/BxN arthritis. In this model, a smaller number of
vesicles could be injected per compartment, but still achieve a higher concentration
of vesicles in the biological space. Again the phenotype of the macrophages in this
setting responded to MVTNFα treatment as supported by all the previous in vitro and
in vivo data. Not only this, but the magnitude of change in antigen expression was
greater than in the peritonitis model (though still not as large as in vitro). While
this experiment also aimed to phenotype synovial fibroblasts using the phenotypic
markers thus far shown to indicate an inflammatory phenotype, not enough cells
could be identified from such a small source of tissue.
The importance of the findings thus far is that microvesicles may represent a
manipulatable mechanism to target the inflammatory diseases, such as arthritides,
including the prospect of using them as autologous therapeutic vectors as previously
CHAPTER 4. DISCUSSION 140
demonstrated in mice158,275. This form of therapy could rely on the generation of
certain populations of microvesicles from the patient and reintroducing them “as
are” or following biochemical manipulation, to form a truly personalised medicine.
4.7 RA MVTNFα as an autologous biologic
therapy
While blood neutrophils from rheumatoid arthritis patients produced anxA1+ mi-
crovesicles in response to TNFα, the relative increase in number was smaller than
generally observed in healthy donors. Additionally, while the expression of anxA1
was comparable between healthy donor and rheumatoid arthritis patient MVTNFα,
the expression of anxA1 on constitutively released microvesicles was higher from
these patients than observed in healthy controls. This is perhaps surprising in that
no major differences are reported between circulating neutrophils of healthy and
rheumatoid arthritis donors276,277, although the sample size is small and patient
blood had to be transported before neutrophil isolation could begin. There were
also no differences in the proportion of anxA1+ neutrophil microvesicles in the
plasma of rheumatoid arthritis patients and healthy controls. This data is surprising,
because overall there is an increase in the proportion of anxA1+ microvesicles, these
differences are not represented across monocyte or neutrophil vesicles, typically the
two main populations to express anxA1.
It would be interesting to compare blood neutrophils from these patients with
their synovial neutrophils, which have been shown to be greatly activated276, but
the logistics of isolating enough neutrophils from the available volume of synovial
fluid was prohibitive in this study.
There is a clear relationship between the number of neutrophils stimulated with
TNFα and the number of microvesicles which could be recovered per cell. This
relationship could suggest that the interaction with other neutrophils increases their
release of microvesicles or, perhaps more likely, that the number of microvesicles
lost during isolation remains largely constant and independent of starting number.
The purpose of comparing this relationship between healthy control and rheumatoid
arthritis patient neutrophils, was to compare whether they have equivalent potential
for ectocytosis. As the volume of blood that could be drawn from rheumatoid
arthritis patients was lower, enough neutrophils could not be isolated to compare
across the range of starting neutrophils collected from healthy controls, although the
relationship is similar in the lower end of neutrophil numbers.
Despite slight differences in the number of microvesicles produced and their in-
creased basal level of anxA1 expression, MVTNFα from rheumatoid arthritis patients
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demonstrated remarkably similar efficacy on macrophage phenotype as those derived
from healthy control neutrophils. The main difference observed between the popula-
tions was in their induction of TGFβ production, despite comparable proportions of
each expressing the protein. This suggested that, at least in a pharmacodynamic
sense, microvesicles generated ex vivo from the neutrophils of rheumatoid arthritis
patients have the potential to restrict classical macrophage activation.
The issue had been considered that use of autologous microvesicles as a therapy
would involved the administration of protective vesicles, into a milieu highly dense
with heterologous vesicles. As such, a model system was created to explore whether
MVTNFα from rheumatoid arthritis patients could outcompete the effects of pro-
inflammatory populations of vesicles. This was performed by using both platelet-
derived vesicles (as an isolated population) and total synovial fluid microvesicles (as
a heterologous, disease-model population).
It was desirable to generate vesicles from platelets using the same stimulation as
neutrophils to examine whether any differences observed between the microvesicles
was purely cell type-dependent. Despite not widely considered a canonical platelet
agonist, platelets do express TNF receptors 1 and 2, are activated by TNFα278, and
as the data demonstrate, release large numbers of microvesicles in response to it.
Platelet microvesicles appeared to mildly induce a pro-inflammatory phenotype
in macrophages, although their lack of cytokine modulation may be due to a lack of
any TLR signal. Although much of the efficacy observed in neutrophil MVTNFα is
attributable to PtdSer, a subset of platelet microvesicles (and those from other cell
types) also express PtdSer83. This suggests that induction of the STAT1 signalling
pathway through MerTK is insufficient on its own to restrict macrophage activation,
and that internalisation of the microvesicles to deliver their luminal cargo via PtdSer
may be more important.
A similar, but more pronounced, effect on macrophage activation is observed
in response to total synovial fluid microvesicles. The small increases observed in
IL-12 p70 and IL-1β release may have been related to residual TLR ligands from
the synovial fluid used to isolate the vesicles, although the changes seen cannot be
considered biologically relevant.
Neutrophil MVTNFα from rheumatoid arthritis patients were able to outcompete
the pro-inflammatory effects of those derived from platelets. This demonstrates that
populations of vesicles with seemingly opposing actions, are in competition to bind
to, and exert their efficacy on their target cells. When the ratio of neutrophil:platelet
vesicles was 1:1, platelet efficacy was reduced to ~50% , suggesting that both popu-
lations of vesicles may be competing for the same binding sites, or that macrophages
have a limited capacity to internalise these structures.
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Neutrophil MVTNFα were also able to compete with the total synovial fluid
vesicles, although a 1:1 ratio was not sufficient to reduce the efficacy of synovial
vesicles to 50%. In fact, a much larger ratio of neutrophil:synovial microvesicles was
required to nullify the effects of the latter, possibly suggestive of an overall more
inflammatory profile compared to platelet microvesicles.
4.8 HEK-AnxA1 cells
Despite the use of a bicistronic expression vector to transfect anxA1 and bsd genes
into HEK293 cells, after antibiotic selection (which completely killed the control-
transfected cells), only 14.7% of cells were positive. Serial dilution of the polyclonal
population identified 5 colonies which were almost completely positive for the anxA1.
Vesicles released from these colonies in response to the Ca2+ ionophore, ionomycin,
were only 3.7% positive for anxA1 despite virtually all the cells being positive. This
may be related to low anxA1 copy numbers per cell post transfection or that HEK
cells lack the cellular machinery to externalise anxA1 onto outer membrane leaflets.
Neutrophils themselves express high levels of anxA1 which is split between two
compartments: the granules (mainly gelatinase), and the cytosol279. Upon cell
activation and Ca2+ flux, the granule pool of anxA1 is rapidly translocated to the
cell surface167, and it is thought that this is the pool of anxA1 which is subsequently
incorporated onto the outer microvesicle membrane leaflet36. HEK cells do not
contain such granules and may therefore lack the machinery to efficiently externalise
anxA1, despite storing a cytosolic pool. It may therefore not be that surprising to
observe such low expression on the surface their vesicles, but may potentially be
luminal instead.
Perhaps to be expected after observing such low anxA1 levels on their surface,
HEK-AnxA1 microvesicles did not induce TGFβ release from macrophages. This
is in stark contrast to microvesicles from primary neutrophils, whose induction of
TGFβ was entirely dependent on their anxA1 exposure. While this may be due to
the low frequency of anxA1+ vesicles released by HEK-AnxA1 cells, even vesicles
from primary neutrophils are only ~20% positive for anxA1, and so an absence of
any effect is quite surprising. The result could also depend on the antigen density
of anxA1 on each vesicle, which may be much higher in primary neutrophils. An
alternative explanation is that anxA1 is serving to target microvesicles to the plasma
membrane of macrophages, rather than directly signalling through FPR2, and that
they achieve their efficacy by another component, perhaps luminal, which is present
in neutrophil microvesicles, but not those from HEK293 cells. These results suggest
that while cells can be engineered to secrete vesicles expressing proteins of interest,
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the process is non-trivial, depends on the level of expression, the protein being
naturally secreted via vesicles, and a more intimate understanding of how the protein
is responsible for the desired efficacy. A more pragmatic approach may be to identify
endogenous populations of vesicles with beneficial components, and attempt to
harness or even manipulate them for therapeutic gain. It is also possible that a
cell line more amenable to become a “neutrophil-like” cell upon specific stimulation
(such as HL60 or NB4 cells) might be more suitable than HEK293 cells.
4.9 Perspective and future work
This project has reproduced initial findings by others, demonstrating that mi-
crovesicles released from neutrophils are able to restrict the classical activation
of macrophages, although do not themselves promote alternative activation. In
a manner similar to the control apoptotic bodies exert control over macrophage
phenotype, microvesicles from neutrophils mediate most of the effects studied by
presenting PtdSer to macrophage-expressed MerTK. In this way, neutrophils, which
are becoming recognised as orchestrators of resolution in their own right, may prime
cells within an inflamed environment for the initiation of resolution.
That the PtdSer-independent induction of TGFβ by MVTNFα has been shown to
depend on anxA1 demonstrates a previously un-reported function of this glucocort-
icoid-induced mediator of resolution. The temporally-appropriate secretion of TGFβ
at sites of inflammation is important for the restoration of the homeostatic tissue
architecture during the resolution phase.
As rheumatoid arthritis is a disease of loss of tolerance, it is unlikely that the use
of microvesicles will offer a curative therapy. However, the regulation of macrophage
phenotypes in vitro and in vivo, and the modulation of the way macrophages
condition cartilage matrix deposition by chondrocytes and fibroblast phenotype,
suggest that neutrophil microvesicles could regulate the inflammation and tissue
damage in the rheumatic joint. They may, therefore, produce potentially long lasting
effects within the joint compartment. Indeed, data on the direct effects of these
vesicles on chondrocyte survival and cartilage integrity in arthritic mice3 suggest
that while they may not induce resolution, they can reverse cartilage destruction,
something no therapy currently does. The data presented here suggest the potential
for neutrophil microvesicles to provide this protection via cell-mediated, as well as a
direct, interactions.
While this project has only touched the surface of exploring the appropriateness
of neutrophil microvesicles as a therapy, there is far more work to be done to explore
both the mechanism of control, and whether disease benefit can be observed in in
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vivo models. For example, the question of whether vesicle internalisation (and by
endocytosis or phagocytosis) is required for the PtdSer-mediated effects is unclear,
and difficult to separate. One way in which this may be addressed is by selectively
inhibiting the PI3 kinase and STAT1 pathways downstream of MerTK, individually,
and establishing if the efficacy is perturbed when one or both pathways is blocked.
While clear effects on phenotype could be observed in the K/BxN model of arthritis,
this study has not been able to evaluate whether this translates into a reduction
in disease score. This is an important pre-clinical experiment to perform for these
vesicles to be considered a credible treatment, but presents challenges, particularly
around dosing. The number of vesicles per dose, frequency of dosing and the route
of administration will need careful planning and experimentation. Vesicles injected
intravenously are readily lost to the spleen, liver and intestinal tract280, and so
vesicles administered by this route may need to be injected in larger numbers, or
otherwise targeted to the joints. Alternatively, intra-articular injection largely avoids
this problem, but repeated administration via this route is likely to cause damage,
and is unjustifiable in both mice and humans.
Whether autologous or cell line-produced vesicles represent the greatest chance
of success depends largely on whether cell lines can be easily engineered to produce
vesicles possessing beneficial properties. While physiological populations of vesicles,
such as those from neutrophils and mesenchymal stem cells, may already possess
these properties physiologically, they represent problems of volume and quality
control. Nevertheless, this study has provided basic evidence of the potential of
vesicles as therapies in inflammatory conditions, that future work can build upon.
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